Abstract is: Synucleins are a family of soluble proteins common to vertebrates, primarily expressed in neural tissue and in certain tumors. The name is a blend of the words "synapse" and "nucleus", as it was first found in the synapses in the of the electric ray.
| protein family | Q417841 |
| group or class of transmembrane transport proteins | Q67101749 |
| pore-forming toxin | Q7230047 |
| P2888 | exact match | http://www.tcdb.org/search/result.php?tc=1.C.77 |
| P646 | Freebase ID | /m/02wvfr4 |
| P2926 | InterPro ID | IPR001058 |
| P3827 | JSTOR topic ID | synucleins |
| P486 | MeSH descriptor ID | D051843 |
| P672 | MeSH tree code | D12.776.631.860 |
| P6366 | Microsoft Academic ID | 2777916540 |
| P10283 | OpenAlex ID | C2777916540 |
| P3519 | Pfam ID | PF01387 |
| P7260 | Transporter Classification Database ID | 1.C.77 |
| P2892 | UMLS CUI | C0165073 |
| Q46198978 | (123)I-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation A. |
| Q55360583 | (Poly)phenol-digested metabolites modulate alpha-synuclein toxicity by regulating proteostasis. |
| Q38937100 | (Poly)phenols protect from α-synuclein toxicity by reducing oxidative stress and promoting autophagy |
| Q58697819 | -Methyl-D-Aspartate Receptor Link to the MAP Kinase Pathway in Cortical and Hippocampal Neurons and Microglia Is Dependent on Calcium Sensors and Is Blocked by α-Synuclein, Tau, and Phospho-Tau in Non-transgenic and Transgenic APP Mice |
| Q57983273 | -Synuclein and Parkinson disease susceptibility |
| Q61782153 | -Synuclein gene duplications in sporadic Parkinson disease |
| Q57983254 | -Synuclein, pesticides, and Parkinson disease: A case-control study |
| Q40561724 | 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells |
| Q57029785 | 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease |
| Q52725644 | 14-3-3 protein sigma isoform co-localizes with phosphorylated α-synuclein in Lewy bodies and Lewy neurites in patients with Lewy body disease. |
| Q33525555 | 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy |
| Q47945493 | 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions |
| Q41840011 | 19F NMR studies of alpha-synuclein conformation and fibrillation |
| Q42378894 | 19F NMR studies of α-synuclein-membrane interactions |
| Q56620174 | 1H, 13C and 15N assignments of a camelid nanobody directed against human α-synuclein |
| Q57298268 | 2D polarization imaging as a low-cost fluorescence method to detect α-synuclein aggregation ex vivo in models of Parkinson's disease |
| Q58022837 | 3-Anhydro-6-hydroxy-ophiobolin A, a fungal sesterterpene from Bipolaris oryzae induced autophagy and promoted the degradation of α-synuclein in PC12 cells |
| Q41694670 | 5-HT2A Receptor Binding in the Frontal Cortex of Parkinson's Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study |
| Q39055876 | 5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease |
| Q36449441 | 5-fluoro-D,L-tryptophan as a dual NMR and fluorescent probe of α-synuclein |
| Q46933074 | 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation |
| Q57982364 | 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes α-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation |
| Q43962602 | 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. |
| Q38868732 | 6-Mer Hyaluronan Oligosaccharides Modulate Neuroinflammation and α-Synuclein Expression in Neuron-Like SH-SY5Y Cells |
| Q50520278 | 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease. |
| Q30628518 | A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations |
| Q47069000 | A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress |
| Q57792623 | A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach |
| Q35999591 | A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid |
| Q47389795 | A Focus on the Beneficial Effects of Alpha Synuclein and a Re-appraisal of Synucleinopathies |
| Q49613405 | A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. |
| Q60960028 | A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism |
| Q38741513 | A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein |
| Q37096051 | A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism |
| Q47799312 | A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the α-Synuclein-Related Inflammatory Response |
| Q36316808 | A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T α-Synuclein Toxicity |
| Q61902986 | A Pilot Study Examining Associations between DYRK1A and a-Synuclein Dementias |
| Q47296303 | A Preliminary Study on Investigation of Serum α-Synuclein and Tau Protein Levels in Children with Attention Deficit Hyperactivity Disorder |
| Q38987992 | A Proposed Atomic Structure of the Self-Assembly of the Non-Amyloid-β Component of Human α-Synuclein As Derived by Computational Tools. |
| Q58598324 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein |
| Q47548619 | A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy |
| Q57181907 | A Protofilament-Protofilament Interface in the Structure of Mouse α-Synuclein Fibrils |
| Q36475337 | A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. |
| Q57227098 | A Rationally Designed Six-Residue Swap Generates Comparability in the Aggregation Behavior of α-Synuclein and β-Synuclein |
| Q40157769 | A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity. |
| Q45590102 | A Saccharomyces cerevisiae strain unable to store neutral lipids is tolerant to oxidative stress induced by α-synuclein |
| Q37438098 | A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction |
| Q47290729 | A Systematic DFT Study of Some Plausible Zn(II) and Al(III) Interaction Sites in N-Terminally Acetylated α-Synuclein. |
| Q52839974 | A Systematic RNAi Screen of Neuroprotective Genes Identifies Novel Modulators of Alpha-Synuclein-Associated Effects in Transgenic Caenorhabditis elegans. |
| Q58592665 | A Systematic Review and Meta-Analysis of Alpha Synuclein Auto-Antibodies in Parkinson's Disease |
| Q24612655 | A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD) |
| Q36086721 | A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy |
| Q38009909 | A brief overview of tyrosine hydroxylase and α-synuclein in the Parkinsonian brain |
| Q34177224 | A broken alpha -helix in folded alpha -Synuclein |
| Q34555497 | A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons. |
| Q43067782 | A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. |
| Q48308537 | A case of α-synuclein gene duplication presenting with head-shaking movements |
| Q38973233 | A cell culture model for monitoring α-synuclein cell-to-cell transfer |
| Q39821184 | A cellular model to monitor proteasome dysfunction by alpha-synuclein |
| Q46061994 | A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. |
| Q24685788 | A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study |
| Q46601588 | A combinatorial code for the interaction of alpha-synuclein with membranes |
| Q48938567 | A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson's disease. |
| Q44061148 | A conformation-switching fluorescent protein probe for detection of alpha synuclein oligomers |
| Q37249041 | A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders |
| Q40374571 | A critical role for alpha-synuclein in development and function of T lymphocytes. |
| Q48493933 | A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. |
| Q37874930 | A deadly spread: cellular mechanisms of α-synuclein transfer |
| Q43473155 | A decrease in gamma-synuclein expression within the nucleus accumbens increases cocaine intravenous self-administration in the rat. |
| Q38765455 | A familial ATP13A2 mutation enhances alpha-synuclein aggregation and promotes cell death |
| Q40488130 | A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein |
| Q54031652 | A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. |
| Q42055565 | A hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillation |
| Q37129697 | A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. |
| Q43180567 | A loss in cellular protein partners promotes α-synuclein aggregation in cells resulting from oxidative stress |
| Q34571460 | A maximum entropy approach to the study of residue-specific backbone angle distributions in α-synuclein, an intrinsically disordered protein |
| Q34795038 | A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons |
| Q36129283 | A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease |
| Q30662678 | A molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of α-synuclein·dopamine adducts |
| Q53292476 | A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. |
| Q30838501 | A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity |
| Q54484969 | A new method for purification of recombinant human alpha-synuclein in Escherichia coli. |
| Q35054003 | A new method for quantitative immunoblotting of endogenous α-synuclein |
| Q50913747 | A new potential biomarker for dementia with Lewy bodies: Skin nerve α-synuclein deposits. |
| Q38465664 | A new role for α-synuclein in Parkinson's disease: Alteration of ER-mitochondrial communication |
| Q50123484 | A noble pathological role for alpha-synuclein in triggering neurodegeneration of Parkinson's disease. |
| Q34030874 | A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo. |
| Q41138073 | A novel autophagy modulator 6-Bio ameliorates SNCA/α-synuclein toxicity. |
| Q57069641 | A novel electrochemical aptasensor based on nontarget-induced high accumulation of methylene blue on the surface of electrode for sensing of α-synuclein oligomer |
| Q55004376 | A novel extended form of alpha-synuclein 3'UTR in the human brain. |
| Q52915436 | A novel link between the conformations, exposure of specific epitopes, and subcellular localization of α-synuclein. |
| Q39511696 | A novel molecular mechanism for nitrated {alpha}-synuclein-induced cell death |
| Q36109452 | A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein |
| Q41069719 | A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. |
| Q53583005 | A novel pathway for transcriptional regulation of alpha-synuclein. |
| Q45064470 | A novel polymorphic triplet repeat in intron five of the alpha-synuclein gene: no evidence of expansion or allelic association with idiopathic Parkinson's disease in the Irish |
| Q48199458 | A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology |
| Q35840376 | A novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression. |
| Q37736517 | A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3'end using CRISPR-Cas9 genome editing technique |
| Q36841475 | A novel α-synuclein missense mutation in Parkinson disease |
| Q34706231 | A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP. |
| Q34010946 | A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation |
| Q42285864 | A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues |
| Q33982546 | A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. |
| Q34230262 | A peptide inhibitor of synuclein-γ reduces neovascularization of human endometriotic lesions |
| Q44520243 | A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein |
| Q37164654 | A peroxisome biogenesis deficiency prevents the binding of alpha-synuclein to lipid droplets in lipid-loaded yeast |
| Q42840974 | A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of α-synuclein |
| Q34612993 | A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions |
| Q57675698 | A porous silicon immunoassay platform for fluorometric determination of α-synuclein in human cerebrospinal fluid |
| Q34581042 | A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration |
| Q40011127 | A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease |
| Q40433173 | A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease |
| Q43247253 | A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats |
| Q39414467 | A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease |
| Q35212177 | A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders |
| Q58559175 | A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ, α-synuclein, and amylin amyloid fibrils as well as amyloid-containing Staphylococcus aureus biofilms |
| Q33698975 | A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease |
| Q47229046 | A refined concept: Alpha synuclein dysregulation disease |
| Q47789033 | A relationship between the aggregation rates of α-synuclein variants and the β-sheet populations in their monomeric forms |
| Q34447530 | A relationship between the transient structure in the monomeric state and the aggregation propensities of α-synuclein and β-synuclein |
| Q24293727 | A role for alpha-synuclein in the regulation of dopamine biosynthesis |
| Q47754806 | A role of BAG3 in regulating SNCA/α-synuclein clearance via selective macroautophagy |
| Q47390530 | A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity |
| Q47580400 | A sensitive assay reveals structural requirements for α-synuclein fibril growth. |
| Q51003543 | A short C-terminal region of alpha-synuclein protects a (R/S)-non-specific esterase from Archaeglobus fulgidus. |
| Q34571131 | A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease |
| Q42276744 | A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone |
| Q40496754 | A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity |
| Q37309484 | A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease |
| Q37137415 | A small-angle X-ray scattering study of alpha-synuclein from human red blood cells |
| Q34050129 | A soluble α-synuclein construct forms a dynamic tetramer |
| Q47298798 | A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein |
| Q34428512 | A spirulina-enhanced diet provides neuroprotection in an α-synuclein model of Parkinson's disease. |
| Q37597181 | A spontaneous deletion of α-synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption. |
| Q48098461 | A sporadic case of Creutzfeldt-Jakob disease with beta-amyloid deposits and alpha-synuclein inclusions |
| Q33203491 | A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders |
| Q52360736 | A stress-enhanced model for discovery of disease-modifying gene: Ece1-suppresses the toxicity of α-synuclein A30P. |
| Q44466072 | A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins |
| Q34520985 | A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers |
| Q42366153 | A study on the modulation of alpha-synuclein fibrillation by Scutellaria pinnatifida extracts and its neuroprotective properties |
| Q54988826 | A tango for two: Dopamine and α-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease. |
| Q30979656 | A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles. |
| Q45935596 | A triple-emission fluorescent probe reveals distinctive amyloid fibrillar polymorphism of wild-type alpha-synuclein and its familial Parkinson's disease mutants. |
| Q38653383 | A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations |
| Q48227930 | A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging |
| Q30498862 | A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain |
| Q61796575 | A30P mutant α-synuclein impairs autophagic flux by inactivating JNK signaling to enhance ZKSCAN3 activity in midbrain dopaminergic neurons |
| Q38309238 | A30P α-Synuclein interferes with the stable integration of adult-born neurons into the olfactory network |
| Q48837167 | A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. |
| Q34989985 | A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration |
| Q27324171 | A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice |
| Q35767234 | A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP |
| Q37618665 | AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease |
| Q40462128 | AMBRA1, a novel α-synuclein-binding protein, is implicated in the pathogenesis of multiple system atrophy. |
| Q50279712 | AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers. |
| Q41333498 | ATP depletion is the major cause of MPP+ induced dopamine neuronal death and worm lethality in alpha-synuclein transgenic C. elegans |
| Q28116203 | ATP13A2 and Alpha-synuclein: a Metal Taste in Autophagy |
| Q34774337 | ATP13A2/PARK9 Deficiency Neither Cause Lysosomal Impairment Nor Alter α-Synuclein Metabolism in SH-SY5Y Cells |
| Q28118666 | ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein |
| Q33444800 | Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy |
| Q39915240 | Aberrant expression and demethylation of gamma-synuclein in colorectal cancer, correlated with progression of the disease |
| Q44852325 | Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease |
| Q36247496 | Abnormal Paraplegin Expression in Swollen Neurites, τ- and α-Synuclein Pathology in a Case of Hereditary Spastic Paraplegia SPG7 with an Ala510Val Mutation |
| Q35969183 | Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease |
| Q32121511 | Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders |
| Q40295592 | Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration |
| Q44852323 | Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. |
| Q34327884 | Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. |
| Q34419885 | Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease |
| Q46974891 | Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease |
| Q35025891 | Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein |
| Q48477663 | Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. |
| Q46198761 | Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment |
| Q45191523 | Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions |
| Q40497435 | Abnormal migration of human wild-type alpha-synuclein upon gel electrophoresis |
| Q34358218 | Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology. |
| Q33835006 | Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats |
| Q33394700 | Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice |
| Q47912425 | Absence of alpha-synuclein pathology in postencephalitic parkinsonism |
| Q48605519 | Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. |
| Q33853344 | Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. |
| Q48480276 | Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. |
| Q52608898 | Abundant fish protein inhibits α-synuclein amyloid formation. |
| Q48831912 | Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. |
| Q57131894 | Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease |
| Q40545381 | Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells |
| Q46111700 | Accelerated alpha-synuclein fibrillation in crowded milieu |
| Q46339706 | Accelerated fibrillation of alpha-synuclein induced by the combined action of macromolecular crowding and factors inducing partial folding |
| Q35698432 | Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations |
| Q48353748 | Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. |
| Q34148293 | Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants |
| Q47947996 | Accelerated proteasomal activity induced by Pb2+, Ga3+, or Cu2+ exposure does not induce degradation of alpha-synuclein |
| Q24293132 | Acceleration of alpha-synuclein aggregation by homologous peptides |
| Q34964783 | Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy |
| Q35048929 | Acceleration of α-synuclein aggregation by exosomes |
| Q50905520 | Acceleration of α-synuclein aggregation. |
| Q46511785 | Accumulated α-synuclein affects the progression of GM2 gangliosidoses |
| Q39992222 | Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging |
| Q41871999 | Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models |
| Q40402499 | Accumulation of Alpha-synuclein Causes Colonic Dysmotility Independently of Enteric Nervous Damage in the Early Stage of Parkinson's Disease (Neurogastroenterol Motil 2012;24:e425-e436). |
| Q57982456 | Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies |
| Q35456966 | Accumulation of NACP/alpha-synuclein in lewy body disease and multiple system atrophy |
| Q48342277 | Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. |
| Q47247812 | Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients |
| Q38966914 | Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo |
| Q48266774 | Accumulation of phosphorylated alpha-synuclein in aging human brain |
| Q48185981 | Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein |
| Q42455519 | Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy |
| Q42481819 | Accumulation of phosphorylated α-synuclein in subpial and periventricular astrocytes in multiple system atrophy of long duration |
| Q36543608 | Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. |
| Q37590843 | Accumulation of α-Synuclein in Cerebellar Purkinje Cells of Diabetic Rats and Its Potential Relationship with Inflammation and Oxidative Stress Markers. |
| Q34739881 | Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1. |
| Q54587822 | Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. |
| Q39221708 | Acetylcorynoline attenuates dopaminergic neuron degeneration and α-synuclein aggregation in animal models of Parkinson's disease |
| Q51734741 | Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function. |
| Q39562553 | Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. |
| Q33555439 | Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death |
| Q48508375 | Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease. |
| Q31856578 | Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. |
| Q36148314 | Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders |
| Q37137895 | Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration |
| Q37110592 | Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. |
| Q35544737 | Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy |
| Q55496331 | Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. |
| Q44170859 | Activity-dependent secretion of alpha-synuclein by enteric neurons |
| Q34572258 | Acute increase of α-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. |
| Q28586519 | Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism |
| Q35215169 | Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. |
| Q40358428 | Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity. |
| Q35799088 | Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease |
| Q36604979 | Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of α-synuclein oligomers and decrease of neurites |
| Q48696952 | Administration of LPS-stimulated autologous macrophages induces α-synuclein aggregation in dopaminergic neurons of rat brain. |
| Q40062265 | Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies |
| Q30428288 | Adsorption of α-synuclein to supported lipid bilayers: positioning and role of electrostatics |
| Q42508245 | Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. |
| Q34589388 | Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. |
| Q52568381 | Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease. |
| Q35196491 | Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. |
| Q36962314 | Age- and brain region-dependent α-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α-synuclein phosphorylation in aging monkey brains |
| Q47780737 | Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinson's Disease. |
| Q48390998 | Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? |
| Q55516142 | Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease. |
| Q48410950 | Age-dependent alpha-synuclein accumulation is correlated with elevation of mitochondrial TRPC3 in the brains of monkeys and mice. |
| Q48461166 | Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. |
| Q42519345 | Age-dependent differential regulation of genes encoding APP and alpha-synuclein in hippocampal synaptic plasticity |
| Q37701053 | Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice |
| Q27330366 | Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function |
| Q47984868 | Age-dependent elevations of oligomeric and phosphorylated alpha-synuclein synchronously occurs in the brain and gastrointestinal tract of cynomolgus monkeys |
| Q34278990 | Age-dependent synuclein pathology following traumatic brain injury in mice |
| Q36435001 | Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate |
| Q54977888 | Age-related Beta-synuclein Alters the p53/Mdm2 Pathway and Induces the Apoptosis of Brain Microvascular Endothelial Cells In Vitro. |
| Q42975991 | Ageing enhances alpha-synuclein, ubiquitin and endoplasmic reticular stress protein expression in the nigral neurons of Asian Indians. |
| Q42322220 | Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome |
| Q36234756 | Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to Lysosomes |
| Q46404588 | Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease |
| Q52678048 | Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. |
| Q44292891 | Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function |
| Q39670380 | Aggregated α-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. |
| Q42940463 | Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons |
| Q37401007 | Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells |
| Q34797480 | Aggregation and neurotoxicity of alpha-synuclein and related peptides |
| Q42246480 | Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization |
| Q53735737 | Aggregation and phosphorylation of α-synuclein with proteinase K resistance in focal α-synucleinopathy predominantly localized to the cardiac sympathetic nervous system. |
| Q44632469 | Aggregation of ?-synuclein in the pathogenesis of Parkinson?s disease |
| Q33344779 | Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine |
| Q35764504 | Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. |
| Q43962738 | Aggregation of alpha-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system |
| Q42491335 | Aggregation of alpha-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. |
| Q41712484 | Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia |
| Q50213594 | Aggregation of α-Synuclein in the Gonadal Tissue of 2 Patients With Parkinson Disease |
| Q35138501 | Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis |
| Q35960402 | Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations |
| Q35786977 | Aggregation of α-synuclein is kinetically controlled by intramolecular diffusion |
| Q35863939 | Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons |
| Q57835605 | Aggregation process of Aβ1-40with non-Aβamyloid component ofα-synuclein |
| Q33836384 | Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations |
| Q39973166 | Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants |
| Q37936556 | Aggresome formation and segregation of inclusions influence toxicity of α-synuclein and synphilin-1 in yeast. |
| Q28185660 | Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective |
| Q42444692 | Aging and alpha-synuclein affect synaptic plasticity in the dentate gyrus. |
| Q48844596 | Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats. |
| Q53271067 | Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. |
| Q38039020 | Agrochemicals, α-synuclein, and Parkinson's disease |
| Q29547175 | Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease |
| Q38174524 | Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker |
| Q40111468 | Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration |
| Q39722408 | Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. |
| Q42726460 | Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding |
| Q59544564 | Alpha Synuclein in Parkinson’s Disease |
| Q34340531 | Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? |
| Q38734880 | Alpha synuclein and crystallin expression in human lens in Parkinson's disease |
| Q38808369 | Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo |
| Q36050277 | Alpha synuclein gene expression profile in the retina of vertebrates |
| Q28276375 | Alpha synuclein in neurodegenerative disorders: murderer or accomplice? |
| Q48326512 | Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease |
| Q47174355 | Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability |
| Q48940293 | Alpha synuclein protein is involved in Aluminum-induced cell death and oxidative stress in PC12 cells. |
| Q36629050 | Alpha synuclein protein levels are increased in serum from recently abstinent cocaine abusers |
| Q49155731 | Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. |
| Q39603212 | Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia |
| Q54410432 | Alpha- and beta-synucleins mRNA expression in lymphocytes of schizophrenia patients. |
| Q49159052 | Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. |
| Q41653656 | Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies |
| Q64065382 | Alpha-Synuclein Continues to Enhance SNARE-Dependent Vesicle Docking at Exorbitant Concentrations |
| Q48121050 | Alpha-Synuclein Disease Mutations Are Structurally Defective and Locally Affect Membrane Binding. |
| Q36736658 | Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain |
| Q54944407 | Alpha-Synuclein Expression in Acute Erythroleukaemia, Acute Megakaryoblastic Leukemia, and Normal Counterparts in Bone Marrow. |
| Q36976868 | Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective |
| Q35734100 | Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an In Vitro and In Vivo Study Using Rodent and Human Models |
| Q46687858 | Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells. |
| Q52373049 | Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. |
| Q57821667 | Alpha-Synuclein Modulates the Physical Properties of DNA |
| Q41115824 | Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease |
| Q28067429 | Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders |
| Q64093651 | Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson's Disease |
| Q35855302 | Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients |
| Q35782721 | Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. |
| Q36131340 | Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant |
| Q64254226 | Alpha-Synuclein RNA Expression is Increased in Major Depression |
| Q40630390 | Alpha-Synuclein Regulates Neuronal Levels of Manganese and Calcium. |
| Q38405829 | Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3β/β-Catenin Signaling Pathway |
| Q58109329 | Alpha-Synuclein Toxicity on Protein Quality Control, Mitochondria and Endoplasmic Reticulum |
| Q36293826 | Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. |
| Q48704701 | Alpha-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level. |
| Q60907697 | Alpha-Synuclein and Calpains Disrupt SNARE-Mediated Synaptic Vesicle Fusion During Manganese Exposure in SH-SY5Y Cells |
| Q38759482 | Alpha-Synuclein as a Biomarker for Parkinson's Disease |
| Q41875033 | Alpha-Synuclein conformation affects its tyrosine-dependent oxidative aggregation |
| Q33552220 | Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models |
| Q28079911 | Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application |
| Q46572025 | Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models. |
| Q40060108 | Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection |
| Q47359464 | Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease |
| Q38955003 | Alpha-Synuclein, a Novel Viral Restriction Factor Hiding in Plain Sight |
| Q55152170 | Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. |
| Q40961889 | Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury |
| Q46487168 | Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice |
| Q54159456 | Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients. |
| Q60699184 | Alpha-synuclein Aggregates in Labial Salivary Glands of Idiopathic Rapid Eye Movement Sleep Behavior Disorder |
| Q37307515 | Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. |
| Q42455430 | Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease |
| Q26776209 | Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease |
| Q48125043 | Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. |
| Q48192079 | Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy |
| Q48148615 | Alpha-synuclein accumulates in the brain of scrapie-affected sheep and goats |
| Q57188685 | Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies |
| Q38743844 | Alpha-synuclein activates BV2 microglia dependent on its aggregation state |
| Q38485003 | Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. |
| Q40197055 | Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia |
| Q40395753 | Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells |
| Q24301946 | Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity |
| Q48334596 | Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. |
| Q51732455 | Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. |
| Q39286106 | Alpha-synuclein aggregates are excluded from calbindin-D28k-positive neurons in dementia with Lewy bodies and a unilateral rotenone mouse model |
| Q45719963 | Alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonism |
| Q35795187 | Alpha-synuclein aggregation |
| Q39601884 | Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice |
| Q39885727 | Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. |
| Q44632120 | Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation |
| Q48957199 | Alpha-synuclein aggregation and its relation to neurodegenerative diseases. |
| Q36295349 | Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy |
| Q34714740 | Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse |
| Q36043181 | Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway |
| Q39670506 | Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells |
| Q33394862 | Alpha-synuclein aggregation variable temperature and variable pH kinetic data: a re-analysis using the Finke-Watzky 2-step model of nucleation and autocatalytic growth |
| Q47338096 | Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease |
| Q37152191 | Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. |
| Q50300614 | Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders. |
| Q54660240 | Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. |
| Q34160107 | Alpha-synuclein and Parkinson's disease |
| Q56637598 | Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients |
| Q37157838 | Alpha-synuclein and Parkinson's disease: a proteomic view |
| Q40880804 | Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo |
| Q37201150 | Alpha-synuclein and autophagy as common steps in neurodegeneration. |
| Q38912045 | Alpha-synuclein and beta-amyloid - different targets, same players: calcium, free radicals and mitochondria in the mechanism of neurodegeneration |
| Q54629108 | Alpha-synuclein and chaperones in dementia with Lewy bodies. |
| Q34426172 | Alpha-synuclein and dopamine metabolism |
| Q36095686 | Alpha-synuclein and familial Parkinson's disease |
| Q59133525 | Alpha-synuclein and familial variants affect the chain order and the thermotropic phase behavior of anionic lipid vesicles |
| Q57780022 | Alpha-synuclein and heroin craving in opiate-dependent patients on injectable heroin maintenance |
| Q38101508 | Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. |
| Q39123736 | Alpha-synuclein and iron: two keys unlocking Parkinson's disease. |
| Q40225441 | Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells |
| Q48613176 | Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. |
| Q36912974 | Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease |
| Q28204386 | Alpha-synuclein and neurodegenerative diseases |
| Q45271574 | Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains |
| Q24311523 | Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling |
| Q34995107 | Alpha-synuclein and presynaptic function: implications for Parkinson's disease. |
| Q43581306 | Alpha-synuclein and protein degradation pathways in Parkinson's disease: a pathological feed-back loop |
| Q28250508 | Alpha-synuclein and tau: teammates in neurodegeneration? |
| Q34318165 | Alpha-synuclein and the Lewy body disorders |
| Q40882515 | Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells |
| Q35795168 | Alpha-synuclein and the pathogenesis of Parkinson's disease |
| Q35913206 | Alpha-synuclein and transgenic mouse models |
| Q48288215 | Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity. |
| Q41775688 | Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease |
| Q37347368 | Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders |
| Q38923669 | Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications. |
| Q48912140 | Alpha-synuclein binding to rab3a in multiple system atrophy. |
| Q39575705 | Alpha-synuclein binds large unilamellar vesicles as an extended helix |
| Q27003541 | Alpha-synuclein biology in Lewy body diseases |
| Q24683059 | Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models |
| Q34541894 | Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles |
| Q27300819 | Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo |
| Q42368640 | Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway |
| Q28587785 | Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration |
| Q46822020 | Alpha-synuclein decreases arachidonic acid incorporation into rat striatal synaptoneurosomes |
| Q48353353 | Alpha-synuclein deficiency affects brain Foxp1 expression and ultrasonic vocalization. |
| Q48419739 | Alpha-synuclein deficiency in the C57BL/6JOlaHsd strain does not modify disease progression in the ME7-model of prion disease. |
| Q34534524 | Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress |
| Q42014854 | Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy |
| Q28202726 | Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies |
| Q33881676 | Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs |
| Q46949239 | Alpha-synuclein deletion decreases motor impulsivity but does not affect risky decision making in a mouse Gambling Task. |
| Q57130569 | Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function |
| Q46263072 | Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease |
| Q33670439 | Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans |
| Q39249815 | Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway |
| Q48377681 | Alpha-synuclein enhances dopamine D2 receptor signaling. |
| Q40627414 | Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone |
| Q55475570 | Alpha-synuclein expression in central nervous system tumors showing neuronal or mixed neuronal/glial differentiation. |
| Q48198986 | Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease |
| Q42470645 | Alpha-synuclein expression in the developing human brain |
| Q46066734 | Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates |
| Q40789949 | Alpha-synuclein expression is up-regulated in NTera2 cells during neuronal differentiation but unaffected by exposure to cytokines and neurotrophic factors |
| Q48220095 | Alpha-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells |
| Q28506842 | Alpha-synuclein expression modulates microglial activation phenotype |
| Q37075769 | Alpha-synuclein expression patterns in the colonic submucosal plexus of the aging Fischer 344 rat: implications for biopsies in aging and neurodegenerative disorders? |
| Q47166653 | Alpha-synuclein facilitates to form short unconventional microtubules that have a unique function in the axonal transport |
| Q47948873 | Alpha-synuclein ferrireductase activity is detectible in vivo, is altered in Parkinson's disease and increases the neurotoxicity of DOPAL. |
| Q58596800 | Alpha-synuclein fibrils recruit TBK1 and OPTN to lysosomal damage sites and induce autophagy in microglial cells |
| Q34774324 | Alpha-synuclein function and dysfunction on cellular membranes |
| Q39508265 | Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase |
| Q35155985 | Alpha-synuclein functions in the nucleus to protect against hydroxyurea-induced replication stress in yeast |
| Q48299443 | Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. |
| Q28510469 | Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding |
| Q50929178 | Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. |
| Q46583182 | Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms |
| Q48904980 | Alpha-synuclein gene variants may predict neurostimulation outcome. |
| Q47930930 | Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study |
| Q34095384 | Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. |
| Q51594209 | Alpha-synuclein has structural and functional similarities to small heat shock proteins. |
| Q57306387 | Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease |
| Q33583061 | Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease |
| Q37386416 | Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. |
| Q48423040 | Alpha-synuclein immunoreactivity and ultrastructural study of glial cytoplasmic inclusions in multiple system atrophy. |
| Q47772222 | Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy |
| Q48105146 | Alpha-synuclein immunoreactivity in neuronal nuclear inclusions and neurites in multiple system atrophy |
| Q28565132 | Alpha-synuclein immunoreactivity in normal and neoplastic Schwann cells |
| Q45300814 | Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models |
| Q50440791 | Alpha-synuclein immunoreactivity patterns in the enteric nervous system. |
| Q39358210 | Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease |
| Q48183703 | Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma |
| Q27860680 | Alpha-synuclein in Lewy bodies |
| Q33750063 | Alpha-synuclein in Lewy body disease and Alzheimer's disease |
| Q30361158 | Alpha-synuclein in Parkinson's disease |
| Q38618665 | Alpha-synuclein in alpha-helical conformation at air-water interface: implication of conformation and orientation changes during its accumulation/aggregation |
| Q47437722 | Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication |
| Q49037483 | Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. |
| Q38797659 | Alpha-synuclein in cutaneous small nerve fibers |
| Q53349523 | Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. |
| Q38930110 | Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker |
| Q35597277 | Alpha-synuclein in motor neuron disease: an immunohistologic study. |
| Q35139572 | Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review |
| Q54419869 | Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. |
| Q28569567 | Alpha-synuclein in the nucleus accumbens induces changes in cocaine behaviour in rats |
| Q39679022 | Alpha-synuclein induced cell death in mouse hippocampal (HT22) cells is mediated by nitric oxide-dependent activation of caspase-3. |
| Q48274235 | Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease |
| Q28590194 | Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism |
| Q27323098 | Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis |
| Q46003762 | Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP. |
| Q47605875 | Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons |
| Q49922714 | Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson's disease. |
| Q28578806 | Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells |
| Q43265252 | Alpha-synuclein inhibits poly (ADP-ribose) polymerase-1 (PARP-1) activity via NO-dependent pathway. |
| Q46437539 | Alpha-synuclein inoculation initiates a neurodegenerative cascade in nontransgenic mice |
| Q35150090 | Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases |
| Q38444535 | Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine β-hydroxylase and is associated with abnormal adaptive responses to immobilization stress |
| Q28591581 | Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII |
| Q33798034 | Alpha-synuclein is a cellular ferrireductase |
| Q48221384 | Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy. |
| Q38884087 | Alpha-synuclein is associated with the synaptic vesicle apparatus in the human and rat enteric nervous system |
| Q48008805 | Alpha-synuclein is expressed in different tissues during human fetal development |
| Q46181063 | Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. |
| Q49019912 | Alpha-synuclein is not a requisite component of synaptic boutons in the adult human central nervous system. |
| Q27934988 | Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity |
| Q51314524 | Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. |
| Q39818363 | Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells |
| Q48835204 | Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). |
| Q53369663 | Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). |
| Q35284843 | Alpha-synuclein levels in blood plasma decline with healthy aging |
| Q47754301 | Alpha-synuclein levels in patients with multiple system atrophy: a meta-analysis |
| Q30153436 | Alpha-synuclein lipid-dependent membrane binding and translocation through the α-hemolysin channel |
| Q29614762 | Alpha-synuclein locus duplication as a cause of familial Parkinson's disease |
| Q41934208 | Alpha-synuclein loss in spinal muscular atrophy |
| Q40694627 | Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease |
| Q34548507 | Alpha-synuclein mRNA expression in oligodendrocytes in MSA. |
| Q46361148 | Alpha-synuclein mRNA levels correspond to beck depression inventory scores in females with eating disorders |
| Q36139579 | Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study |
| Q39692786 | Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability |
| Q37294354 | Alpha-synuclein misfolding and neurodegenerative diseases |
| Q45016370 | Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease |
| Q38890512 | Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. |
| Q38873771 | Alpha-synuclein modulates dopamine neurotransmission. |
| Q38762283 | Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease. |
| Q57983230 | Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus? |
| Q46459763 | Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation |
| Q34159183 | Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease. |
| Q53214786 | Alpha-synuclein negatively regulates Notch1 intracellular domain protein stability through promoting interaction with Fbw7. |
| Q43095357 | Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease |
| Q46243605 | Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes |
| Q42705840 | Alpha-synuclein oligomerization in manganese-induced nerve cell injury in brain slices: a role of NO-mediated S-nitrosylation of protein disulfide isomerase |
| Q57982348 | Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study |
| Q49845923 | Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. |
| Q46321755 | Alpha-synuclein oligomers: a new hope. |
| Q39848404 | Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells |
| Q40418370 | Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death |
| Q57821109 | Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson's disease |
| Q33545484 | Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells |
| Q39135730 | Alpha-synuclein overexpression increases phospho-protein phosphatase 2A levels via formation of calmodulin/Src complex |
| Q50988517 | Alpha-synuclein overexpression induced mitochondrial damage by the generation of endogenous neurotoxins in PC12 cells. |
| Q45154622 | Alpha-synuclein overexpression model. |
| Q38894507 | Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling |
| Q41920050 | Alpha-synuclein overexpression promotes aggregation of mutant huntingtin |
| Q40163413 | Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells |
| Q34330786 | Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. |
| Q48370522 | Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. |
| Q48771705 | Alpha-synuclein pathology and Parkinsonism associated with POLG1 mutations and multiple mitochondrial DNA deletions. |
| Q36554589 | Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease |
| Q33340612 | Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia |
| Q47779956 | Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study |
| Q48144998 | Alpha-synuclein pathology in the olfactory pathways of dementia patients |
| Q42493232 | Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals |
| Q53243970 | Alpha-synuclein pathology is highly dependent on the case selection. |
| Q48566508 | Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. |
| Q46440747 | Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease |
| Q40412045 | Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. |
| Q57983231 | Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population |
| Q35065209 | Alpha-synuclein populates both elongated and broken helix states on small unilamellar vesicles |
| Q57824025 | Alpha-synuclein pore forming activity upon membrane association |
| Q37388974 | Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies |
| Q42320467 | Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress |
| Q62780803 | Alpha-synuclein promoter haplotypes and dementia in Parkinson's Disease |
| Q24629968 | Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro |
| Q48147544 | Alpha-synuclein promotes early neurite outgrowth in cultured primary neurons |
| Q38582573 | Alpha-synuclein propagation: New insights from animal models |
| Q28582019 | Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death |
| Q44478511 | Alpha-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity |
| Q43568141 | Alpha-synuclein protein is not scavenged in neuronal loss induced by kainic acid or focal ischemia |
| Q46493884 | Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving |
| Q30856480 | Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. |
| Q40704930 | Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway |
| Q34231155 | Alpha-synuclein repeat variants and survival in Parkinson's disease |
| Q52921597 | Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains. |
| Q34685028 | Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases |
| Q28580852 | Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis |
| Q33557077 | Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA. |
| Q28082548 | Alpha-synuclein spreading in Parkinson's disease |
| Q57068655 | Alpha-synuclein staining in non-neural structures of the gastrointestinal tract is non-specific in Parkinson disease |
| Q42412086 | Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection |
| Q28075526 | Alpha-synuclein structure, functions, and interactions |
| Q34548154 | Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers |
| Q37692773 | Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease |
| Q45950766 | Alpha-synuclein structures probed by 5-fluorotryptophan fluorescence and 19F NMR spectroscopy. |
| Q48499657 | Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. |
| Q33658913 | Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra |
| Q34573229 | Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast |
| Q36844186 | Alpha-synuclein tertiary contact dynamics |
| Q48372074 | Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. |
| Q35079415 | Alpha-synuclein transfers from neurons to oligodendrocytes |
| Q52626698 | Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. |
| Q48358304 | Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. |
| Q49045276 | Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro. |
| Q53770042 | Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder? |
| Q40642550 | Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease |
| Q40595894 | Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide |
| Q42617687 | Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. |
| Q35911698 | Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease |
| Q35054427 | Alpha-synuclein, Abeta and Alzheimer's disease |
| Q34316503 | Alpha-synuclein, Parkinson's disease, and Alzheimer's disease |
| Q34670663 | Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study |
| Q47676959 | Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management |
| Q39632694 | Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils |
| Q37767943 | Alpha-synuclein, lipids and Parkinson's disease |
| Q47348189 | Alpha-synuclein, proteotoxicity and Parkinson's disease: Search for neuroprotective therapy |
| Q38829333 | Alpha-synuclein-based models of Parkinson's disease |
| Q43664472 | Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons |
| Q45940253 | Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. |
| Q37020862 | Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? |
| Q53342727 | Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. |
| Q30481396 | Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae |
| Q42205441 | Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice |
| Q38757787 | Alpha-synuclein-induced oxidative stress correlates with altered superoxide dismutase and glutathione synthesis in human neuroblastoma SH-SY5Y cells |
| Q48290275 | Alpha-synuclein-positive structures in association with diffuse neurofibrillary tangles with calcification |
| Q49097736 | Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. |
| Q28570595 | Alpha-synuclein-positive structures induced in leupeptin-infused rats |
| Q39235649 | Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease |
| Q34230416 | Alpha-synuclein: between synaptic function and dysfunction |
| Q38028819 | Alpha-synuclein: from secretion to dysfunction and death |
| Q35148669 | Alpha-synuclein: its biological function and role in neurodegenerative diseases |
| Q35749928 | Alpha-synuclein: normal function and role in neurodegenerative diseases. |
| Q45015107 | Alpha-synuclein: one key opens many locks |
| Q38728563 | Alpha-synuclein: relating metals to structure, function and inhibition |
| Q46560479 | Alpha-synuclein: stable compact and extended monomeric structures and pH dependence of dimer formation |
| Q42347600 | AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson's disease diagnosis |
| Q33198539 | Alteration in alpha-synuclein mRNA expression in Parkinson's disease |
| Q38773110 | Alteration of Structure and Aggregation of a-Synuclein by Familial Parkinson's Disease Associated Mutations. |
| Q37420985 | Alteration of dynein function affects α-synuclein degradation via the autophagosome-lysosome pathway |
| Q41905102 | Alteration of the alpha-synuclein folding landscape by a mutation related to Parkinson's disease |
| Q37161459 | Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein |
| Q48581414 | Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. |
| Q50976184 | Altered CSF orexin and α-synuclein levels in dementia patients. |
| Q28591852 | Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies |
| Q47583560 | Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human α-Synuclein: Comparison with Dopaminergic and Serotonergic Denervation |
| Q28256424 | Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin |
| Q34093055 | Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease |
| Q42647427 | Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides. |
| Q36336723 | Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease. |
| Q34760606 | Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| Q42437390 | Altered short-term hippocampal synaptic plasticity in mutant alpha-synuclein transgenic mice |
| Q52147948 | Altered α-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains. |
| Q47839926 | Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies. |
| Q36356015 | Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform |
| Q36862730 | Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology |
| Q57830133 | Alzheimer's disease and alpha-synuclein pathology in the olfactory bulbs of infants, children, teens and adults ≤ 40 years in Metropolitan Mexico City. APOE4 carriers at higher risk of suicide accelerate their olfactory bulb pathology |
| Q37462136 | Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice |
| Q64269362 | Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease |
| Q33337367 | Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle |
| Q48624696 | Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. |
| Q33646206 | Amplification of distinct α-synuclein fibril conformers through protein misfolding cyclic amplification. |
| Q38797714 | Amygdala α-Synuclein Pathology in the Population-Based Vantaa 85+ Study. |
| Q46703068 | Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases |
| Q42923540 | Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR) |
| Q37376532 | Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases |
| Q34148953 | Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. |
| Q36787715 | Amyloid-β and α-Synuclein Decrease the Level of Metal-Catalyzed Reactive Oxygen Species by Radical Scavenging and Redox Silencing |
| Q50587098 | Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. |
| Q38823780 | Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling and contributes to α-synuclein-induced cytotoxicity |
| Q36907399 | Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice |
| Q41142736 | Amyloids of alpha-synuclein affect the structure and dynamics of supported lipid bilayers. |
| Q37053806 | An Efficient Procedure for Removal and Inactivation of Alpha-Synuclein Assemblies from Laboratory Materials |
| Q57489791 | An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease1 |
| Q38961774 | An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics |
| Q47941297 | An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression |
| Q48308434 | An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation |
| Q43865449 | An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model |
| Q38405069 | An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology |
| Q42291075 | An enhanced recombinant amino-terminal acetylation system and novel in vivo high-throughput screen for molecules affecting α-synuclein oligomerisation. |
| Q42143433 | An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer |
| Q38039084 | An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain |
| Q51122403 | An extract of the marine alga Alaria esculenta modulates α-synuclein folding and amyloid formation. |
| Q42524820 | An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. |
| Q48468237 | An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker. |
| Q33317678 | An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity |
| Q47764323 | An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice |
| Q41874717 | An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons |
| Q35164411 | An α-synuclein gene (SNCA) polymorphism moderates the association of PTSD symptomatology with hazardous alcohol use, but not with aggression-related measures. |
| Q34310903 | Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations. |
| Q45416148 | Analysis of a single α-synuclein fibrillation by the interaction with a protein nanopore |
| Q34379982 | Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay |
| Q48319369 | Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra |
| Q49247066 | Analysis of alpha-synuclein, parkin, tau, and UCH-L1 in a Japanese family with autosomal dominant parkinsonism. |
| Q44964546 | Analysis of alpha-synuclein-associated proteins by quantitative proteomics |
| Q48891280 | Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation. |
| Q35728813 | Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons |
| Q24298693 | Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay |
| Q43827127 | Analysis of the coding and the 5' flanking regions of the alpha-synuclein gene in patients with Parkinson's disease. |
| Q48787937 | Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. |
| Q61449885 | Analysis of α-Synuclein Pathology in PINK1 Knockout Rat Brains |
| Q40075301 | Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro |
| Q60546105 | Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy |
| Q28505185 | Ankyrin repeat and BTB/POZ domain containing protein-2 inhibits the aggregation of alpha-synuclein: implications for Parkinson's disease |
| Q48152305 | Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates. |
| Q36003878 | Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis |
| Q48521558 | Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. |
| Q44959859 | Annular alpha-synuclein species from purified multiple system atrophy inclusions. |
| Q48484091 | Antemortem detection of colonic α-synuclein pathology in a patient with pure autonomic failure. |
| Q46087126 | Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro |
| Q39006845 | Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA) |
| Q48227923 | Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro |
| Q35058359 | Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease |
| Q47953864 | Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates |
| Q37586721 | Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy |
| Q28254530 | Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity |
| Q28743313 | Antibodies against alpha-synuclein reduce oligomerization in living cells |
| Q51317458 | Antibodies against the C-terminus of α-synuclein modulate its fibrillation. |
| Q48266946 | Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease |
| Q37117527 | Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission |
| Q28395248 | Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy |
| Q46980744 | Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro |
| Q40542041 | Apocyanin, NADPH oxidase inhibitor prevents lipopolysaccharide induced α-synuclein aggregation and ameliorates motor function deficits in rats: Possible role of biochemical and inflammatory alterations |
| Q34717871 | Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice |
| Q36501660 | Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance |
| Q39967250 | Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients |
| Q38113037 | Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease |
| Q39348525 | Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein |
| Q55307741 | Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools. |
| Q52549323 | Are tau and alpha synuclein filamentous inclusions in neurons and glia analogous to accumulation of myosin/actin filaments in myofiber hypertrophy? |
| Q48280288 | Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein |
| Q48186447 | Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease. |
| Q37821550 | Assays for α-synuclein aggregation |
| Q46784550 | Assembly of alpha-synuclein fibrils in nanoscale studied by peptide truncation and AFM. |
| Q40010392 | Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. |
| Q30539260 | Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. |
| Q40061455 | Assessment of brain metabolite correlates of adeno-associated virus-mediated over-expression of human alpha-synuclein in cortical neurons by in vivo (1) H-MR spectroscopy at 9.4 T. |
| Q59690255 | Assessment of α-Synuclein Pathology: A Study of the BrainNet Europe Consortium |
| Q47871750 | Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. |
| Q28479033 | Assessment of α-synuclein secretion in mouse and human brain parenchyma |
| Q34295323 | Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. |
| Q44737169 | Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication |
| Q63869268 | Association of Alcohol Craving With ?-Synuclein (SNCA) |
| Q36504239 | Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease |
| Q46158259 | Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions. |
| Q60637415 | Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers |
| Q33666297 | Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease |
| Q54244837 | Association of polymorphism in rs2736990 of the α-synuclein gene with Parkinson's disease in a Chinese population. |
| Q46283192 | Astragaloside IV attenuates the H2O2-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via the p38 MAPK pathway |
| Q36517148 | Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model |
| Q30494594 | Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. |
| Q30481562 | At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation |
| Q40916287 | Atomic force microscopy based nanoassay: a new method to study α-Synuclein-dopamine bioaffinity interactions |
| Q58007462 | Atomic-resolution structure of alpha-synuclein fibrils |
| Q36787223 | Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits |
| Q34187960 | Attenuation of dopamine transporter activity by alpha-synuclein |
| Q35538563 | Attenuation of the early events of α-synuclein aggregation: a fluorescence correlation spectroscopy and laser scanning microscopy study in the presence of surface-coated Fe3O4 nanoparticles. |
| Q24323344 | Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein |
| Q48183448 | Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with α-synuclein. |
| Q35894586 | Atypical parkinsonism combining alpha-synuclein inclusions and polyglucosan body disease |
| Q41525124 | Au nanostructured surfaces for electrochemical and localized surface plasmon resonance-based monitoring of α-synuclein-small molecule interactions |
| Q30981327 | Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease |
| Q39441767 | Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. |
| Q48525995 | Author Correction: Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease. |
| Q57032362 | Author Correction: The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress α-synuclein aggregation |
| Q52659686 | Author response: A new potential biomarker for dementia with Lewy bodies: Skin nerve α-synuclein deposits. |
| Q35159805 | Autoantibodies to alpha-synuclein in inherited Parkinson's disease. |
| Q40681738 | Autoimmune encephalomyelitis and uveitis induced by T cell immunity to self beta-synuclein |
| Q39888001 | Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, beta-synuclein |
| Q64104737 | Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells |
| Q33640037 | Autonomic dysfunction and plasticity in micturition reflexes in human α-synuclein mice |
| Q36907208 | Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein. |
| Q38712646 | Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies |
| Q30840562 | Autophagy down regulates pro-inflammatory mediators in BV2 microglial cells and rescues both LPS and alpha-synuclein induced neuronal cell death. |
| Q47126958 | Autophagy enhancement is rendered ineffective in presence of α-synuclein in melanoma cells |
| Q45990397 | Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. |
| Q35853020 | Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment |
| Q39745945 | Autophagy protects the rotenone-induced cell death in alpha-synuclein overexpressing SH-SY5Y cells |
| Q60907590 | Autophagy-lysosome pathway alterations and alpha-synuclein up-regulation in the subtype of neuronal ceroid lipofuscinosis, CLN5 disease |
| Q24632795 | Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry |
| Q58568770 | Autopsied centenarian case of Alzheimer's disease combined with hippocampal sclerosis, TDP-43, and α-synuclein pathologies |
| Q48389467 | Autosomal dominant Parkinson's disease and alpha-synuclein. |
| Q47621759 | Autosomal dominant parkinsonism associated with variable synuclein and tau pathology |
| Q30577415 | Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity |
| Q36677512 | Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein |
| Q46851020 | Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease |
| Q36680329 | Axonal transport and secretion of fibrillar forms of α-synuclein, Aβ42 peptide and HTTExon 1 |
| Q54965145 | Axonal transport of human α-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations |
| Q36658992 | Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein |
| Q54964999 | Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases |
| Q47577647 | Aβ exacerbates α-synuclein-induced neurotoxicity through impaired insulin signaling in α-synuclein-overexpressed human SK-N-MC neuronal cells. |
| Q43234936 | B1 is involved in autophagy inhibition caused by SNCA/a-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. |
| Q40562508 | BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line |
| Q42703916 | Backbone assignment and dynamics of human α-synuclein in viscous 2 M glucose solution |
| Q35806485 | Bacterial Chaperones CsgE and CsgC Differentially Modulate Human α-Synuclein Amyloid Formation via Transient Contacts |
| Q33577056 | Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein |
| Q30421397 | Bacterial in-cell NMR of human α-synuclein: a disordered monomer by nature? |
| Q48039285 | Baicalein attenuates α-synuclein aggregation, inflammasome activation and autophagy in the MPP+-treated nigrostriatal dopaminergic system in vivo |
| Q48212439 | Baicalein blocks α-synuclein secretion from SN4741 cells and facilitates α-synuclein polymerization to big complex |
| Q44582977 | Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation |
| Q57104189 | Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease |
| Q34020622 | Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. |
| Q57804932 | Baseline concentration of misfolded α-synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease |
| Q30356412 | Bcl-2 homologue Debcl enhances α-synuclein-induced phenotypes in Drosophila. |
| Q33613123 | Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases |
| Q43025000 | Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells |
| Q37151427 | Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson's disease alpha-synuclein transgenic mice |
| Q51545497 | Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field. |
| Q34991077 | Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression |
| Q43992501 | Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice |
| Q35025876 | Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein |
| Q46197584 | Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of L-DOPA. |
| Q41755041 | Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein |
| Q36373170 | Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. |
| Q43839209 | Besides fibrillization: putative role of the peptide fragment 71-82 on the structural and assembly behavior of α-synuclein |
| Q50199812 | Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. |
| Q34743196 | Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients |
| Q38738726 | Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression |
| Q34214842 | Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease |
| Q45097964 | Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein |
| Q24684579 | Beta-synuclein gene alterations in dementia with Lewy bodies |
| Q35994987 | Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study |
| Q34564479 | Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression |
| Q39407567 | Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein |
| Q54427859 | Beta-synuclein protein from Xenopus laevis: overexpression in Escherichia coli of the GST-tagged protein and production of polyclonal antibodies. |
| Q34306521 | Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease |
| Q37252444 | Beyond the SNARE: Munc18-1 chaperones α-synuclein |
| Q34232288 | Beyond α-synuclein transfer: pathology propagation in Parkinson's disease |
| Q64242757 | Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity |
| Q41875310 | Bicarbonate enhances alpha-synuclein oligomerization and nitration: intermediacy of carbonate radical anion and nitrogen dioxide radical |
| Q56342045 | Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons |
| Q36185625 | Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ |
| Q48392786 | Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment. |
| Q43152620 | Binding Interactions of Agents That Alter α-Synuclein Aggregation |
| Q24530132 | Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC |
| Q45202255 | Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease |
| Q37083478 | Binding of Dopamine to Alpha-Synuclein is Mediated by Specific Conformational States |
| Q46925606 | Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles |
| Q48384247 | Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. |
| Q50058597 | Binding of alpha-synuclein to partially oxidized glyceraldehyde-3-phosphate dehydrogenase induces subsequent inactivation of the enzyme. |
| Q33665421 | Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. |
| Q48459760 | Binding of the PET radiotracer [¹⁸F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice. |
| Q34584062 | Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent |
| Q46943733 | Bioactivity profiling with parallel mass spectrometry reveals an assemblage of green tea metabolites affording protection against human huntingtin and alpha-synuclein toxicity |
| Q48338222 | Biochemical analysis of α-synuclein extracted from control and Parkinson's disease colonic biopsies. |
| Q34769745 | Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background |
| Q30827075 | Biochemical characterization of the core structure of alpha-synuclein filaments |
| Q35593764 | Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies |
| Q38618629 | Bioinorganic Chemistry of Parkinson's Disease: Affinity and Structural Features of Cu(I) Binding to the Full-Length β-Synuclein Protein. |
| Q57278510 | Bioinorganic Chemistry of Parkinson’s Disease: Structural Determinants for the Copper-Mediated Amyloid Formation of Alpha-Synuclein |
| Q58484303 | Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson's disease |
| Q50696857 | Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils. |
| Q39871699 | Biophysical Characterization of α-Synuclein and Rotenone Interaction |
| Q26828504 | Biophysical characterization of α-synuclein and its controversial structure |
| Q38180144 | Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity |
| Q39318340 | Biophysical properties and cellular toxicity of covalent crosslinked oligomers of α-synuclein formed by photoinduced side-chain tyrosyl radicals |
| Q34111411 | Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins |
| Q33470625 | Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein |
| Q35732516 | Biophysics of α-synuclein induced membrane remodelling |
| Q30405705 | Biophysics of α-synuclein membrane interactions. |
| Q47722212 | Biotemplated synthesis of metallic nanoparticle chains on an alpha-synuclein fiber scaffold |
| Q34660600 | Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils. |
| Q39570119 | Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of α-synuclein in a cellular model of Parkinson's disease |
| Q64085132 | Blocking meningeal lymphatic drainage aggravates Parkinson's disease-like pathology in mice overexpressing mutated α-synuclein |
| Q37443736 | Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity. |
| Q23922069 | Blood alpha-synuclein in agricultural pesticide handlers in central Washington State |
| Q38925423 | Bone loss in C57BL/6J-OlaHsd mice, a substrain of C57BL/6J carrying mutated alpha-synuclein and multimerin-1 genes |
| Q50479107 | Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. |
| Q40964871 | Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation |
| Q43244813 | Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation |
| Q33997655 | Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease |
| Q46341817 | Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice. |
| Q48550878 | Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. |
| Q28513350 | Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice |
| Q41007816 | Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. |
| Q36507462 | Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia |
| Q52149583 | Brain region-dependent differential expression of alpha-synuclein. |
| Q48473253 | Brain reward in the absence of alpha-synuclein. |
| Q38700710 | Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology |
| Q33714875 | Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity |
| Q39067303 | Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections. |
| Q33411281 | Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity |
| Q43584713 | Broken helix in vesicle and micelle-bound alpha-synuclein: insights from site-directed spin labeling-EPR experiments and MD simulations. |
| Q58618532 | C-Terminal Cu Coordination to α-Synuclein Enhances Aggregation |
| Q44470865 | C-Terminal Truncated α-Synuclein Fibrils Contain Strongly Twisted β-Sheets. |
| Q27931024 | C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease. |
| Q33889124 | C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders |
| Q49829897 | C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction. |
| Q46741879 | C-terminal part of alpha-synuclein mediates its activity in promoting proliferation of dopaminergic cells |
| Q39589964 | C-terminal part of α-synuclein mediates its activity in promoting proliferation of dopaminergic cells |
| Q57043830 | C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease |
| Q57986252 | C-terminal truncation of α-synuclein promotes amyloid fibril amplification at physiological pH |
| Q28472271 | C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging |
| Q38699148 | CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein. |
| Q55546710 | CD4 T cells react to local increase of α-synuclein in a pathology-associated variant-dependent manner and modify brain microglia in absence of brain pathology. |
| Q39988391 | CHIP targets toxic alpha-Synuclein oligomers for degradation |
| Q35122963 | CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy |
| Q38694498 | CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons. |
| Q58765503 | CRISPR/Cas9-Mediated Generation of Guangxi Bama Minipigs Harboring Three Mutations in α-Synuclein Causing Parkinson's Disease |
| Q47432311 | CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. |
| Q35906655 | CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease |
| Q48176610 | CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies |
| Q63456912 | CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders |
| Q53417603 | CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias. |
| Q48837599 | CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans. |
| Q42905310 | CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease |
| Q37266166 | CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease |
| Q57814997 | CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients |
| Q43510499 | Ca(2+) modulating α-synuclein membrane transient interactions revealed by solution NMR spectroscopy |
| Q24291150 | Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization |
| Q36970424 | Ca2+ is a key factor in α-synuclein-induced neurotoxicity |
| Q53262782 | Ca2+-dependent intracellular drug delivery system developed with "raspberry-type" particles-on-a-particle comprising mesoporous silica core and α-synuclein-coated gold nanoparticles. |
| Q55050091 | Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. |
| Q34120215 | Calcineurin determines toxic versus beneficial responses to α-synuclein |
| Q38717826 | Calcipotriol inhibits α-synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism |
| Q36928454 | Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons |
| Q36527246 | Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain |
| Q46168709 | Calcium-triggered membrane interaction of the alpha-synuclein acidic tail |
| Q39075636 | Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies |
| Q39826509 | Caloric restriction alleviates alpha-synuclein toxicity in aged yeast cells by controlling the opposite roles of Tor1 and Sir2 on autophagy |
| Q35757239 | Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation |
| Q51127346 | Calpain-resistant fragment(s) of alpha-synuclein regulates the synuclein-cleaving activity of 20S proteasome. |
| Q52624714 | Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease? |
| Q38556918 | Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease |
| Q61808028 | Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology |
| Q50495072 | Capillary microsampling and analysis of 4-µl blood, plasma and serum samples to determine human α-synuclein elimination rate in mice. |
| Q38904211 | Carbosilane dendrimers inhibit α-synuclein fibrillation and prevent cells from rotenone-induced damage. |
| Q54322842 | Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the α synuclein gene. |
| Q48212769 | Cardiac sympathetic denervation precedes nigrostriatal loss in the E46K mutation of the alpha-synuclein gene (SNCA). |
| Q50338475 | Cardiolipin exposure on the outer mitochondrial membrane modulates α-synuclein. |
| Q57983305 | Case-control study of the ?-synuclein interacting protein gene and Parkinson's disease |
| Q28188133 | Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation |
| Q37247475 | Caspase-1 clipping causes complications for α-synuclein |
| Q53668710 | Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. |
| Q36335146 | Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein. |
| Q37102231 | Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. |
| Q33360061 | Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species |
| Q37040842 | Caudo-rostral brain spreading of α-synuclein through vagal connections |
| Q35594818 | Caught in the act: alpha-synuclein is the culprit in Parkinson's disease |
| Q38334095 | Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression |
| Q41877125 | Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro |
| Q39097048 | Cell Biology and Pathophysiology of α-Synuclein |
| Q53481241 | Cell Models to Study Cell-to-Cell Transmission of α-Synuclein. |
| Q61817079 | Cell Responses to Extracellular α-Synuclein |
| Q44529077 | Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. |
| Q36440972 | Cell systems and the toxic mechanism(s) of alpha-synuclein |
| Q37347595 | Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival |
| Q46351241 | Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome |
| Q34989307 | Cell-specific post-transcriptional regulation of γ-synuclein gene by micro-RNAs |
| Q42426303 | Cell-to-cell transmission of α-synuclein aggregates |
| Q38787483 | Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors |
| Q33877643 | Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies |
| Q38694463 | Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type |
| Q59066979 | Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies |
| Q39318811 | Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease. |
| Q40085533 | Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence |
| Q44219245 | Cellular polyamines promote the aggregation of alpha-synuclein |
| Q52661615 | Cellular prion protein and γ-synuclein overexpression in LS 174T colorectal cancer cell drives endothelial proliferation-to-differentiation switch. |
| Q38827784 | Cellular response of human neuroblastoma cells to α-synuclein fibrils, the main constituent of Lewy bodies |
| Q37344106 | Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease |
| Q49113581 | Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. |
| Q58565535 | Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease |
| Q26744782 | Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease |
| Q57750814 | Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias |
| Q38247307 | Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. |
| Q46120183 | Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. |
| Q48819771 | Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? |
| Q34806122 | Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease |
| Q48408694 | Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro. |
| Q35151444 | Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease |
| Q53396870 | Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease. |
| Q45729318 | Cerebrospinal fluid α-synuclein levels in Parkinson's disease--changed or unchanged? |
| Q30405991 | Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort |
| Q50241761 | Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. |
| Q44445879 | Certain Metals Trigger Fibrillation of Methionine-oxidized α-Synuclein |
| Q35548840 | Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease |
| Q39297723 | Challenging drug target for Parkinson's disease: Pathological complex of the chameleon TPPP/p25 and alpha-synuclein proteins |
| Q51066366 | Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology. |
| Q38355849 | Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein |
| Q46844887 | Changes in interfacial properties of alpha-synuclein preceding its aggregation |
| Q48466817 | Changes in presynaptic protein NACP/alpha-synuclein in an ischemic gerbil hippocampus. |
| Q37038032 | Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains |
| Q46707144 | Changes in secondary structure of α-synuclein during oligomerization induced by reactive aldehydes |
| Q39420079 | Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression |
| Q51592951 | Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. |
| Q53324772 | Chaperome screening leads to identification of Grp94/Gp96 and FKBP4/52 as modulators of the α-synuclein-elicited immune response. |
| Q36642450 | Chaperone and anti-chaperone: two-faced synuclein as stimulator of synaptic evolution |
| Q24312452 | Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip |
| Q43874109 | Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease |
| Q51174254 | Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases. |
| Q33903337 | Chaperone-like activity of synucleins |
| Q36543702 | Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein |
| Q35285839 | Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype |
| Q53587661 | Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma. |
| Q33181095 | Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain |
| Q35975683 | Characterization of a disordered protein during micellation: interactions of α-synuclein with sodium dodecyl sulfate. |
| Q45308122 | Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast |
| Q46681949 | Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules |
| Q37148311 | Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions |
| Q27318127 | Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors |
| Q42002364 | Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. |
| Q43758292 | Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells |
| Q33323132 | Characterization of fibrillation process of alpha-synuclein at the initial stage |
| Q35709805 | Characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase early amyloid-like oligomers and their implication in α-synuclein aggregation. |
| Q37378632 | Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization |
| Q33515443 | Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding. |
| Q43256880 | Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein |
| Q35795019 | Characterization of kinases involved in the phosphorylation of aggregated α-synuclein |
| Q46072698 | Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein |
| Q45204526 | Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence |
| Q35054395 | Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease |
| Q36217340 | Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein |
| Q38511747 | Characterization of surface-confined alpha-synuclein by surface plasmon resonance measurements |
| Q34147962 | Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms. |
| Q46214263 | Characterization of the non-fibrillar α-synuclein oligomers |
| Q46870532 | Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice |
| Q44738578 | Characterization of three synuclein genes in Xenopus laevis. |
| Q28828388 | Characterization of α-Synuclein Multimer Stoichiometry in Complex Biological Samples by Electrophoresis |
| Q46579839 | Characterizing the dynamics of α-synuclein oligomers using hydrogen/deuterium exchange monitored by mass spectrometry |
| Q37380542 | Charge State Dependent Fragmentation of Gaseous α-Synuclein Cations via Ion Trap and Beam-Type Collisional Activation |
| Q42044982 | Charge neutralization and collapse of the C-terminal tail of alpha-synuclein at low pH. |
| Q30558189 | Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control |
| Q35939982 | Chemical induction of Hsp70 reduces α-synuclein aggregation in neuroglioma cells |
| Q28831283 | Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein |
| Q30968775 | Chicken synucleins: cloning and expression in the developing embryo. |
| Q46680864 | Cholesterol facilitates interactions between α-synuclein oligomers and charge-neutral membranes |
| Q46332709 | Chromatin-Bound Oxidized α-Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease |
| Q35000199 | Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice |
| Q34056025 | Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons |
| Q39175300 | Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. |
| Q47398688 | Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice |
| Q28538890 | Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss |
| Q40157240 | Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by downregulation of DNMT3B. |
| Q39980342 | Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. |
| Q30379490 | Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells. |
| Q44777524 | Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. |
| Q51732038 | Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease. |
| Q46504036 | Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. |
| Q46688857 | Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. |
| Q41917948 | Clinical Neuropathology image 5-2014: α-synuclein pathology in the ependyma in Parkinson's disease. |
| Q48647976 | Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. |
| Q42501526 | Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation |
| Q59544661 | Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr ?-synuclein mutation |
| Q44444456 | Clinical characteristics of the alpha‐synuclein mutation (G209A)‐associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece |
| Q35207288 | Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α-synuclein triplication (Iowa kindred). |
| Q54626622 | Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. |
| Q35462051 | Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease |
| Q44700598 | Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer |
| Q40415532 | Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice |
| Q30374521 | Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration |
| Q55472821 | Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies. |
| Q34093915 | Co-association of parkin and alpha-synuclein |
| Q42939567 | Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. |
| Q33942843 | Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. |
| Q37284871 | Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies |
| Q38355256 | Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines |
| Q46658702 | Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum |
| Q44396203 | Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. |
| Q27306687 | Cofilin 1 activation prevents the defects in axon elongation and guidance induced by extracellular alpha-synuclein |
| Q57977634 | Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease |
| Q34193835 | Colocalization of Tau and Alpha-Synuclein Epitopes in Lewy Bodies |
| Q63740278 | Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates |
| Q35106243 | Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease |
| Q37565960 | Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy |
| Q41078572 | Combinational losses of synucleins reveal their differential requirements for compensating age-dependent alterations in motor behavior and dopamine metabolism |
| Q47728261 | Combustion-derived nanoparticles, the neuroenteric system, cervical vagus, hyperphosphorylated alpha synuclein and tau in young Mexico City residents |
| Q44802793 | Commentary on "Alpha-synuclein and mitochondria: a tangled skein". |
| Q40279223 | Commentary: Parkinson's Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein |
| Q45936241 | Commentary: α-Synuclein Interacts with Lipoproteins in Plasma. |
| Q40422038 | Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells |
| Q46239099 | Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein |
| Q42517974 | Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein |
| Q36107686 | Common structural features of toxic intermediates from α-synuclein and GroES fibrillogenesis detected using cryogenic coherent X-ray diffraction imaging. |
| Q57267827 | Compact conformations of α-synuclein induced by alcohols and copper |
| Q40577758 | Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells |
| Q64266885 | Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils |
| Q39528832 | Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation |
| Q64057961 | Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease |
| Q48566458 | Comparative study of commercially available anti-alpha-synuclein antibodies. |
| Q41569621 | Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model |
| Q47356023 | Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid |
| Q48506843 | Comparison of alpha-synuclein immunoreactivity and protein levels in ischemic hippocampal CA1 region between adult and aged gerbils and correlation with Cu,Zn-superoxide dismutase. |
| Q36313225 | Comparison of alpha-synuclein immunoreactivity in the spinal cord between the adult and aged beagle dog. |
| Q36329972 | Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases. |
| Q28241852 | Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications |
| Q42517568 | Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains. |
| Q36523637 | Comparison of strategies for non-perturbing labeling of α-synuclein to study amyloidogenesis |
| Q46705919 | Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants |
| Q52804602 | Comparison of the 3D structures of mouse and human α-synuclein fibrils by solid-state NMR and STEM. |
| Q34186437 | Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease |
| Q47647268 | Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice |
| Q46312110 | Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors. |
| Q43483324 | Comparison of α-synuclein immunoreactivity in the hippocampus between the adult and aged beagle dogs |
| Q53286477 | Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. |
| Q36884715 | Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo |
| Q33761828 | Complex proteinopathy with accumulations of prion protein, hyperphosphorylated tau, α-synuclein and ubiquitin in experimental bovine spongiform encephalopathy of monkeys |
| Q47245456 | Complexation of NAC derived peptide ligands with C-terminus of α-synuclein accelerates its aggregation |
| Q42373287 | Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology |
| Q59794619 | Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein |
| Q60912226 | Computational insights into the role of α-strand/sheet in aggregation of α-synuclein |
| Q48058974 | Computational investigation on the effects of H50Q and G51D mutations on the α-Synuclein aggregation propensity |
| Q57470613 | Computational study on the role of γ-synuclein in inhibiting the α-synuclein aggregation |
| Q42022717 | Concentration dependence of alpha-synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory |
| Q37179687 | Concerted action of metals and macromolecular crowding on the fibrillation of alpha-synuclein |
| Q48550467 | Concomitant accumulation of α-synuclein and TDP-43 in a patient with corticobasal degeneration. |
| Q47901127 | Concomitant alpha-synuclein pathology in an autopsy case of amyotrophic lateral sclerosis presenting with orthostatic hypotension and cardiac arrests. |
| Q46396965 | Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies |
| Q31080866 | Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred |
| Q36158367 | Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1 |
| Q37294051 | Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons |
| Q38311234 | Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies |
| Q28476468 | Confocal fluorescence anisotropy and FRAP imaging of α-synuclein amyloid aggregates in living cells |
| Q53753076 | Conformation-Specific Detection of α-Synuclein: The Search for a Biomarker in Parkinson Disease. |
| Q33300201 | Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy |
| Q53142348 | Conformational Compatibility Is Essential for Heterologous Aggregation of α-Synuclein. |
| Q47119009 | Conformational Ensembles of α-Synuclein Derived Peptide with Different Osmolytes from Temperature Replica Exchange Sampling |
| Q44339521 | Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes |
| Q44214168 | Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. |
| Q41256282 | Conformational dynamics of α-synuclein: insights from mass spectrometry |
| Q56966078 | Conformational ensemble of human α-synuclein physiological form predicted by molecular simulations |
| Q64114775 | Conformational ensemble of native α-synuclein in solution as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations |
| Q21563559 | Conformational equilibria in monomeric alpha-synuclein at the single-molecule level |
| Q34325107 | Conformational heterogeneity of α-synuclein in membrane |
| Q43564642 | Conformational properties of alpha-synuclein in its free and lipid-associated states |
| Q41494001 | Conformational templating of α-synuclein aggregates in neuronal-glial cultures |
| Q57180136 | Conformational-switch based Strategy Triggered by [18] Heteroannulenes towards Reduction of Alpha Synuclein (α-Syn) Oligomer Toxicity |
| Q41906684 | Conserved C-terminal charge exerts a profound influence on the aggregation rate of α-synuclein |
| Q41845690 | Conserved core of amyloid fibrils of wild type and A30P mutant α-synuclein |
| Q34384948 | Considerations in the identification of endogenous substrates for protein L-isoaspartyl methyltransferase: the case of synuclein |
| Q61799114 | Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy |
| Q28141645 | Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein |
| Q36855866 | Constitutive translation of human α-synuclein is mediated by the 5'-untranslated region |
| Q40782770 | Construction of lentiviral vector of siRNA specific for γ-synuclein and its inhibition effect on colorectal carcinoma cell line SW1116 |
| Q53196220 | Contact between the β1 and β2 Segments of α-Synuclein that Inhibits Amyloid Formation. |
| Q36492845 | Contrasting effects of α-synuclein and γ-synuclein on the phenotype of cysteine string protein α (CSPα) null mutant mice suggest distinct function of these proteins in neuronal synapses. |
| Q41994729 | Contribution of Alanine-76 and Serine Phosphorylation in α-Synuclein Membrane Association and Aggregation in Yeasts |
| Q46027829 | Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells. |
| Q45938214 | Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. |
| Q37240113 | Controlling the mass action of alpha-synuclein in Parkinson's disease |
| Q35662291 | Convergence of Parkin, PINK1, and α-Synuclein on Stress-induced Mitochondrial Morphological Remodeling |
| Q35088093 | Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies |
| Q34049272 | Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease |
| Q33784044 | Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease |
| Q48370099 | Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity. |
| Q39774554 | Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron |
| Q42131522 | Conversion of natively unstructured α-synuclein to its α-helical conformation significantly attenuates production of reactive oxygen species |
| Q37134437 | Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. |
| Q35998743 | Coordination and redox properties of copper interaction with α-synuclein. |
| Q24293110 | Coordination features and affinity of the Cu²+ site in the α-synuclein protein of Parkinson's disease |
| Q36530499 | Coordination of copper to the membrane-bound form of α-synuclein |
| Q51575497 | Copper Binding and Subsequent Aggregation of α-Synuclein Are Modulated by N-Terminal Acetylation and Ablated by the H50Q Missense Mutation. |
| Q57982392 | Copper Coordination by Familial Mutants of Parkinson’s Disease-Associated α-Synuclein |
| Q39742060 | Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity |
| Q48194580 | Copper binding to the N-terminally acetylated, naturally occurring form of alpha-synuclein induces local helical folding |
| Q46538022 | Copper(I) Forms a Redox-Stable 1:2 Complex with α-Synuclein N-Terminal Peptide in a Membrane-Like Environment. |
| Q63434491 | Copper(I)-α-Synuclein Interaction: Structural Description of Two Independent and Competing Metal Binding Sites |
| Q35764236 | Copper(I/II), α/β-Synuclein and Amyloid-β: Menage à Trois? |
| Q48152661 | Copper(II) Binding Sites in N-Terminally Acetylated α-Synuclein: A Theoretical Rationalization |
| Q41906373 | Copper(II) and the pathological H50Q α-synuclein mutant: Environment meets genetics |
| Q37148963 | Copper(II) binding to alpha-synuclein, the Parkinson's protein |
| Q35385538 | Copper(II) enhances membrane-bound α-synuclein helix formation |
| Q42158800 | Copper(II)-induced self-oligomerization of alpha-synuclein. |
| Q57459956 | Copper- and iron-induced differential fibril formation in α-synuclein: TEM study |
| Q54986300 | Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. |
| Q58547275 | Correction to: N-Terminal Fusion Potentiates α-Synuclein Secretion |
| Q57452533 | Correction to: Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson's disease pathogenesis |
| Q63359417 | Correction to: The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity |
| Q46063291 | Correction: Alpha-Synuclein Is a Cellular Ferrireductase. |
| Q41356433 | Correction: Comparison of strategies for non-perturbing labeling of α-synuclein to study amyloidogenesis |
| Q46470256 | Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells. |
| Q49478102 | Correction: Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. |
| Q46180219 | Correction: Redistribution of DAT/α-Synuclein Complexes Visualized by “In Situ” Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. |
| Q46177460 | Correction: Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation. |
| Q60553058 | Correction: Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease |
| Q42366501 | Correction: The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease |
| Q58797935 | Correction: Ubiquitination of alpha-synuclein filaments by Nedd4 ligases |
| Q42552218 | Correction: shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity |
| Q38421118 | Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease. |
| Q34714560 | Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease |
| Q34667737 | Correlation of amyloid fibril beta-structure with the unfolded state of alpha-synuclein |
| Q49887142 | Corrigendum to "Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways" [Free Rad. Biol. Med. (2017) 421-431]. |
| Q53823672 | Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146]. |
| Q60777171 | Corrigendum to “Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases” [Neuroscience 242 (2013) 140–150] |
| Q43198799 | Corrigendum: Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth |
| Q49192552 | Corrigendum: Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. |
| Q42020227 | Corrigendum: Structural basis of synaptic vesicle assembly promoted by α-synuclein. |
| Q37062735 | Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease |
| Q39024437 | Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway |
| Q35800096 | Could a loss of alpha-synuclein function put dopaminergic neurons at risk? |
| Q60938765 | Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson's Disease and Diabetes as Well as Potential Therapies? |
| Q41876014 | Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion? |
| Q39089828 | Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level |
| Q30419579 | Counteracting chemical chaperone effects on the single-molecule α-synuclein structural landscape |
| Q39999661 | Coupling of the non-amyloid-component (NAC) domain and the KTK(E/Q)GV repeats stabilize the α-synuclein fibrils |
| Q34524912 | Covalent α-synuclein dimers: chemico-physical and aggregation properties |
| Q33760744 | CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease |
| Q38625149 | CpG demethylation in the neurotoxicity of 1-methyl-4-phenylpyridinium might mediate transcriptional up-regulation of α-synuclein in SH-SY5Y cells |
| Q46069820 | Creation of aggregation-defective α-synuclein variants by engineering the sequence connecting β-strand-forming domains |
| Q47619917 | Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders. |
| Q33894382 | Critical role of truncated α-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease |
| Q38745911 | Cross-linking for the analysis of α-synuclein in the enteric nervous system |
| Q44888059 | Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles |
| Q34284218 | Cross-seeding effects of amyloid β-protein and α-synuclein |
| Q41494811 | Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy |
| Q49019886 | Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? |
| Q37729058 | Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein |
| Q57909510 | Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel |
| Q56811524 | Cryo-EM structure of alpha-synuclein fibrils |
| Q61345661 | Cryo-EM structure of alpha-synuclein fibrils |
| Q57982400 | Cu2+Binding Modes of Recombinant α-Synuclein − Insights from EPR Spectroscopy |
| Q28267154 | Cuminaldehyde as the Major Component of Cuminum cyminum, a Natural Aldehyde with Inhibitory Effect on Alpha-Synuclein Fibrillation and Cytotoxicity |
| Q30410869 | Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein |
| Q35650069 | Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic Mice |
| Q47659411 | Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model |
| Q39209459 | Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy |
| Q33314363 | Curcumin inhibits aggregation of alpha-synuclein |
| Q39178579 | Curcumin modulates α-synuclein aggregation and toxicity. |
| Q35841861 | Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. |
| Q33569173 | Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model |
| Q46443371 | Curcumin-Loaded Amine-Functionalized Mesoporous Silica Nanoparticles Inhibit α-Synuclein Fibrillation and Reduce Its Cytotoxicity-Associated Effects |
| Q57459919 | Curcumin-glucoside, A Novel Synthetic Derivative of Curcumin, Inhibits α-Synuclein Oligomer Formation: Relevance to Parkinson's Disease |
| Q37119779 | Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms |
| Q50239959 | Cutaneous Alpha-Synuclein From Paraffin Embedded Autopsy Specimens in Parkinson's Disease. |
| Q34044570 | Cutting the vagal highway blocks one point of entry for prion-like alpha-synuclein. |
| Q54240535 | Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. |
| Q34718087 | Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study |
| Q51197884 | Cyclization of alpha-synuclein derived peptide increases its chaperone-like activity. |
| Q64098158 | Cyclized NDGA modifies dynamic α-synuclein monomers preventing aggregation and toxicity |
| Q48153970 | Cyclodextrins 3-Functionalized with 8-Hydroxyquinolines: Copper-Binding Ability and Inhibition of Synuclein Aggregation |
| Q39993264 | Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells |
| Q42703703 | Cyclosporine A and MnTMPyP Alleviate α-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism |
| Q35910069 | Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. |
| Q46972456 | Cysteine misincorporation in bacterially expressed human alpha-synuclein |
| Q42124780 | Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells |
| Q40226743 | Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. |
| Q48440013 | Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. |
| Q62470970 | Cytotoxic Oligomers and Fibrils Trapped in a Gel-like State of α-Synuclein Assemblies |
| Q62470971 | Cytotoxic Oligomers and Fibrils Trapped in a Gel-like State of α-Synuclein Assemblies |
| Q55516103 | D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model. |
| Q42288800 | DJ-1 Inhibits α-Synuclein Aggregation by Regulating Chaperone-Mediated Autophagy |
| Q30493811 | DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease |
| Q47786526 | DJ-1 deficiency impairs autophagy and reduces alpha-synuclein phagocytosis by microglia. |
| Q38972171 | DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease |
| Q21146396 | DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation |
| Q48871222 | DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. |
| Q28574285 | DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity |
| Q45933000 | DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction. |
| Q38732636 | DNA damage preceding dopamine neuron degeneration in A53T human α-synuclein transgenic mice |
| Q45239060 | DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism |
| Q37663204 | DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease |
| Q50992334 | DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes. |
| Q52148669 | DNA methylation levels of α-synuclein intron 1 in the aging brain. |
| Q52324924 | DNP-Enhanced MAS NMR: A Tool to Snapshot Conformational Ensembles of α-Synuclein in Different States. |
| Q37584540 | DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. |
| Q36494097 | DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells. |
| Q36801715 | DT-Diaphorase Prevents Aminochrome-Induced Alpha-Synuclein Oligomer Formation and Neurotoxicity |
| Q38704492 | DT-diaphorase Protects Against Autophagy Induced by Aminochrome-Dependent Alpha-Synuclein Oligomers. |
| Q54441670 | Dangerous duet: LRRK2 and α-synuclein jam at CMA. |
| Q31055860 | Data in support of the identification of neuronal and astrocyte proteins interacting with extracellularly applied oligomeric and fibrillar α-synuclein assemblies by mass spectrometry |
| Q37491380 | Dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson׳s disease. |
| Q42635838 | Deamidation of alpha-synuclein |
| Q38663505 | Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model |
| Q42069393 | Decontamination of medical devices from pathological amyloid-β-, tau- and α-synuclein aggregates |
| Q28545821 | Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference |
| Q33715071 | Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study |
| Q50551448 | Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. |
| Q35746279 | Decreased Phosphorylation and Increased Methionine Oxidation of α-Synuclein in the Methionine Sulfoxide Reductase A Knockout Mouse |
| Q43267775 | Decreased alpha-synuclein expression in the aging mouse substantia nigra |
| Q48438362 | Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. |
| Q54118349 | Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells. |
| Q38299101 | Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis |
| Q42483202 | Decreased reuptake of dopamine in the dorsal striatum in the absence of α-synuclein. |
| Q53426831 | Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. |
| Q47861075 | Decreases in soluble alpha-synuclein in frontal cortex correlate with cognitive decline in the elderly |
| Q43866953 | Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein |
| Q33802862 | Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease |
| Q41515458 | Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation |
| Q40694082 | Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture |
| Q34636872 | Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity |
| Q35181773 | Defined α-synuclein prion-like molecular assemblies spreading in cell culture |
| Q58484319 | Defining Long-Range Order and Local Disorder in Native α-Synuclein Using Residual Dipolar Couplings |
| Q38160130 | Defining the native state of α-synuclein |
| Q37598290 | Defining the oligomerization state of γ-synuclein in solution and in cells |
| Q31019452 | Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrate |
| Q26269832 | Definition of a molecular pathway mediating α-synuclein neurotoxicity |
| Q48315686 | Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease |
| Q52591539 | Degradation of alpha-synuclein by dendritic cell factor 1 delays neurodegeneration and extends lifespan in Drosophila. |
| Q45205515 | Degradation of wild-type alpha-synuclein by a molecular chaperone leads to reduced aggregate formation |
| Q28511388 | Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons |
| Q48348755 | Delay discounting of reward and caudate nucleus volume in individuals with α-synuclein gene duplication before and after the development of Parkinson's disease. |
| Q30470224 | Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons |
| Q48307330 | Deletion in exon 5 of the SNCA gene and exposure to rotenone leads to oligomerization of α-synuclein and toxicity to PC12 cells |
| Q42151730 | Deletion of alpha-synuclein decreases impulsivity in mice. |
| Q47395628 | Deletion of multimerin-1 in alpha-synuclein-deficient mice |
| Q24805405 | Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice |
| Q35944960 | Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis |
| Q40568588 | Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines |
| Q34345614 | Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein |
| Q34524887 | Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment |
| Q44129175 | Dependence of alpha-synuclein aggregate morphology on solution conditions |
| Q56908619 | Depleting Trim28 in adult mice is well tolerated and reduces levels of α-synuclein and tau |
| Q55102428 | Depleting Trim28 in adult mice is well tolerated and reduces levels of α-synuclein and tau. |
| Q35771639 | Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons |
| Q35743295 | Depth of α-synuclein in a bilayer determined by fluorescence, neutron reflectometry, and computation. |
| Q33322685 | Dequalinium-induced cell death of yeast expressing alpha-synuclein-GFP fusion protein |
| Q24298122 | Dequalinium-induced protofibril formation of alpha-synuclein |
| Q47923611 | Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity |
| Q39264615 | Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA. |
| Q60951154 | Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene |
| Q30841744 | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease |
| Q42547583 | Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR. |
| Q36218847 | Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils. |
| Q52684572 | Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation. |
| Q37438733 | Desipramine induced changes in the norepinephrine transporter, alpha- and gamma-synuclein in the hippocampus, amygdala and striatum |
| Q28573979 | Desipramine modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an animal model of depression |
| Q33399653 | Detecting morphologically distinct oligomeric forms of alpha-synuclein |
| Q35975840 | Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein |
| Q52575324 | Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease. |
| Q51049958 | Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders. |
| Q33326182 | Detection of compounds that rescue Rab1-synuclein toxicity |
| Q34118169 | Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study |
| Q44143951 | Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. |
| Q53417610 | Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. |
| Q36648796 | Detection of hyperphosphorylated tau protein and α-synuclein in spinal cord of patients with Alzheimer's disease |
| Q33258991 | Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging |
| Q53244268 | Detection of oligomers and fibrils of α-synuclein by AIEgen with strong fluorescence. |
| Q42703911 | Detection of transient interchain interactions in the intrinsically disordered protein alpha-synuclein by NMR paramagnetic relaxation enhancement |
| Q48549348 | Detection of α-synuclein aggregates by fluorescence microscopy. |
| Q39226863 | Detection of α-synuclein amyloidogenic aggregates in vitro and in cells using light-switching dipyridophenazine ruthenium(II) complexes |
| Q48165629 | Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease |
| Q40205123 | Determination of alpha-synuclein concentration in human plasma using ELISA. |
| Q34089470 | Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements |
| Q39788499 | Determining nuclear localization of alpha-synuclein in mouse brains |
| Q37181996 | Deubiquitinase Usp8 regulates α-synuclein clearance and modifies its toxicity in Lewy body disease. |
| Q36275962 | Deuterium isotope shifts for backbone ¹H, ¹⁵N and ¹³C nuclei in intrinsically disordered protein α-synuclein |
| Q45143048 | Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone |
| Q38730277 | Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein |
| Q48405878 | Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. |
| Q30845414 | Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides |
| Q48132477 | Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease |
| Q40859149 | Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector |
| Q58109323 | Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models |
| Q37998823 | Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid |
| Q34995002 | Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein |
| Q48189089 | Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex |
| Q28594631 | Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice |
| Q52180064 | Developmentally regulated expression of persyn, a member of the synuclein family, in skin. |
| Q47611418 | Dexamethasone Inhibits Copper-Induced Alpha-Synuclein Aggregation by a Metallothionein-Dependent Mechanism |
| Q34049427 | Dexamethasone induces the expression of LRRK2 and α-synuclein, two genes that when mutated cause Parkinson's disease in an autosomal dominant manner. |
| Q45185168 | Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis |
| Q36051094 | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
| Q40053985 | Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis. |
| Q64778970 | Diagnostic utility of gut α-synuclein in Parkinson's disease: A systematic review and meta-analysis. |
| Q48125197 | Diarylheptanoids from Rhizomes of Alpinia officinarum Inhibit Aggregation of α-Synuclein |
| Q35716090 | Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease |
| Q40403500 | Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death |
| Q48677086 | Diet-induced obesity accelerates the onset of terminal phenotypes in α-synuclein transgenic mice. |
| Q36400251 | Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α-synuclein |
| Q48136534 | Dietary restriction modulates alpha-synuclein expression in the aging rat cortex and hippocampus |
| Q40000181 | Differences between normal and alpha-synuclein overexpressing SH-SY5Y neuroblastoma cells after Abeta(1-42) and NAC treatment |
| Q46003760 | Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. |
| Q33210673 | Differences in extinction of conditioned fear in C57BL/6 substrains are unrelated to expression of alpha-synuclein |
| Q28910327 | Differences in the binding of copper(I) to α- and β-synuclein |
| Q35763165 | Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms |
| Q54945931 | Different Conformational Subensembles of the Intrinsically Disordered Protein α-Synuclein in Cells. |
| Q57948233 | Different Structural Conformers of Monomeric α-Synuclein Identified after Lyophilizing and Freezing |
| Q28581833 | Different levels of gamma-synuclein mRNA in the cerebral cortex of dominant, neutral and submissive rats selected in the competition test |
| Q52581429 | Different species of alpha-synuclein oligomers induce calcium influx and seeding. |
| Q64093661 | Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease |
| Q21090572 | Differential Co-Expression between α-Synuclein and IFN-γ Signaling Genes across Development and in Parkinson’s Disease |
| Q51286153 | Differential copper binding to alpha-synuclein and its disease-associated mutants affect the aggregation and amyloid formation. |
| Q40650717 | Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants |
| Q40560108 | Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine |
| Q35492403 | Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells |
| Q34238665 | Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy |
| Q46124320 | Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy |
| Q40002308 | Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells |
| Q39723568 | Differential effects of wild-type and A53T mutant isoform of alpha-synuclein on the mitochondrial proteome of differentiated SH-SY5Y cells |
| Q33938966 | Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra |
| Q35107062 | Differential expression of alpha-synuclein in hippocampal neurons |
| Q53265500 | Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. |
| Q53392035 | Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. |
| Q52150820 | Differential expression of α-synuclein splice variants in the brain of alcohol misusers: Influence of genotype. |
| Q55003043 | Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology. |
| Q48520068 | Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract. |
| Q53641665 | Differential interaction between iron and mutant alpha-synuclein causes distinctive Parkinsonian phenotypes in Drosophila. |
| Q34721951 | Differential involvement of the gamma-synuclein in cognitive abilities on the model of knockout mice |
| Q48176593 | Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease |
| Q28577681 | Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS |
| Q42523541 | Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters |
| Q33627226 | Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy |
| Q35637134 | Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment |
| Q33371063 | Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors |
| Q38641189 | Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease |
| Q41163005 | Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia |
| Q44629922 | Differential up-regulation of striatal dopamine transporter and α-synuclein by the pyrethroid insecticide permethrin |
| Q51744776 | Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. |
| Q48090438 | Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study. |
| Q38624671 | Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. |
| Q35957568 | Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice |
| Q33318989 | Dimeric structures of alpha-synuclein bind preferentially to lipid membranes |
| Q38726845 | Dimerization of Tyr136Cys alpha-synuclein prevents amyloid transformation of wild type alpha-synuclein. |
| Q48184724 | Dimerization propensities of Synucleins are not predictive for Synuclein aggregation. |
| Q46419842 | Dioleoyl-phosphatidic acid selectively binds to α-synuclein and strongly induces its aggregation. |
| Q41785479 | Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth |
| Q35529960 | Direct Detection of α-Synuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis |
| Q48717050 | Direct MRI-guided stereotaxic viral mediated gene transfer of alpha-synuclein in the Göttingen minipig CNS. |
| Q35996987 | Direct Observation of α-Synuclein Amyloid Aggregates in Endocytic Vesicles of Neuroblastoma Cells |
| Q41040224 | Direct Visualization of Model Membrane Remodeling by α-Synuclein Fibrillization |
| Q26799306 | Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity |
| Q33941736 | Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. |
| Q37180232 | Direct detection of alpha synuclein oligomers in vivo |
| Q39562119 | Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease |
| Q35063363 | Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein |
| Q34277399 | Direct observation of the interconversion of normal and toxic forms of α-synuclein |
| Q35175448 | Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour |
| Q40071251 | Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration |
| Q33726660 | Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies |
| Q27314815 | Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics |
| Q24321216 | Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain |
| Q36531366 | Direct α-synuclein promoter transactivation by the tumor suppressor p53. |
| Q47096637 | Discovering the 3' UTR-mediated regulation of alpha-synuclein |
| Q40084749 | Discovery and characterization of three novel synuclein genes in zebrafish |
| Q41906933 | Discovery of functional non-coding conserved regions in the α-synuclein gene locus |
| Q43445685 | Disintegration of amyloid fibrils of alpha-synuclein by dequalinium |
| Q24599233 | Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain |
| Q46898835 | Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein |
| Q40363580 | Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter |
| Q57477745 | Disruptive membrane interactions of alpha-synuclein aggregates |
| Q48327037 | Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation |
| Q37176469 | Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease |
| Q33524953 | Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease |
| Q35813797 | Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities |
| Q31157430 | Dissociation of amyloid fibrils of alpha-synuclein in supercooled water. |
| Q48045097 | Distinct Mechanisms Determine α-Synuclein Fibril Morphology during Growth and Maturation. |
| Q61449551 | Distinct Stress Response and Altered Striatal Transcriptome in Alpha-Synuclein Overexpressing Mice |
| Q44530279 | Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro |
| Q38889881 | Distinct higher-order α-synuclein oligomers induce intracellular aggregation |
| Q34070003 | Distinct hydration properties of wild-type and familial point mutant A53T of α-synuclein associated with Parkinson's disease |
| Q42136446 | Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein |
| Q40869755 | Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease |
| Q45115569 | Distinct phases of free α-synuclein--a Monte Carlo study |
| Q33747872 | Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration |
| Q36653589 | Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein |
| Q44007437 | Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone |
| Q48019506 | Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies |
| Q28293967 | Distinct α-synuclein strains differentially promote tau inclusions in neurons |
| Q53426391 | Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. |
| Q57982330 | Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p |
| Q36063245 | Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons |
| Q28581427 | Distribution of α‐ and γ‐synucleins in the adult rat brain and their modification by high‐dose cocaine treatment |
| Q33771253 | Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. |
| Q37119983 | Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases |
| Q21132346 | Diverse metastable structures formed by small oligomers of α-synuclein probed by force spectroscopy |
| Q43199009 | DnaK/DnaJ/GrpE of Hsp70 system have differing effects on alpha-synuclein fibrillation involved in Parkinson's disease. |
| Q43826436 | Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. |
| Q38021197 | Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model? |
| Q38067885 | Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? |
| Q35726062 | Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? |
| Q36491690 | Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? |
| Q34861594 | Domain a' of protein disulfide isomerase plays key role in inhibiting alpha-synuclein fibril formation |
| Q39824278 | Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity |
| Q57084718 | Dopamine Affects the Stability, Hydration, and Packing of Protofibrils and Fibrils of the Wild Type and Variants of α-Synuclein† |
| Q37717851 | Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's Disease |
| Q64778786 | Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of α-Synuclein and Relevance in the Neurodegeneration of Sporadic Parkinson’s Disease |
| Q36444116 | Dopamine Transporter Activity Is Modulated by α-Synuclein. |
| Q52307189 | Dopamine Transporter Activity Is Modulated by α-synuclein. |
| Q55715226 | Dopamine Transporter/α-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinson's Disease: An In Situ Proximity Ligation Assay Study. |
| Q39052245 | Dopamine and Cu+/2+ can induce oligomerization of α-synuclein in the absence of oxygen: Two types of oligomerization mechanisms for α-synuclein and related cell toxicity studies |
| Q28392011 | Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance |
| Q46053822 | Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner |
| Q39208098 | Dopamine and α-synuclein dysfunction in Smad3 null mice |
| Q46221038 | Dopamine auto-oxidation aggravates non-apoptotic cell death induced by over-expression of human A53T mutant alpha-synuclein in dopaminergic PC12 cells |
| Q40044611 | Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease |
| Q39777212 | Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells |
| Q44516595 | Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells |
| Q46305258 | Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration. |
| Q36888986 | Dopamine prevents lipid peroxidation-induced accumulation of toxic α-synuclein oligomers by preserving autophagy-lysosomal function |
| Q46537593 | Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway |
| Q34901494 | Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. |
| Q43131429 | Dopamine quinones interact with alpha-synuclein to form unstructured adducts. |
| Q46981158 | Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease |
| Q40331686 | Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease |
| Q57982362 | Dopamine-Induced α-Synuclein Oligomers |
| Q44013447 | Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease |
| Q49029284 | Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice. |
| Q33500157 | Dopamine-induced conformational changes in alpha-synuclein |
| Q30364908 | Dopamine-induced α-synuclein oligomers show self- and cross-propagation properties. |
| Q34606278 | Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein |
| Q24683089 | Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy |
| Q40349633 | Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant alpha-synuclein |
| Q35746518 | Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators |
| Q43935058 | Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra |
| Q46657177 | Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein |
| Q33269934 | Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra |
| Q44478507 | Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein |
| Q39700323 | Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells |
| Q26269963 | Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions |
| Q48548334 | Down-regulating α-synuclein for treating synucleopathies. |
| Q40320292 | Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model |
| Q36309145 | Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma |
| Q53693124 | Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP+ )-induced α-synuclein accumulation and neurotoxicity. |
| Q41430883 | Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma |
| Q38895944 | Drift diffusion model of reward and punishment learning in rare alpha-synuclein gene carriers |
| Q33948478 | Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation |
| Q48508385 | Drp-1 dependent mitochondrial fragmentation and protective autophagy in dopaminergic SH-SY5Y cells overexpressing alpha-synuclein. |
| Q41865629 | Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies |
| Q37916635 | Drug targets from genetics: α-synuclein |
| Q38588392 | Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic? |
| Q39685688 | Dual effects of alpha-synuclein on neurotoxicity induced by low dosage of rotenone are dependent on exposure time in dopaminergic neuroblastoma cells |
| Q43287401 | Dual effects of different concentrations of alpha-synuclein on the neurotoxicity of 6-hydroxydopamine in SH-SY5Y cells |
| Q50850710 | Dual effects of β-synuclein on the pathogenesis of Parkinson disease. |
| Q47580972 | Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study |
| Q48442616 | Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease. |
| Q39447688 | Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy |
| Q26770060 | Dynamic structural flexibility of α-synuclein |
| Q30493426 | Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons. |
| Q35994848 | Dynamical Behavior of Human α-Synuclein Studied by Quasielastic Neutron Scattering |
| Q40155070 | Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein |
| Q48426203 | Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. |
| Q38041991 | Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets? |
| Q34290006 | Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. |
| Q58568853 | E46K Mutant α-Synuclein Is Degraded by Both Proteasome and Macroautophagy Pathway |
| Q42672293 | E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein |
| Q35266392 | E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment |
| Q46308077 | E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation |
| Q33842865 | EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. |
| Q47147437 | EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the 'Active Oligomer' of α-Synuclein |
| Q55024134 | ELISA method to detect α-synuclein oligomers in cell and animal models. |
| Q51471477 | ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease. |
| Q36678823 | ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. |
| Q34468291 | ER stress response plays an important role in aggregation of α-synuclein |
| Q30650119 | ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo |
| Q53267389 | Earliest events in α-synuclein fibrillation probed with the fluorescence of intrinsic tyrosines. |
| Q27301058 | Early Parkinson's disease symptoms in α-synuclein transgenic monkeys |
| Q61797140 | Early Stage Alpha-Synuclein Amyloid Fibrils are Reservoirs of Membrane-Binding Species |
| Q33550002 | Early aggregation steps in alpha-synuclein as measured by FCS and FRET: evidence for a contagious conformational change. |
| Q48339321 | Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. |
| Q48460839 | Early and persistent expression of phosphorylated α-synuclein in the enteric nervous system of A53T mutant human α-synuclein transgenic mice. |
| Q48404173 | Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging. |
| Q46441823 | Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. |
| Q54986684 | Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice. |
| Q57835612 | Early oligomerization stages for the non-amyloid component of α-synuclein amyloid |
| Q54279116 | Early sodium dodecyl sulfate induced collapse of α-synuclein correlates with its amyloid formation. |
| Q61797045 | Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution |
| Q36265332 | Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice |
| Q40108542 | Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease. |
| Q48770284 | Early-onset motor impairment and increased accumulation of phosphorylated α-synuclein in the motor cortex of normal aging mice are ameliorated by coenzyme Q. |
| Q40833150 | Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family. |
| Q38345046 | Ectopic expression of α-synuclein affects the migration of neural stem cells in mouse subventricular zone |
| Q52659689 | Editors' note: A new potential biomarker for dementia with Lewy bodies: Skin nerve α-synuclein deposits. |
| Q33267617 | Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation |
| Q43191766 | Effect of N-methyl-D-aspartate (NMDA) receptor antagonists on alpha-synuclein-evoked neuronal nitric oxide synthase activation in the rat brain. |
| Q33599013 | Effect of SUMO-1 on mitochondria subcellular localization of alpha-synuclein and its degradation via ubiquitin-proteasome system |
| Q38734429 | Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. |
| Q41634522 | Effect of acidic pH on the stability of α-synuclein dimers |
| Q40761847 | Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system |
| Q40115210 | Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene |
| Q58752961 | Effect of chemokine CC ligand 2 (CCL2) on α‑synuclein‑induced microglia proliferation and neuronal apoptosis |
| Q39659132 | Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity. |
| Q33665675 | Effect of dioxygen on copper(II) binding to alpha-synuclein. |
| Q34517780 | Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein |
| Q44298076 | Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. |
| Q43225121 | Effect of gamma-synuclein silencing on apoptotic pathways in retinal ganglion cells |
| Q35681438 | Effect of lysosomal and ubiquitin-proteasome system dysfunction on the abnormal aggregation of α-synuclein in PC12 cells |
| Q40714967 | Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line |
| Q37317606 | Effect of pseudorepeat rearrangement on alpha-synuclein misfolding, vesicle binding, and micelle binding |
| Q38843614 | Effect of reparation of repeat sequences in the human alpha-synuclein on fibrillation ability |
| Q34291522 | Effect of spermidine on misfolding and interactions of alpha-synuclein |
| Q61811209 | Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process |
| Q47386127 | Effect of the cross-talk between autophagy and endoplasmic reticulum stress on Mn-induced alpha-synuclein oligomerization |
| Q31961798 | Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult |
| Q47608338 | Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease. |
| Q34307308 | Effect of trehalose on PC12 cells overexpressing wild-type or A53T mutant α-synuclein |
| Q48173246 | Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease |
| Q48297617 | Effect of α-synuclein on membrane permeability and synaptic transmission: a clue to neurodegeneration? |
| Q38825717 | Effects of Alpha-Synuclein on Primary Spinal Cord Neurons Associated with Apoptosis and CNTF Expression |
| Q52366869 | Effects of Ginkgo Biloba Extract on A53T α-Synuclein Transgenic Mouse Models of Parkinson's Disease. |
| Q35101612 | Effects of Human Alpha-Synuclein A53T-A30P Mutations on SVZ and Local Olfactory Bulb Cell Proliferation in a Transgenic Rat Model of Parkinson Disease. |
| Q57279944 | Effects of Metformin on Apoptosis and Alpha Synuclein in Rat Model of Pentylenetetrazole-induced Epilepsy |
| Q28834531 | Effects of Mutations on the Reconfiguration Rate of α-Synuclein |
| Q44850741 | Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein |
| Q36744478 | Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization |
| Q41196398 | Effects of Trehalose on Thermodynamic Properties of Alpha-synuclein Revealed through Synchrotron Radiation Circular Dichroism |
| Q40010564 | Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease |
| Q34211735 | Effects of Various Flavonoids on the α-Synuclein Fibrillation Process |
| Q44769508 | Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease |
| Q47862181 | Effects of antiparkinsonian agents on β-amyloid and α-synuclein oligomer formation in vitro |
| Q43580759 | Effects of bacterial endotoxin on α-synuclein expression in the lymph node leukocytes of rats. |
| Q35083125 | Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease |
| Q34590790 | Effects of curvature and composition on α-synuclein binding to lipid vesicles |
| Q39964170 | Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson's disease |
| Q49051594 | Effects of exogenous alpha-synuclein on stimulated dopamine overflow in dorsal striatum. |
| Q35691076 | Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity |
| Q48494475 | Effects of in vitro and in vivo avermectin exposure on alpha synuclein expression and proteasomal activity in pigeons. |
| Q39268294 | Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity |
| Q46338049 | Effects of nitration on the structure and aggregation of alpha-synuclein |
| Q44832313 | Effects of novel peptides derived from the acidic tail of synuclein (ATS) on the aggregation and stability of fusion proteins. |
| Q44511146 | Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications |
| Q37204488 | Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients |
| Q47393229 | Effects of saffron and its constituents, crocin-1, crocin-2, and crocetin on α-synuclein fibrils. |
| Q28610102 | Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease |
| Q64282808 | Effects of α-Synuclein Monomers Administration in the Gigantocellular Reticular Nucleus on Neurotransmission in Mouse Model |
| Q39036678 | Effects of α-synuclein on axonal transport |
| Q37098708 | Effects of α-synuclein overexpression in transgenic Caenorhabditis elegans strains |
| Q39106273 | Effects of γ-synuclein on the tumorigenicity and metastasis of colon cancer SW1116 cells in vitro and in vivo |
| Q38947309 | Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event |
| Q36584899 | Efficient, Traceless Semi-Synthesis of α-Synuclein Labeled with a Fluorophore/Thioamide FRET Pair |
| Q35666953 | Electroacupuncture remediates glial dysfunction and ameliorates neurodegeneration in the astrocytic α-synuclein mutant mouse model |
| Q39293862 | Electrochemical analysis of the fibrillation of Parkinson's disease α-synuclein |
| Q41879283 | Electron paramagnetic resonance spectroscopy measures the distance between the external β-strands of folded α-synuclein in amyloid fibrils |
| Q50082672 | Electrostatic and hydrophobic interactions of lipid-associated α-synuclein: The role of a water-limited interfaces in amyloid fibrillation. |
| Q47194996 | Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson’s Disease Relative to Alzheimer’s Disease and Controls |
| Q45188678 | Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism |
| Q34994184 | Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease |
| Q33323265 | Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease |
| Q52589669 | Elevated expression of CYP1A1 and gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium. |
| Q39166838 | Elevated levels of alpha-synuclein blunt cellular signal transduction downstream of Gq protein-coupled receptors |
| Q34242682 | Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. |
| Q40299700 | Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization |
| Q40441648 | Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease |
| Q53456743 | Elevated neuronal α-synuclein promotes microglia activation after spinal cord ischemic/reperfused injury. |
| Q34069284 | Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia |
| Q36585297 | Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein |
| Q27329722 | Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells |
| Q30372672 | Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis. |
| Q41837154 | Elucidating the aggregation number of dopamine-induced α-synuclein oligomeric assemblies |
| Q41420722 | Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. |
| Q52714245 | Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease. |
| Q34539193 | Emerging evidence for the neuroprotective role of alpha-synuclein |
| Q34185956 | Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease |
| Q35765035 | Emotional memory impairments induced by AAV-mediated overexpression of human α-synuclein in dopaminergic neurons of the ventral tegmental area |
| Q47367869 | Endogenous Alpha-Synuclein Protein Analysis from Human Brain Tissues Using Single-Molecule Pull-Down Assay. |
| Q42740346 | Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra |
| Q48473494 | Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. |
| Q43260035 | Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein |
| Q28300290 | Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease |
| Q46765805 | Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity |
| Q37576386 | Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity |
| Q38717493 | Endothelin-converting enzymes degrade α-synuclein and are reduced in dementia with Lewy bodies |
| Q48888111 | Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). |
| Q33221124 | Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation. |
| Q40043261 | Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease |
| Q48155944 | Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. |
| Q37524138 | Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. |
| Q35312446 | Enhanced autophagy from chronic toxicity of iron and mutant A53T α-synuclein: implications for neuronal cell death in Parkinson disease |
| Q40102845 | Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies |
| Q47325206 | Enhanced motivation to alcohol in transgenic mice expressing human α-synuclein. |
| Q44379856 | Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. |
| Q44802800 | Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. |
| Q37706391 | Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. |
| Q33832643 | Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity |
| Q38398341 | Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease |
| Q53792403 | Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease. |
| Q36300054 | Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder |
| Q54942969 | Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression |
| Q37369400 | Environmental and genetic factors support the dissociation between α-synuclein aggregation and toxicity. |
| Q35073958 | Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. |
| Q51031453 | Environmental neurotoxicant manganese regulates exosome-mediated extracellular miRNAs in cell culture model of Parkinson's disease: Relevance to α-synuclein misfolding in metal neurotoxicity. |
| Q36161877 | Environmental toxins and alpha-synuclein in Parkinson's disease |
| Q30528818 | Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice |
| Q38695484 | Enzymatic O-GlcNAcylation of α-synuclein reduces aggregation and increases SDS-resistant soluble oligomers |
| Q46258858 | Eosin interaction of alpha-synuclein leading to protein self-oligomerization |
| Q51671122 | Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease. |
| Q54952470 | Epigenetic Modifications of the α-Synuclein Gene and Relative Protein Content Are Affected by Ageing and Physical Exercise in Blood from Healthy Subjects. |
| Q48439110 | Epigenetic upregulation of alpha-synuclein in the rats exposed to methamphetamine. |
| Q42735183 | Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls. |
| Q57082948 | Erratum to “Chaperone-mediated autophagy in aging and neurodegeneration: Lessons from α-synuclein” [Exp. Gerontol. 42 (2007) 120–128] |
| Q58905679 | Erratum to “Decreased Phosphorylation and Increased Methionine Oxidation of -Synuclein in the Methionine Sulfoxide Reductase A Knockout Mouse” |
| Q45762762 | Erratum to: A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity In Vitro and In Vivo |
| Q50208188 | Erratum to: Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons. |
| Q55032332 | Erratum: Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact. |
| Q55043106 | Erratum: Impairment of PDGF-induced chemotaxis by extracellular α-synuclein through selective inhibition of Rac1 activation. |
| Q50107487 | Erratum: T cells from patients with Parkinson's disease recognize α-synuclein peptides. |
| Q64055149 | Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease |
| Q36973910 | Essential Oils May Lead α-Synuclein towards Toxic Fibrils Formation |
| Q39789515 | Establishment of stably transfected rat neuronal cell lines expressing alpha-synuclein GFP fusion proteins |
| Q60632236 | Ethanol (EtOH)-Related Behaviors in α-Synuclein Mutant Mice and Association of SNCA SNPs with Anxiety in EtOH-Dependent Patients |
| Q48910255 | Ethanol protects cultured neurons against amyloid-β and α-synuclein-induced synapse damage. |
| Q34591096 | Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease |
| Q36765692 | Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies |
| Q30488694 | Evaluation of alpha-synuclein immunohistochemical methods used by invited experts |
| Q35887768 | Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease |
| Q46149381 | Evaluation of the effects of vitamin A supplementation on adult rat substantia nigra and striatum redox and bioenergetic states: mitochondrial impairment, increased 3-nitrotyrosine and alpha-synuclein, but decreased D2 receptor contents |
| Q35163628 | Evaluation of the synuclein-γ (SNCG) gene as a PPARγ target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue. |
| Q60689238 | Evaluation of the γ-synuclein gene in German Parkinson's disease patients |
| Q39167831 | Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases |
| Q48771698 | Evidence against a reliable staging system of alpha-synuclein pathology in Parkinson's disease. |
| Q42328729 | Evidence for Intramolecular Antiparallel Beta-Sheet Structure in Alpha-Synuclein Fibrils from a Combination of Two-Dimensional Infrared Spectroscopy and Atomic Force Microscopy. |
| Q46097239 | Evidence for a partially folded intermediate in alpha-synuclein fibril formation |
| Q33893227 | Evidence for copper-dioxygen reactivity during alpha-synuclein fibril formation. |
| Q26782028 | Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism |
| Q38826919 | Evidence from spatial pattern analysis for the anatomical spread of α-synuclein pathology in Parkinson's disease dementia |
| Q37635873 | Evidence of native α-synuclein conformers in the human brain |
| Q24316900 | Evidence that alpha-synuclein does not inhibit phospholipase D |
| Q24306916 | Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets |
| Q50057879 | Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. |
| Q44064458 | Evolutionary aspects of the synuclein super-family and sub-families based on large-scale phylogenetic and group-discrimination analysis |
| Q50176511 | Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein. |
| Q38006559 | Examining the mechanisms that link β-amyloid and α-synuclein pathologies |
| Q41488989 | Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages |
| Q28732131 | Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1 |
| Q47575916 | Excessive Iron and α-Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease |
| Q46585664 | Exocytosis and Spreading of Normal and Aberrant α-Synuclein |
| Q60810349 | Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation |
| Q42705823 | Exogenous Alpha-Synuclein Alters Pre- and Post-Synaptic Activity by Fragmenting Lipid Rafts |
| Q37446544 | Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells |
| Q46314161 | Exogenous α-Synuclein Monomers Alter Dopamine Metabolism in Murine Brain |
| Q48284075 | Exogenous α-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release. |
| Q35484581 | Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death |
| Q55220148 | Exogenous α-synuclein hinders synaptic communication in cultured cortical primary rat neurons. |
| Q35766124 | Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes |
| Q36353854 | Exosomal cell-to-cell transmission of alpha synuclein oligomers. |
| Q55617564 | Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy. |
| Q39135878 | Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD. |
| Q48195020 | Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing α-Synuclein |
| Q38927256 | Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease. |
| Q37295073 | Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. |
| Q40099053 | Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification. |
| Q39485110 | Explaining the structural plasticity of α-synuclein |
| Q46097598 | Explorations of the application of cyanine dyes for quantitative alpha-synuclein detection |
| Q55312267 | Exploring the Structural Diversity in Inhibitors of α-Synuclein Amyloidogenic Folding, Aggregation, and Neurotoxicity. |
| Q39640785 | Exploring the Transition of Human α-Synuclein from Native to the Fibrillar State: Insights into the Pathogenesis of Parkinson's Disease |
| Q26852660 | Exploring the accessible conformations of N-terminal acetylated α-synuclein |
| Q42778564 | Exploring the structural details of Cu(I) binding to α-synuclein by NMR spectroscopy |
| Q37151315 | Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril |
| Q43735119 | Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. |
| Q37315005 | Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans |
| Q28395564 | Expression and Transport of α-Synuclein at the Blood-Cerebrospinal Fluid Barrier and Effects of Manganese Exposure |
| Q48418284 | Expression and subcellular location of alpha-synuclein during mouse-embryonic development. |
| Q43819951 | Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. |
| Q35534334 | Expression of ERα, its ERαΔ3 Splice Variant and γ-SYNUCLEIN in Ovarian Cancer: A Pilot Study. |
| Q52738423 | Expression of Pink1 with α-synuclein in the dopaminergic neurons of Drosophila leads to increases in both lifespan and healthspan. |
| Q34202479 | Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas |
| Q40915381 | Expression of alpha-synuclein during eye development of mice (Mus musculus), chick (Gallus gallus domisticus) and fish (Ctenopharyngodon idella) in a comparison study. |
| Q40795016 | Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta |
| Q28584254 | Expression of alpha-synuclein in different brain parts of adult and aged rats |
| Q42166319 | Expression of alpha-synuclein is increased in the hippocampus of rats with high levels of innate anxiety |
| Q48234545 | Expression of alpha-synuclein mRNA in Parkinson's disease |
| Q28512712 | Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage |
| Q48586574 | Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. |
| Q34093920 | Expression of beta-synuclein in normal human astrocytes |
| Q53594769 | Expression of breast cancer specific gene-1 (BCSG-1/gamma-synuclein) is associated with tumour grade but not with clinical outcome of patients with breast cancer. |
| Q37402449 | Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116. |
| Q34321875 | Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t |
| Q36553302 | Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. |
| Q40844291 | Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity |
| Q35014520 | Expression of mutant alpha-synuclein modulates microglial phenotype in vitro |
| Q40713950 | Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro |
| Q43467428 | Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer |
| Q38762543 | Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32. |
| Q58552163 | Expression of α-synuclein is regulated in a neuronal cell type-dependent manner |
| Q34360563 | Expression pattern and localization of alpha-synuclein in the human enteric nervous system |
| Q43995715 | Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development |
| Q52169006 | Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. |
| Q58696119 | Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein |
| Q37485162 | Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site |
| Q33773655 | Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. |
| Q34574672 | Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody |
| Q38816038 | Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage |
| Q46962603 | Extent of inhibition of α-synuclein aggregation in vitro by SUMOylation is conjugation site- and SUMO isoform-selective |
| Q43129915 | Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. |
| Q60947930 | Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy |
| Q61444765 | Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose |
| Q43447647 | Extracellular alpha-synuclein induces calpain-dependent overactivation of cyclin-dependent kinase 5 in vitro. |
| Q39292701 | Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. |
| Q55332346 | Extracellular gamma-synuclein promotes tumor cell motility by activating β1 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion. |
| Q43093480 | Extracellular neurosin degrades α-synuclein in cultured cells. |
| Q39374677 | Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1. |
| Q38898891 | Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation |
| Q38182337 | Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases. |
| Q52689581 | Extracellular α-Synuclein Disrupts Membrane Nanostructure and Promotes S-Nitrosylation-Induced Neuronal Cell Death. |
| Q48335373 | Extracellular α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. |
| Q52720559 | Extracellular α-synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G protein signaling. |
| Q42316026 | Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact |
| Q35144986 | Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent Tau phosphorylation in PC12 cells |
| Q52691746 | Extracellular α-synuclein levels are regulated by neuronal activity. |
| Q38785276 | Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease |
| Q47449183 | Eye movements in genetic parkinsonisms affecting the α-synuclein, PARK9, and manganese network |
| Q41957319 | FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity |
| Q34571668 | FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy |
| Q28117902 | FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy |
| Q33873286 | FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression |
| Q24311758 | FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T |
| Q41467076 | FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease |
| Q47304900 | FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome |
| Q49029474 | FLZ Attenuates α-Synuclein-Induced Neurotoxicity by Activating Heat Shock Protein 70. |
| Q42259815 | FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. |
| Q38718275 | FTY720 (Fingolimod) reverses α-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells |
| Q56394766 | FYCO1 mediates clearance of α-synuclein aggregates through a Rab7-dependent mechanism |
| Q39038040 | Facile "stop codon" method reveals elevated neuronal toxicity by discrete S87p-α-synuclein oligomers |
| Q57342347 | Faculty of 1000 evaluation for Alpha-synuclein has structural and functional similarities to small heat shock proteins |
| Q57342414 | Faculty of 1000 evaluation for Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein |
| Q56884531 | Faculty of 1000 evaluation for Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice |
| Q57342603 | Faculty of 1000 evaluation for Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers |
| Q57342649 | Faculty of 1000 evaluation for alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons |
| Q54685674 | Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. |
| Q47671629 | Failure to replicate a protective effect of allele 2 of NACP/alpha-synuclein polymorphism in Alzheimer's disease: an association study |
| Q58484320 | Familial Mutants of α-Synuclein with Increased Neurotoxicity Have a Destabilized Conformation |
| Q39027293 | Familial Mutations May Switch Conformational Preferences in α-Synuclein Fibrils |
| Q35199433 | Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein |
| Q46784053 | Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans |
| Q40579299 | Familial Parkinson's Disease Mutant E46K α-Synuclein Localizes to Membranous Structures, Forms Aggregates, and Induces Toxicity in Yeast Models |
| Q34366748 | Familial Parkinson's disease. Alpha-synuclein and parkin |
| Q47702872 | Familial frontotemporal dementia: a report of three cases of severe cerebral atrophy with rare inclusions that are negative for tau and synuclein, but positive for ubiquitin |
| Q34267719 | Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease |
| Q47288069 | Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. |
| Q43619529 | Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. |
| Q35741283 | Fast flow microfluidics and single-molecule fluorescence for the rapid characterization of α-synuclein oligomers |
| Q36825541 | Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease |
| Q38810676 | Fasudil, a Rho kinase inhibitor, promotes the autophagic degradation of A53T α-synuclein by activating the JNK 1/Bcl-2/beclin 1 pathway |
| Q46610362 | Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice |
| Q34287439 | Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. |
| Q40570024 | FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis |
| Q40627675 | Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay |
| Q58695961 | Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4) |
| Q26996688 | Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease |
| Q64124342 | Femtosecond Hydration Map of Intrinsically Disordered α-Synuclein |
| Q35700288 | Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation |
| Q47831625 | Fibril breaking accelerates α-synuclein fibrillization. |
| Q36751579 | Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death |
| Q36045483 | Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells |
| Q47602087 | Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation |
| Q42620617 | Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid |
| Q35627057 | Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy |
| Q48401512 | Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. |
| Q39728732 | Filamentous phages reduce alpha-synuclein oligomerization in the membrane fraction of SH-SY5Y cells |
| Q40335730 | Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein |
| Q43076384 | First appraisal of brain pathology owing to A30P mutant alpha-synuclein |
| Q37664213 | First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers |
| Q26777065 | Fish Synucleins: An Update |
| Q38821003 | Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology |
| Q34325209 | Fluorescence correlation spectroscopy to determine the diffusion coefficient of α-synuclein and follow early oligomer formation |
| Q40160660 | Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged alpha-synuclein |
| Q51347463 | Fluorescence lifetime measurements of intrinsically unstructured proteins: application to α-synuclein. |
| Q24318841 | Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells |
| Q47192321 | Fluorescence spectroscopy reveals N-terminal order in fibrillar forms of α-synuclein |
| Q24337688 | Fluorescence studies suggest a role for alpha-synuclein in the phosphatidylinositol lipid signaling pathway |
| Q38630185 | Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein. |
| Q43057389 | Fluorescent ratiometric MFC probe sensitive to early stages of alpha-synuclein aggregation. |
| Q35654251 | Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model |
| Q36627511 | Focus on molecules: the synucleins: "When friends become foes". |
| Q37938437 | Folding and misfolding of alpha-synuclein on membranes. |
| Q35773786 | Following the leader: fibrillization of alpha-synuclein and tau. |
| Q44834015 | Forcing nonamyloidogenic beta-synuclein to fibrillate |
| Q41827902 | Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption |
| Q48466936 | Formaldehyde-fixed brain tissue from spontaneously ill α-synuclein transgenic mice induces fatal α-synucleinopathy in transgenic hosts. |
| Q36260495 | Formation and Implications of Alpha-Synuclein Radical in Maneb- and Paraquat-Induced Models of Parkinson's Disease |
| Q43810148 | Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors |
| Q57092800 | Formation of a High Affinity Lipid-Binding Intermediate during the Early Aggregation Phase of α-Synuclein† |
| Q41786303 | Formation of covalent di-tyrosine dimers in recombinant α-synuclein. |
| Q33413268 | Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation |
| Q34658008 | Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease |
| Q28472448 | Formation of toxic oligomeric alpha-synuclein species in living cells |
| Q30607522 | Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes |
| Q63740281 | Found in Translation: The Utility of C. elegans Alpha-Synuclein Models of Parkinson’s Disease |
| Q35808359 | Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease. |
| Q35591414 | Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration |
| Q48467345 | Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. |
| Q39037462 | Free-standing gold-nanoparticle monolayer film fabricated by protein self-assembly of α-synuclein. |
| Q49935761 | From a highly-disordered to a metastable state: Uncovering insights of α-synuclein. |
| Q34190818 | From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases |
| Q35946297 | From intrinsically disordered protein to context-dependent folding: The α-synuclein tetramer is teased out of hiding |
| Q41658114 | From the Cover: Arsenic Induces Accumulation of α-Synuclein: Implications for Synucleinopathies and Neurodegeneration |
| Q38007671 | From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. |
| Q48383295 | Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. |
| Q40057219 | Frontotemporal lobar degeneration with ubiquitinated tau-negative inclusions and additional alpha-synuclein pathology but also unusual cerebellar ubiquitinated p62-positive, TDP-43-negative inclusions |
| Q27026292 | Function and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescence |
| Q38263747 | Function of α-synuclein and PINK1 in Lewy body dementia (Review). |
| Q42750853 | Functional Defect Conferred by the Parkinson's Disease-Causing α-Synuclein (Ala30Pro) Mutation |
| Q36172332 | Functional alterations of the dopaminergic and glutamatergic systems in spontaneous α-synuclein overexpressing rats. |
| Q35159808 | Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family |
| Q44955226 | Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene |
| Q36103304 | Functional characterization of alpha-synuclein protein with antimicrobial activity |
| Q45057099 | Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. |
| Q24338935 | Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219 |
| Q46810246 | Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. |
| Q41860926 | Functionalization of α-synuclein fibrils |
| Q39065652 | Functionally different α-synuclein inclusions yield insight into Parkinson's disease pathology. |
| Q47662496 | Fundamental limit of alpha-synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson's disease: Comparison with surgical specimens |
| Q39289367 | Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies |
| Q39784124 | G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression |
| Q59353444 | G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice |
| Q37096048 | G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. |
| Q40539190 | G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage |
| Q34335126 | G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome |
| Q36825286 | GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein |
| Q36777244 | GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A. |
| Q47193126 | GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers |
| Q39516461 | GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease |
| Q34596893 | GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein |
| Q46548122 | GM1 specifically interacts with alpha-synuclein and inhibits fibrillation |
| Q42119505 | GRP78 clustering at the cell surface of neurons transduces the action of exogenous alpha-synuclein. |
| Q27331743 | GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein |
| Q39425043 | GSM-900MHz at low dose temperature-dependently downregulates α-synuclein in cultured cerebral cells independently of chaperone-mediated-autophagy |
| Q46068316 | GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson's Disease |
| Q34040737 | Gallic acid interacts with α-synuclein to prevent the structural collapse necessary for its aggregation |
| Q61445780 | Gallic acid loaded onto polyethylenimine-coated human serum albumin nanoparticles (PEI-HSA-GA NPs) stabilizes α-synuclein in the unfolded conformation and inhibits aggregation |
| Q55339912 | Gamma synuclein is a novel Twist1 target that promotes TGF-β-induced cancer cell migration and invasion. |
| Q47254957 | Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis |
| Q34105358 | Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction |
| Q36849093 | Gamma-synuclein and the progression of cancer |
| Q28571838 | Gamma-synuclein as a marker of retinal ganglion cells |
| Q48678407 | Gamma-synuclein binds synaptic vesicles but does not interact with SNARE-complex proteins. |
| Q51452297 | Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation. |
| Q35178256 | Gamma-synuclein is an adipocyte-neuron gene coordinately expressed with leptin and increased in human obesity |
| Q34994452 | Gamma-synuclein pathology in amyotrophic lateral sclerosis |
| Q34139335 | Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways |
| Q39979540 | Gamma-synuclein: cell-type-specific promoter activity and binding to transcription factors |
| Q58794919 | Ganglioside lipids accelerate α-synuclein amyloid formation |
| Q42487446 | Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology |
| Q38528899 | Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease |
| Q48965916 | Gaucher cells are not associated with α-synuclein neuropathology in infants. |
| Q24307627 | Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies |
| Q40517262 | Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro |
| Q39499103 | Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro |
| Q38074839 | Gender differences in Parkinson's disease: focus on plasma α-synuclein |
| Q64768214 | Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein. |
| Q35621190 | Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. |
| Q46723409 | Generation of a alpha-synuclein-based rat model of Parkinson's disease |
| Q44498193 | Generation of ferric iron links oxidative stress to α-synuclein oligomer formation |
| Q43218554 | Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein |
| Q50710454 | Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. |
| Q28544679 | Genetic and chemical activation of TFEB mediates clearance of aggregated α-synuclein |
| Q53240084 | Genetic association between Alzheimer disease and the alpha-synuclein gene. |
| Q57623794 | Genetic association between α-synuclein and idiopathic parkinson's disease |
| Q64068812 | Genetic background modifies phenotypic and transcriptional responses in a C. elegans model of α-synuclein toxicity |
| Q28591516 | Genetic deletion of the GATA1-regulated protein α-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes |
| Q55000943 | Genetic inactivation of alpha-synuclein affects embryonic development of dopaminergic neurons of the substantia nigra, but not the ventral tegmental area, in mouse brain. |
| Q33510936 | Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues |
| Q48956337 | Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. |
| Q56637599 | Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain |
| Q21142744 | Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy |
| Q36915908 | Genetic variants of α-synuclein are not associated with essential tremor |
| Q36597550 | Genetic variation in the alpha synuclein gene (SNCA) is associated with BOLD response to alcohol cues |
| Q54376428 | Genetic variation in α-synuclein kinases (CK-2β and GRK-5) and risk of Parkinson's disease. |
| Q38771447 | Geniposide reduces α-synuclein by blocking microRNA-21/lysosome-associated membrane protein 2A interaction in Parkinson disease models |
| Q34550197 | Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways |
| Q39817758 | Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation |
| Q49885463 | Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model. |
| Q37362778 | Genomic investigation of alpha-synuclein multiplication and parkinsonism |
| Q22007967 | Genomic organization and expression of the human beta-synuclein gene (SNCB) |
| Q48351178 | Genomic organization, chromosome location, and expression analysis of mouse beta-synuclein, a candidate for involvement in neurodegeneration. |
| Q44629824 | Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner |
| Q42285859 | Getting in charge of β-synuclein fibrillation |
| Q47885617 | Ginkgolide B and bilobalide ameliorate neural cell apoptosis in α-synuclein aggregates |
| Q48163417 | Ginkgolide K promotes the clearance of A53T mutation alpha-synuclein in SH-SY5Y cells |
| Q36941956 | Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. |
| Q64074915 | Ginsenoside Rb1 prevents MPTP-induced changes in hippocampal memory via regulation of the α-synuclein/PSD-95 pathway |
| Q49061257 | Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra. |
| Q52718062 | Gintonin Mitigates MPTP-Induced Loss of Nigrostriatal Dopaminergic Neurons and Accumulation of α-Synuclein via the Nrf2/HO-1 Pathway. |
| Q26851153 | Glia and alpha-synuclein in neurodegeneration: A complex interaction |
| Q30620210 | Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice |
| Q43728426 | Glial cell death induced by overexpression of alpha-synuclein |
| Q48389356 | Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. |
| Q30991616 | Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants |
| Q27300869 | Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death |
| Q35971649 | Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration |
| Q52149452 | Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. |
| Q35674483 | Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein |
| Q47366721 | Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course |
| Q35960413 | Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders |
| Q57908797 | Glucocerebrosidase rescues alpha-synuclein from amyloid formation |
| Q51691934 | Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions. |
| Q36085373 | Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. |
| Q38605208 | Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson's disease. |
| Q41113409 | Glutamine promotes Hsp70 and inhibits α-Synuclein accumulation in pheochromocytoma PC12 cells |
| Q55085565 | Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson's Disease. |
| Q54789333 | Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease. |
| Q51063701 | Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. |
| Q44155992 | Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion |
| Q33399100 | Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress |
| Q50939945 | Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study. |
| Q26769620 | Gut Feelings About α-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making? |
| Q39394670 | HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. |
| Q52650035 | HMGB1 promotes the starvation-induced autophagic degradation of α-synuclein in SH-SY5Y cells Atg 5-dependently. |
| Q40580669 | HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. |
| Q40684026 | Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease |
| Q46612908 | Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra |
| Q36246469 | Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates |
| Q45980981 | Head injury, α-synuclein Rep1 and Parkinson's disease: a meta-analytic view of gene-environment interaction. |
| Q35726904 | Head injury, α-synuclein Rep1, and Parkinson's disease |
| Q35327353 | Head injury, α-synuclein genetic variability and Parkinson's disease |
| Q57361084 | Heat Shock Protein 70 Inhibits α-Synuclein Fibril Formation via Interactions with Diverse Intermediates |
| Q46624111 | Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease |
| Q38857706 | Heat shock protein 70 induction by glutamine increases the α-synuclein degradation in SH-SY5Y neuroblastoma cells |
| Q28910363 | Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species |
| Q42252886 | Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease. |
| Q47355256 | Heat shock protein 70 suppresses neuroinflammation induced by α-synuclein in astrocytes |
| Q34638333 | Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications |
| Q34421765 | Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity |
| Q36476930 | Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein |
| Q35920719 | Heme Stabilization of α-Synuclein Oligomers during Amyloid Fibril Formation. |
| Q45991009 | Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. |
| Q36474387 | Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration |
| Q30870225 | Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red. |
| Q55040758 | High Dietary Iron Supplement Induces the Nigrostriatal Dopaminergic Neurons Lesion in Transgenic Mice Expressing Mutant A53T Human Alpha-Synuclein. |
| Q35771016 | High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model |
| Q33827945 | High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast |
| Q36748956 | High expression of α-synuclein in damaged mitochondria with PLA2G6 dysfunction |
| Q45969544 | High level of alpha-synuclein mRNA in peripheral lymphocytes of patients with alcohol dependence syndrome. |
| Q36322512 | High pressure promotes alpha-synuclein aggregation in cultured neuronal cells |
| Q46839463 | High stability and cooperative unfolding of α-synuclein oligomers |
| Q48180411 | High-Density Single-Layer Coating of Gold Nanoparticles onto Multiple Substrates by Using an Intrinsically Disordered Protein of α-Synuclein for Nanoapplications |
| Q46281280 | High-Pressure-Driven Reversible Dissociation of α-Synuclein Fibrils Reveals Structural Hierarchy. |
| Q36296440 | High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
| Q38815707 | High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease |
| Q51233170 | High-density lipoprotein-like particle formation of Synuclein variants. |
| Q30493900 | High-resolution temperature-concentration diagram of alpha-synuclein conformation obtained from a single Förster resonance energy transfer image in a microfluidic device |
| Q57829038 | High-speed atomic force microscopy reveals structural dynamics of α-synuclein monomers and dimers |
| Q30466953 | High-throughput study of alpha-synuclein expression in yeast using microfluidics for control of local cellular microenvironment |
| Q33647059 | Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss |
| Q34497765 | Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication |
| Q40246572 | Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. |
| Q40150743 | Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies |
| Q39048630 | Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology |
| Q31060511 | Hippocampal α-synuclein and interneurons in Parkinson's disease: Data from human and mouse models |
| Q40576550 | Histochemical features of stress-induced aggregates in alpha-synuclein overexpressing cells. |
| Q48763007 | Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response. |
| Q48386650 | Histones facilitate α-synuclein aggregation during neuronal apoptosis. |
| Q33734084 | Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects |
| Q38640173 | Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease. |
| Q48217498 | Homozygous alpha-synuclein p.A53V in familial Parkinson's disease |
| Q38790881 | How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease? |
| Q38987375 | How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro |
| Q53366737 | How not to synthesize synuclein. |
| Q61229547 | Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses |
| Q35266716 | Hsc70 protein interaction with soluble and fibrillar alpha-synuclein |
| Q36835739 | Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease |
| Q39002960 | Hsp27 suppresses the Cu(2+)-induced amyloidogenicity, redox activity, and cytotoxicity of α-synuclein by metal ion stripping |
| Q40573441 | Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity |
| Q39109956 | Hsp90 inhibits α-synuclein aggregation by interacting with soluble oligomers. |
| Q27332460 | Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons |
| Q47144356 | Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes |
| Q35753373 | Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils |
| Q43705465 | Human Neural Progenitor Transplantation Rescues Behavior and Reduces α-Synuclein in a Transgenic Model of Dementia with Lewy Bodies. |
| Q56782469 | Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation |
| Q57837849 | Human Wild-Type α-Synuclein Impairs Neurogenesis |
| Q45711545 | Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. |
| Q30476254 | Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice |
| Q30377817 | Human and Tree Shrew Alpha-synuclein: Comparative cDNA Sequence and Protein Structure Analysis. |
| Q35031554 | Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element |
| Q41499639 | Human beta-synuclein rendered fibrillogenic by designed mutations |
| Q46084408 | Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease |
| Q36894433 | Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein. |
| Q24317509 | Human α-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1 |
| Q34598256 | Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein |
| Q36913539 | Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms |
| Q40921688 | Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson's disease, a triggering role in the disease? |
| Q37995991 | Hunting the chameleon: structural conformations of the intrinsically disordered protein alpha-synuclein. |
| Q41314313 | Hydrogen exchange of monomeric alpha-synuclein shows unfolded structure persists at physiological temperature and is independent of molecular crowding in Escherichia coli |
| Q44738407 | Hyperbranching axons template α-synuclein deposits and non-localizing clinical manifestations of Parkinson disease |
| Q60924121 | Hyperglycemia aggravates decrease in alpha-synuclein expression in a middle cerebral artery occlusion model |
| Q41161445 | Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease |
| Q64258107 | Hyperosmotic stress induces cell-dependent aggregation of α-synuclein |
| Q34917354 | Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease |
| Q42724546 | Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes |
| Q36383985 | Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease |
| Q30504583 | Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins |
| Q37631054 | Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson's disease |
| Q44302057 | Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma |
| Q47255115 | Hypothalamic α-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease. |
| Q35022473 | Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting γ-synuclein |
| Q35849000 | Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation |
| Q51515591 | Identification and affinity-quantification of ß-amyloid and α-synuclein polypeptides using on-line SAW-biosensor-mass spectrometry. |
| Q62746751 | Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases |
| Q28191445 | Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation |
| Q43164646 | Identification and localization of alpha-synuclein in human cornea |
| Q57986235 | Identification and nanomechanical characterization of the fundamental single-strand protofilaments of amyloid α-synuclein fibrils |
| Q33616462 | Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons |
| Q58007164 | Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the α-synuclein gene in early onset patients |
| Q34279026 | Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation |
| Q37024615 | Identification of a specific α-synuclein peptide (α-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons |
| Q34453988 | Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein |
| Q42185349 | Identification of fibril-like tertiary contacts in soluble monomeric α-synuclein |
| Q38837373 | Identification of gamma-synuclein as a new PCBP1-interacting protein |
| Q38518569 | Identification of gene expression changes in transgenic C. elegans overexpressing human alpha-synuclein |
| Q33257593 | Identification of human alpha-synuclein specific single chain antibodies |
| Q48264245 | Identification of new α-synuclein regulator by nontraditional drug development pipeline |
| Q24337043 | Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity |
| Q57055182 | Identification of novel protein phosphatases as modifiers of alpha-synuclein aggregation in yeast |
| Q28576892 | Identification of novel proteins associated with both alpha-synuclein and DJ-1 |
| Q33933189 | Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method |
| Q36294832 | Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p. |
| Q50943311 | Identification of proteins involved in microglial endocytosis of alpha-synuclein. |
| Q52666335 | Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. |
| Q35557260 | Identification of synaptosomal proteins binding to monomeric and oligomeric α-synuclein. |
| Q39863347 | Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation. |
| Q37401579 | Identification of the minimal copper(II)-binding alpha-synuclein sequence. |
| Q34341909 | Identification of two distinct synucleins from human brain |
| Q34700572 | Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry |
| Q48023048 | Identification, localization and characterization of the human gamma-synuclein gene |
| Q38250405 | Ignored avenues in alpha-synuclein associated proteopathy |
| Q41613707 | Imaging nanometer-sized α-synuclein aggregates by superresolution fluorescence localization microscopy. |
| Q48486817 | Immune receptor for pathogenic α-synuclein. |
| Q47662675 | Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model |
| Q38927111 | Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels |
| Q48653495 | Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. |
| Q28287237 | Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies |
| Q37592238 | Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study. |
| Q59673726 | Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4) |
| Q42493792 | Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy |
| Q42521749 | Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system |
| Q44448230 | Immunohistochemical study on the distribution of alpha-synuclein in the central nervous system of transgenic mice expressing a human Cu/Zn superoxide dismutase mutation |
| Q37474296 | Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein. |
| Q46177796 | Immunolocalization of alpha-synuclein in the rat spinal cord by two novel monoclonal antibodies |
| Q48621693 | Immunolocalization of human alpha-synuclein in the Thy1-aSyn ("Line 61") transgenic mouse line. |
| Q37232067 | Immunological features of alpha-synuclein in Parkinson's disease |
| Q59352500 | Immunology of West Nile Virus Infection and the Role of Alpha-Synuclein as a Viral Restriction Factor |
| Q36484413 | Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders |
| Q26781130 | Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation |
| Q58793525 | Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation |
| Q39188281 | Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice |
| Q38184645 | Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders |
| Q36058297 | Impact of N-terminal acetylation of α-synuclein on its random coil and lipid binding properties |
| Q46436825 | Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties |
| Q38720177 | Impact of high cholesterol in a Parkinson's disease model: Prevention of lysosomal leakage versus stimulation of α-synuclein aggregation. |
| Q30652467 | Impact of hydrostatic pressure on an intrinsically disordered protein: a high-pressure NMR study of α-synuclein |
| Q44675901 | Impact of subunit linkages in an engineered homodimeric binding protein to α-synuclein |
| Q45194802 | Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro |
| Q39942444 | Impact of the α-Synuclein Initial Ensemble Structure on Fibrillation Pathways and Kinetics |
| Q54998709 | Impacts of increased α-synuclein on clathrin-mediated endocytosis at synapses: implications for neurodegenerative diseases. |
| Q41837152 | Impaired baroreflex function in mice overexpressing alpha-synuclein |
| Q27334377 | Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice |
| Q29614178 | Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy |
| Q34915213 | Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease |
| Q38631574 | Impaired endo-lysosomal membrane integrity accelerates the seeding progression of α-synuclein aggregates |
| Q35807528 | Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons |
| Q38323425 | Impaired olfactory bulb neurogenesis depends on the presence of human wild-type alpha-synuclein. |
| Q50974323 | Impaired spatial and working memory in ageing mice with targeted inactivation of α-synuclein gene. |
| Q42363534 | Impairment of PDGF-induced chemotaxis by extracellular α-synuclein through selective inhibition of Rac1 activation |
| Q50860483 | Impairment of microtubule system increases alpha-synuclein aggregation and toxicity. |
| Q40199182 | Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein |
| Q38730062 | Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. |
| Q34718257 | Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synuclein |
| Q40432185 | Impairment of redox state and dopamine level induced by alpha-synuclein aggregation and the prevention effect of hsp70. |
| Q42506222 | Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice. |
| Q61804454 | Implications of alpha-synuclein nitration at tyrosine 39 in methamphetamine-induced neurotoxicity and |
| Q55339738 | Import and Export of Misfolded α-Synuclein. |
| Q35172657 | Improved immunodetection of endogenous α-synuclein |
| Q36517512 | Improved spatial learning and memory by perilla diet is correlated with immunoreactivities to neurofilament and α-synuclein in hilus of dentate gyrus. |
| Q38993636 | In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons |
| Q52330497 | In Situ Proximity Ligation Assay Reveals Co-Localization of Alpha-Synuclein and SNARE Proteins in Murine Primary Neurons. |
| Q33772734 | In silico modeling of the effects of alpha-synuclein oligomerization on dopaminergic neuronal homeostasis. |
| Q41821396 | In vitro aggregation assays for the characterization of α-synuclein prion-like properties. |
| Q45940314 | In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. |
| Q39306066 | In vitro evidence that an aqueous extract of Centella asiatica modulates α-synuclein aggregation dynamics |
| Q43005488 | In vitro formation of amyloid from alpha-synuclein is dominated by reactions at hydrophobic interfaces. |
| Q36691547 | In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain |
| Q37535579 | In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants |
| Q53371986 | In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein. |
| Q36939712 | In vitro study of α-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway |
| Q50210634 | In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. |
| Q42502439 | In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration |
| Q36976137 | In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? |
| Q34322594 | In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells |
| Q34652122 | In vivo demonstration that alpha-synuclein oligomers are toxic |
| Q37441397 | In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism. |
| Q46245987 | In vivo gastric detection of α-synuclein inclusions in Parkinson's disease. |
| Q33582289 | In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility |
| Q48463770 | In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody. |
| Q46252300 | In vivo models of alpha-synuclein transmission and propagation. |
| Q38311912 | In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain |
| Q57088466 | In vivo quantification of glial activation in minipigs overexpressing human α-synuclein |
| Q37033987 | In vivo silencing of alpha-synuclein using naked siRNA |
| Q43079464 | In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy |
| Q28535612 | In-cell NMR characterization of the secondary structure populations of a disordered conformation of α-synuclein within E. coli cells |
| Q24655848 | Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein |
| Q48942077 | Increase of the plasma α-synuclein levels in patients with multiple system atrophy. |
| Q49093762 | Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels. |
| Q61448701 | Increased DJ-1 and α-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson's Disease |
| Q24316244 | Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases |
| Q53145159 | Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. |
| Q38296498 | Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein |
| Q35058315 | Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis |
| Q47906051 | Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury |
| Q39385017 | Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli |
| Q37692508 | Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection |
| Q34092416 | Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease |
| Q36245278 | Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease |
| Q36485151 | Increased lipolysis and altered lipid homeostasis protect γ-synuclein-null mutant mice from diet-induced obesity |
| Q34450431 | Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies |
| Q48091913 | Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains |
| Q46591781 | Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. |
| Q28593809 | Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein |
| Q36004226 | Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra |
| Q46266933 | Incubation with Cu(II) and Zn(II) salts enhances MALDI-TOF mass spectra of amyloid-beta and α-synuclein toward in-vivo analysis |
| Q46349223 | Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein |
| Q52580024 | Inducible alpha-synuclein expression affects human Neural Stem Cell behavior. |
| Q34441722 | Inducible dopaminergic glutathione depletion in an α-synuclein transgenic mouse model results in age-related olfactory dysfunction |
| Q43579795 | Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis |
| Q39846072 | Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death |
| Q40463982 | Induction of C/EBP beta and GADD153 expression by dopamine in human neuroblastoma cells. Relationship with alpha-synuclein increase and cell damage. |
| Q37484884 | Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein |
| Q40776570 | Induction of alpha-synuclein aggregation by intracellular nitrative insult. |
| Q47552497 | Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology |
| Q36607413 | Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease |
| Q35065979 | Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. |
| Q40810658 | Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein |
| Q58009056 | Induction of neuronal death by α-synuclein |
| Q55305758 | Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders. |
| Q39618931 | Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. |
| Q36722186 | Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies |
| Q58091986 | Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice |
| Q27022728 | Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link? |
| Q54123277 | Inflammation kinase PKR phosphorylates α-synuclein and causes α-synuclein-dependent cell death. |
| Q37555992 | Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice |
| Q50533167 | Influence of 6-Hydroxydopamine Toxicity on α-Synuclein Phosphorylation, Resting Vesicle Expression, and Vesicular Dopamine Release. |
| Q48191027 | Influence of EGCG on α-synuclein (αS) aggregation and identification of their possible binding mode: A computational study using molecular dynamics simulation |
| Q38860090 | Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology. |
| Q35160746 | Influence of RNA interference on the mitochondrial subcellular localization of alpha-synuclein and on the formation of Lewy body-like inclusions in the cytoplasm of human embryonic kidney 293 cells induced by the overexpression of alpha-synuclein |
| Q40297921 | Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice. |
| Q46069836 | Influence of gold nanoparticles on the kinetics of α-synuclein aggregation. |
| Q36738118 | Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease. |
| Q38675540 | Influence of physical exercise on β-amyloid, α-synuclein and tau accumulation: an in vitro model of oxidative stress in human red blood cells |
| Q33198999 | Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments |
| Q28476061 | Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies |
| Q24298231 | Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds |
| Q36237308 | Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model |
| Q52664421 | Inhibition effects of tanshinone on the aggregation of α-synuclein. |
| Q43158706 | Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. |
| Q40436578 | Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain |
| Q38872092 | Inhibition of UCH-L1 in oligodendroglial cells results in microtubule stabilization and prevents α-synuclein aggregate formation by activating the autophagic pathway: implications for multiple system atrophy |
| Q37472054 | Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model |
| Q54409967 | Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. |
| Q46594060 | Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration |
| Q33375727 | Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region |
| Q48116098 | Inhibition of amyloid-β plaque formation by α-synuclein |
| Q28389635 | Inhibition of calpain prevents manganese-induced cell injury and alpha-synuclein oligomerization in organotypic brain slice cultures |
| Q47861119 | Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue |
| Q28587358 | Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein |
| Q46824424 | Inhibition of formation of α-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease |
| Q35014097 | Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson's disease |
| Q39655865 | Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. |
| Q38954711 | Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers |
| Q40268098 | Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment |
| Q40768273 | Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. |
| Q40526144 | Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells |
| Q28256395 | Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells |
| Q46413566 | Inhibition of α-Synuclein Fibril Elongation by Hsp70 Is Governed by a Kinetic Binding Competition between α-Synuclein Species |
| Q47839262 | Inhibition of α-Synuclein contributes to the ameliorative effects of dietary flavonoids luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells |
| Q53322022 | Inhibition of α-synuclein aggregation by small heat shock proteins. |
| Q36492162 | Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders |
| Q38485515 | Initial neuropsychological impairments in patients with the E46K mutation of the α-synuclein gene (PARK 1). |
| Q48325566 | Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein |
| Q38762286 | Innate immunity regulates α-synuclein clearance. |
| Q55018260 | Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. |
| Q38907566 | Insight into conformational modification of alpha-synuclein in the presence of neuronal whole cells and of their isolated membranes |
| Q54676819 | Insight into residues involved in the structure and function of the breast cancer associated protein human gamma synuclein. |
| Q37624629 | Insight into α-synuclein plasticity and misfolding from differential micelle binding |
| Q33365370 | Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data |
| Q37813450 | Insights into the thermodynamics of copper association with amyloid-β, α-synuclein and prion proteins |
| Q57824046 | Insights on Channel-Like Activity of Membrane Bound Alpha-Synuclein |
| Q38343049 | Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease |
| Q49160153 | Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation. |
| Q36737235 | Instantaneous amyloid fibril formation of alpha-synuclein from the oligomeric granular structures in the presence of hexane |
| Q38739408 | Insulin on activation of autophagy with integrins and syndecans against MPP+-induced α-synuclein neurotoxicity. |
| Q57821719 | Insulin-degrading enzyme is activated by the C-terminus of α-synuclein |
| Q42409261 | Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner |
| Q47819407 | Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology |
| Q62021902 | Integration of Single Cell Traps, Chemical Gradient Generator and Photosensors in a Microfluidic Platform for the Study of Alpha-Synuclein Toxicity in Yeast |
| Q49885321 | Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway. |
| Q48431408 | Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. |
| Q35834043 | Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease |
| Q37577611 | Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. |
| Q40598180 | Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats |
| Q40420217 | Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. |
| Q62559645 | Interaction between viologen-phosphorus dendrimers and α-synuclein |
| Q53324250 | Interaction between α-synuclein and other proteins in neurodegenerative disorders. |
| Q47794314 | Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease |
| Q43816330 | Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218. |
| Q57983286 | Interaction of ?-synuclein and tau genotypes in Parkinson's disease |
| Q47402887 | Interaction of Alpha-synuclein with Cytogaligin, a protein encoded by the proapoptotic gene GALIG. |
| Q57453946 | Interaction of Cu(i) with the Met-X-Met motif of alpha-synuclein: binding ligands, affinity and structural features |
| Q51082143 | Interaction of LRRK2 and α-Synuclein in Parkinson's Disease. |
| Q36514883 | Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra |
| Q28186641 | Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations |
| Q52165843 | Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. |
| Q50328842 | Interaction of manganese with striatal dopamine turnover in human alpha-synuclein transgenic mice. |
| Q28504823 | Interaction of myocilin with gamma-synuclein affects its secretion and aggregation |
| Q37827529 | Interaction of prolyl oligopeptidase with α-synuclein |
| Q47241011 | Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity |
| Q58484316 | Interaction of α-Synuclein with Divalent Metal Ions Reveals Key Differences: A Link between Structure, Binding Specificity and Fibrillation Enhancement |
| Q35869830 | Interaction of α-synuclein and a cell penetrating fusion peptide with higher eukaryotic cell membranes assessed by ¹⁹F NMR |
| Q47809290 | Interaction of α-synuclein with Rhus typhina tannin - Implication for Parkinson's disease |
| Q35878181 | Interaction of α-synuclein with biomembranes in Parkinson's disease--role of cardiolipin. |
| Q35740225 | Interaction of α-synuclein with vesicles that mimic mitochondrial membranes |
| Q42074579 | Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation. |
| Q24317181 | Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication |
| Q38954686 | Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders |
| Q35764303 | Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease |
| Q28910341 | Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly |
| Q30577687 | Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease |
| Q38254376 | Interactions between calcium and alpha-synuclein in neurodegeneration |
| Q24336967 | Interactions between fatty acids and alpha-synuclein |
| Q36872892 | Interactions between metals and alpha-synuclein--function or artefact? |
| Q34207247 | Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein |
| Q46284513 | Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal |
| Q38473449 | Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells |
| Q48647283 | Interference of α-Synuclein Uptake by Monomeric β-Amyloid1-40 and Potential Core Acting Site of the Interference. |
| Q57192922 | Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease |
| Q38890982 | Internalization, axonal transport and release of fibrillar forms of alpha-synuclein |
| Q37180671 | Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons |
| Q36657560 | Interplay between desolvation and secondary structure in mediating cosolvent and temperature induced alpha-synuclein aggregation |
| Q42983118 | Interplay between sumoylation and phosphorylation for protection against α-synuclein inclusions |
| Q57052511 | Interplay between α-synuclein amyloid formation and membrane structure |
| Q37153744 | Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. |
| Q39501866 | Interplay of salicylaldehyde, lysine, and M2+ ions on α-synuclein aggregation: cancellation of aggregation effects and determination of salicylaldehyde neurotoxicity. |
| Q40324674 | Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system |
| Q38651392 | Intracellular Dynamics of Synucleins: "Here, There and Everywhere". |
| Q42140713 | Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells |
| Q38765224 | Intracellular formation of α-synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy |
| Q48749969 | Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread. |
| Q36534162 | Intracellular repair of oxidation-damaged α-synuclein fails to target C-terminal modification sites |
| Q35548280 | Intracellular screening of a peptide library to derive a potent peptide inhibitor of α-synuclein aggregation |
| Q41493407 | Intracellular soluble α-synuclein oligomers reduce pyramidal cell excitability. |
| Q47941357 | Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells |
| Q35946149 | Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice |
| Q48590839 | Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. |
| Q57044271 | Intramolecular Diffusion in α-Synuclein: It Depends on How You Measure It |
| Q30585365 | Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. |
| Q34292532 | Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein |
| Q48379365 | Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. |
| Q48485896 | Intranigral dopamine toxicity and alpha-synuclein response in rats. |
| Q30373366 | Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration |
| Q33735667 | Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity |
| Q40405368 | Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. |
| Q36569512 | Intrinsic and membrane-facilitated α-synuclein oligomerization revealed by label-free detection through solid-state nanopores |
| Q59796184 | Investigating the neuroprotective effect of AAV-mediated β-synuclein overexpression in a transgenic model of synucleinopathy |
| Q41899331 | Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein |
| Q34638156 | Investigation of alpha-synuclein fibril structure by site-directed spin labeling |
| Q28539243 | Investigation of intramolecular dynamics and conformations of α-, β- and γ-synuclein |
| Q41206175 | Investigation of the Polymeric Properties of α-Synuclein and Comparison with NMR Experiments: A Replica Exchange Molecular Dynamics Study |
| Q47142619 | Investigation of the effects of carbon-based nanomaterials on A53T alpha-synuclein aggregation using a whole-cell recombinant biosensor |
| Q58710388 | Investigation of α-Synuclein Amyloid Fibrils Using the Fluorescent Probe Thioflavin T |
| Q51025638 | Investigation on the Molecular Interactions Stabilizing the Structure of α-synuclein Fibril: An In silico Study. |
| Q38817063 | Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease. |
| Q40321151 | Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons. |
| Q40224449 | Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility |
| Q33901731 | Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders |
| Q38911466 | Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein |
| Q60765817 | Ion Mobility Mass Spectrometry Studies of the Inhibition of Alpha Synuclein Amyloid Fibril Formation by ( - )-Epigallocatechin-3-Gallate |
| Q60765516 | Ion Mobility—Mass Spectrometry-Based Screening for Inhibition of α-Synuclein Aggregation |
| Q48302165 | Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. |
| Q41369321 | Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson's disease therapy |
| Q37587232 | Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction |
| Q45227789 | Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate |
| Q47648956 | Iron promotes α-synuclein aggregation and transmission by inhibiting TFEB-mediated autophagosome-lysosome fusion |
| Q47832644 | Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson's Disease |
| Q41837003 | Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates |
| Q33316521 | Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? |
| Q45300712 | Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? |
| Q45118902 | Is trehalose an autophagic inducer? Unraveling the roles of non-reducing disaccharides on autophagic flux and alpha-synuclein aggregation |
| Q45891840 | Is α-synuclein rising to the surface as a diagnostic biomarker for Parkinson disease? |
| Q49374861 | Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein. |
| Q46814164 | Isolation and functional analysis of yeast ubiquitin ligase Rsp5 variants that alleviate the toxicity of human α-synuclein |
| Q33280345 | Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity |
| Q42967896 | Isolation of short peptide fragments from alpha-synuclein fibril core identifies a residue important for fibril nucleation: a possible implication for diagnostic applications. |
| Q39437985 | Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. |
| Q45282581 | Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence |
| Q37716380 | KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. |
| Q35946269 | KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity |
| Q53285842 | Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. |
| Q57986229 | Kinetic barriers to α-synuclein protofilament formation and conversion into mature fibrils |
| Q36659034 | Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading |
| Q31029246 | Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct |
| Q38914810 | Knockdown of α-synuclein in cerebral cortex improves neural behavior associated with apoptotic inhibition and neurotrophin expression in spinal cord transected rats |
| Q48938965 | Kurtosis imaging reveals microstructural changes of late-stage α-synuclein accumulation in a mouse model of Parkinson's disease. |
| Q51005871 | L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro. |
| Q28588670 | LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance |
| Q35898177 | LK6/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration |
| Q41539639 | LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model |
| Q54977439 | LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. |
| Q64098788 | LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice |
| Q24304959 | LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models |
| Q39432630 | LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease |
| Q58701452 | LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation |
| Q48693369 | LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. |
| Q30658867 | Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. |
| Q35699583 | Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease |
| Q40346142 | Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates. |
| Q41881379 | Lack of involvement of alpha-synuclein in unconditioned anxiety in mice |
| Q42912837 | Lack of mutation G209A in the alpha-synuclein gene in French patients with familial and sporadic Parkinson's disease |
| Q43665738 | Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter |
| Q50109111 | Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients. |
| Q36673364 | Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking |
| Q40834797 | Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease. |
| Q31032932 | Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging. |
| Q36469322 | Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain |
| Q37713838 | Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease |
| Q36512589 | Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. |
| Q43244868 | Letter to the editor on "Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals". |
| Q55419948 | Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein. |
| Q35925767 | Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration |
| Q36208453 | Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia. |
| Q37829776 | Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? |
| Q37181158 | Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies |
| Q37294382 | Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions |
| Q38267597 | Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway |
| Q33594388 | Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. |
| Q48489167 | Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. |
| Q33822641 | Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease |
| Q48378357 | Levels of mRNA coding for alpha-, beta-, and gamma-synuclein in the brains of newborn, juvenile, and adult rats. |
| Q46278803 | Levels of α- and β-synuclein regulate cellular susceptibility to toxicity from α-synuclein oligomers. |
| Q38689029 | Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under α-synuclein-induced toxicity |
| Q35754459 | Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes |
| Q33961445 | Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. |
| Q33983772 | Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions |
| Q46970748 | Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. |
| Q48390394 | Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. |
| Q53239408 | Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. |
| Q51888287 | Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. |
| Q54486835 | Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. |
| Q36873680 | Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy |
| Q36353090 | Lewy pathological study on α-synuclein in gastrointestinal tissues of prodromal Parkinson's disease |
| Q36603477 | Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo |
| Q35146028 | Life-time expression of the proteins peroxiredoxin, beta-synuclein, PARK7/DJ-1, and stathmin in the primary visual and primary somatosensory cortices in rats |
| Q52682083 | Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease. |
| Q54973959 | Lighting Up Alpha-synuclein Oligomers. |
| Q38961743 | Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. |
| Q38165680 | Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. |
| Q55242370 | Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis. |
| Q60934477 | LincRNA-p21 Inhibits Cell Viability and Promotes Cell Apoptosis in Parkinson’s Disease through Activating α-Synuclein Expression |
| Q40231793 | Linkage disequilibrium and association analysis of alpha-synuclein and alcohol and drug dependence in two American Indian populations |
| Q38967501 | Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells |
| Q38182901 | Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation |
| Q58727604 | Lipid Extraction by α-Synuclein Generates Semi-Transmembrane Defects and Lipoprotein Nanoparticles |
| Q45908123 | Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. |
| Q44350640 | Lipid binding inhibits alpha-synuclein fibril formation |
| Q33724346 | Lipid classes and fatty acid patterns are altered in the brain of γ-synuclein null mutant mice |
| Q40763309 | Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein |
| Q44326531 | Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and H2O2. |
| Q35752895 | Lipid peroxidation is essential for α-synuclein-induced cell death |
| Q42116613 | Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein |
| Q44999245 | Lipid rafts mediate the synaptic localization of alpha-synuclein. |
| Q61641268 | Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers |
| Q41065976 | Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation |
| Q57472629 | Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age |
| Q37363512 | Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype |
| Q64074236 | Lipids at the Crossroad of α-Synuclein Function and Dysfunction: Biological and Pathological Implications |
| Q37237861 | Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expression |
| Q48372893 | Lipoprotein lipase deficiency leads to α-synuclein aggregation and ubiquitin C-terminal hydrolase L1 reduction. |
| Q38333893 | Lithium protects against oxidative stress-mediated cell death in α-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease |
| Q60922145 | Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology |
| Q47348583 | LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells |
| Q58618927 | Local and Global Dynamics in Intrinsically Disordered Synuclein |
| Q28577395 | Localization of alpha-, beta-, and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma |
| Q46988909 | Localization of alpha-synuclein to mitochondria within midbrain of mice |
| Q30484963 | Localization of synucleins in the mammalian cochlea |
| Q46801030 | Localization of α-synuclein in teleost central nervous system: immunohistochemical and Western blot evidence by 3D5 monoclonal antibody in the common carp, Cyprinus carpio |
| Q47917529 | Locally resolved membrane binding affinity of the N-terminus of α-synuclein. |
| Q46768370 | Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein |
| Q51767457 | Locomotor differences in mice expressing wild-type human α-synuclein. |
| Q46757199 | Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice |
| Q37705985 | Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of γ-synuclein in hepatocellular carcinoma cells |
| Q47547717 | Long-lasting pathological consequences of overexpression-induced α-synuclein spreading in the rat brain |
| Q41908259 | Long-range distances in amyloid fibrils of α-synuclein from PELDOR spectroscopy |
| Q34010535 | Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children an |
| Q40231021 | Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease |
| Q48655959 | Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. |
| Q35759141 | Longitudinal Metabolomics Profiling of Parkinson's Disease-Related α-Synuclein A53T Transgenic Mice. |
| Q39466212 | Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. |
| Q42174645 | Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors |
| Q42095746 | Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies |
| Q39297100 | Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism. |
| Q47936425 | Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide. |
| Q47959536 | Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo |
| Q46405617 | Loss of PINK1 inhibits apoptosis by upregulating α-synuclein in inflammation-sensitized hypoxic-ischemic injury in the immature brains. |
| Q38128456 | Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? |
| Q35152964 | Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation |
| Q28507051 | Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice |
| Q47801119 | Loss of native α-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells |
| Q44904779 | Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice. |
| Q33617563 | Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons. |
| Q28118642 | Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells |
| Q42078981 | Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies |
| Q34544824 | Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy |
| Q60923407 | Low CSF α-synuclein levels may facilitate the prediction of synucleinopathies |
| Q50343189 | Low Serum Level α-Synuclein and Tau Protein in Autism Spectrum Disorder Compared to Controls. |
| Q48429674 | Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. |
| Q41150477 | Low alpha-synuclein levels in the blood are associated with insulin resistance |
| Q36492769 | Low doses of single or combined agrichemicals induces α-synuclein aggregation in nigrostriatal system of mice through inhibition of proteasomal and autophagic pathways |
| Q48039687 | Low frequency of alpha-synuclein mutations in familial Parkinson's disease |
| Q43180542 | Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation. |
| Q38687589 | Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways |
| Q46480688 | Low-Intensity Ultrasound Decreases α-Synuclein Aggregation via Attenuation of Mitochondrial Reactive Oxygen Species in MPP(+)-Treated PC12 Cells |
| Q34602533 | Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation |
| Q64108354 | Lower Posttraumatic α-Synuclein Level Associated With Altered Default Mode Network Connectivity Following Acute Mild Traumatic Brain Injury |
| Q46369373 | Lrrk2 and alpha-synuclein are co-regulated in rodent striatum |
| Q39781327 | Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease |
| Q24310608 | Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications |
| Q34073890 | Lys-63-linked ubiquitination by E3 ubiquitin ligase Nedd4-1 facilitates endosomal sequestration of internalized α-synuclein |
| Q38987540 | Lysine residues at the first and second KTKEGV repeats mediate α-Synuclein binding to membrane phospholipids |
| Q38675441 | Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin |
| Q38753762 | Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. |
| Q33810012 | Lysosomal degradation of alpha-synuclein in vivo. |
| Q39595928 | Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. |
| Q39914071 | Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity |
| Q44212285 | Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease |
| Q40447154 | Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. |
| Q50420820 | Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy. |
| Q34043163 | Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death. |
| Q45284312 | MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies |
| Q41894807 | MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration |
| Q30400256 | MOAG-4 promotes the aggregation of α-synuclein by competing with self-protective electrostatic interactions |
| Q46087817 | MPP+ impairs autophagic clearance of alpha-synuclein by impairing the activity of dynein. |
| Q40725645 | MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells |
| Q47101012 | MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation |
| Q38647359 | Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). |
| Q36424977 | Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation |
| Q30395345 | Macromolecular and Small Molecular Crowding Have Similar Effects on α-Synuclein Structure. |
| Q54473816 | Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder. |
| Q37364049 | Macrophages are unsuccessful in clearing aggregated alpha-synuclein from the gastrointestinal tract of healthy aged Fischer 344 rats |
| Q24292317 | Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein |
| Q34908991 | Mammalian ribosomal and chaperone protein RPS3A counteracts α-synuclein aggregation and toxicity in a yeast model system |
| Q28397442 | Manganese exposure induces α-synuclein aggregation in the frontal cortex of non-human primates |
| Q47593851 | Manganese exposure: Linking down-regulation of miRNA-7 and miRNA-433 with α-synuclein overexpression and risk of idiopathic Parkinson's disease. |
| Q54654107 | Manganese induces the overexpression of α-synuclein in PC12 cells via ERK activation |
| Q47242442 | Manganese-induced alpha-synuclein overexpression impairs synaptic vesicle fusion by disrupting the Rab3 cycle in primary cultured neurons |
| Q36100354 | Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease |
| Q57976902 | Mapping Long-Range Interactions in α-Synuclein using Spin-Label NMR and Ensemble Molecular Dynamics Simulations |
| Q58090111 | Mapping Surface Hydrophobicity of α-Synuclein Oligomers at the Nanoscale |
| Q48164117 | Mapping of Rat Brain Using the Synuclein-1 Monoclonal Antibody Reveals Somatodendritic Expression of α-Synuclein in Populations of Neurons Homologous to those Vulnerable to Lewy Body Formation in Human Synucleopathies |
| Q41620729 | Mapping of Surface-Exposed Epitopes of In Vitro and In Vivo Aggregated Species of Alpha-Synuclein |
| Q37012885 | Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis |
| Q58739239 | Mass spectrometry data confirming tetrameric α-synuclein N-terminal acetylation |
| Q40041056 | Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson's disease |
| Q38981601 | Mathematical models of α-synuclein transport in axons |
| Q37147697 | May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of sporadic Parkinson's disease? |
| Q51766023 | Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. |
| Q64240914 | Mechanical and thermodynamic properties of Aβ, Aβ, and α-synuclein fibrils: a coarse-grained method to complement experimental studies |
| Q47289725 | Mechanical stress increases brain amyloid β, tau, and α-synuclein concentrations in wild-type mice |
| Q26772943 | Mechanism of Anti-α-Synuclein Immunotherapy |
| Q37064014 | Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies |
| Q49102090 | Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines. |
| Q52617078 | Mechanism of membrane interaction and disruption by α-synuclein. |
| Q30152694 | Mechanism of α-synuclein translocation through a VDAC nanopore revealed by energy landscape modeling of escape time distributions. |
| Q36575028 | Mechanisms and models of alpha-synuclein-related neurodegeneration. |
| Q36325784 | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. |
| Q36610346 | Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery |
| Q45158445 | Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. |
| Q38488082 | Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role |
| Q35789622 | Mechanisms of protein oligomerization: inhibitor of functional amyloids templates α-synuclein fibrillation |
| Q52363911 | Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease. |
| Q48847188 | Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. |
| Q33805180 | Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates. |
| Q36891660 | Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane |
| Q57042872 | Mechanistic insight into the binding profile of DCVJ and α-synuclein fibril revealed by multi-scale simulations |
| Q28533560 | Mechanistic insight into the relationship between N-terminal acetylation of α-synuclein and fibril formation rates by NMR and fluorescence |
| Q46525987 | Mechanistic study of the inhibitory activity of Geum urbanum extract against α-Synuclein fibrillation. |
| Q48513255 | Medullary neuronal loss is not associated with α-synuclein burden in multiple system atrophy. |
| Q36777303 | Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation. |
| Q48098240 | Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of alpha-synuclein |
| Q44931875 | Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α-synuclein aggregation. |
| Q46260574 | Melatonin improves survival and respiratory activity of yeast cells challenged by alpha-synuclein and menadione |
| Q39992817 | Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells |
| Q52576880 | Melatonin inhibits maneb-induced aggregation of alpha-synuclein in rat pheochromocytoma cells. |
| Q43811011 | Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. |
| Q48944269 | Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. |
| Q41539970 | Membrane Binding of Parkinson's Protein α-Synuclein: Effect of Phosphorylation at Positions 87 and 129 by the S to D Mutation Approach |
| Q24633488 | Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins |
| Q61844382 | Membrane Interaction of α-Synuclein in Different Aggregation States |
| Q27315907 | Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism |
| Q33893738 | Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations |
| Q52543652 | Membrane binding and self-association of alpha-synucleins. |
| Q44120459 | Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing |
| Q58783524 | Membrane binding, internalization, and sorting of alpha-synuclein in the cell |
| Q44507185 | Membrane bound α-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain. |
| Q35604940 | Membrane curvature sensing by amphipathic helices: a single liposome study using α-synuclein and annexin B12 |
| Q42442931 | Membrane interaction of α-synuclein in different aggregation states |
| Q46807031 | Membrane interactions and fibrillization of α-synuclein play an essential role in membrane disruption |
| Q37737733 | Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease |
| Q35023098 | Membrane lipid co-aggregation with α-synuclein fibrils. |
| Q39665306 | Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of α-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress |
| Q28066666 | Membrane remodeling and mechanics: Experiments and simulations of α-Synuclein |
| Q37383252 | Membrane remodeling by α-synuclein and effects on amyloid formation. |
| Q51281121 | Membrane-Bound Alpha Synuclein Clusters Induce Impaired Lipid Diffusion and Increased Lipid Packing. |
| Q37117422 | Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease |
| Q43198829 | Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles |
| Q28567172 | Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form |
| Q36554541 | Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. |
| Q47223416 | Membrane-induced initial structure of α-synuclein control its amyloidogenesis on model membranes |
| Q38802652 | Mesenchymal Stem Cells Inhibit Transmission of α-Synuclein by Modulating Clathrin-Mediated Endocytosis in a Parkinsonian Model |
| Q38744332 | Mesenchymal Stem Cells Stabilize Axonal Transports for Autophagic Clearance of α-Synuclein in Parkinsonian Models. |
| Q48469192 | Mesenchymal stem cells enhance α-synuclein clearance via M2 microglia polarization in experimental and human parkinsonian disorder. |
| Q43069962 | Meta-analysis of alpha synuclein/ NACP polymorphism in Parkinson's disease in Japan |
| Q37624100 | Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice. |
| Q37278480 | Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein |
| Q39878715 | Metal binding to alpha-synuclein peptides and its contribution to toxicity |
| Q37347089 | Metal catalyzed oxidation of alpha-synuclein--a role for oligomerization in pathology? |
| Q46323541 | Metal chelator EGCG attenuates Fe(III)-induced conformational transition of α-synuclein and protects AS-PC12 cells against Fe(III)-induced death. |
| Q53235896 | Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. |
| Q43735123 | Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure |
| Q37808957 | Metalloproteomics and metal toxicology of α-synuclein |
| Q37737068 | Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies. |
| Q33720188 | Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. |
| Q47954089 | Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease |
| Q44026039 | Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro |
| Q30476575 | Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions |
| Q36023887 | Methionine oxidation, alpha-synuclein and Parkinson's disease |
| Q60456080 | Methyl-branched lipids promote the membrane adsorption of α-synuclein by enhancing shallow lipid-packing defects |
| Q46462682 | Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients |
| Q34660005 | Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. |
| Q42636786 | Methylphenidate modifies overflow and presynaptic compartmentalization of dopamine via an α-synuclein-dependent mechanism. |
| Q38961925 | MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-γ. |
| Q33817178 | Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior |
| Q28511475 | Mice lacking alpha-synuclein are resistant to mitochondrial toxins |
| Q28594502 | Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system |
| Q45003281 | Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration |
| Q37016812 | Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation |
| Q52159615 | Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1 |
| Q61645355 | MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56 |
| Q37702119 | MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian |
| Q44618765 | MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy |
| Q38836903 | MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson's disease mouse |
| Q47969417 | Microarray analysis of an synthetic α-synuclein induced cellular model reveals the expression profile of long non-coding RNA in Parkinson's disease |
| Q58799080 | Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention |
| Q33526342 | Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. |
| Q64263518 | Microglia as modulators of exosomal alpha-synuclein transmission |
| Q48122029 | Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. |
| Q36640417 | Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein |
| Q58610287 | Microglial glutamate release evoked by α-synuclein aggregates is prevented by dopamine |
| Q24813664 | Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition |
| Q39986517 | Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease |
| Q39692472 | Microtubule depolymerization potentiates alpha-synuclein oligomerization |
| Q37164569 | Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy |
| Q28141728 | Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments |
| Q48180540 | Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia |
| Q48905945 | Microwave fields have little effect on α-synuclein aggregation in a Caenorhabditis elegans model of Parkinson's disease. |
| Q41985945 | Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy. |
| Q43441572 | Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. |
| Q44031071 | Mind the gut: secretion of α-synuclein by enteric neurons |
| Q38401326 | Mini review: linkage between α-Synuclein protein and cognition |
| Q47123483 | Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease. |
| Q47958898 | Minimal Nucleation State of α-Synuclein Is Stabilized by Dynamic Threonine-Water Networks |
| Q46445900 | Minimally Toxic Dose of Lipopolysaccharide and α-Synuclein Oligomer Elicit Synergistic Dopaminergic Neurodegeneration: Role and Mechanism of Microglial NOX2 Activation. |
| Q54877808 | Miro1 overexpression protects against α-synuclein-induced mitochondrial loss in neuronal culture. |
| Q24554351 | Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies |
| Q37968039 | Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease |
| Q47239603 | Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson's Disease? |
| Q60614456 | Mitochondria-Targeted Cholesterol Oximes Increase Dopamine-Related Gene Expression and Behavior in Mice Over-Expressing Alpha-Synuclein, a Model of Pre-Manifest Parkinson’s Disease |
| Q35412397 | Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? |
| Q42580316 | Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. |
| Q46292411 | Mitochondrial ROS-mediated post-transcriptional regulation of α-synuclein through miR-7 and miR-153. |
| Q45310519 | Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease |
| Q40005336 | Mitochondrial association of alpha-synuclein causes oxidative stress |
| Q41308603 | Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's disease. |
| Q41664833 | Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? |
| Q36539066 | Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue |
| Q42709899 | Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication |
| Q38717872 | Mitochondrial ferritin protects SH-SY5Y cells against H2O2-induced oxidative stress and modulates α-synuclein expression |
| Q38849169 | Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of α-synuclein in oligodendroglial cells |
| Q36727241 | Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain |
| Q33914242 | Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy |
| Q24537310 | Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein |
| Q30573776 | Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice |
| Q37556779 | Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases |
| Q36791338 | Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification |
| Q42391404 | Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo |
| Q58804178 | Model Senescent Microglia Induce Disease Related Changes in α-Synuclein Expression and Activity |
| Q40044736 | Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain |
| Q48323464 | Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations |
| Q31165000 | Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers |
| Q38286574 | Models of α-synuclein aggregation in Parkinson's disease |
| Q47677223 | Modification of C Terminus Provides New Insights into the Mechanism of α-Synuclein Aggregation |
| Q55250469 | Modification of α-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization: its relevance to Parkinson disease. |
| Q42321742 | Modulating membrane binding of α-synuclein as a therapeutic strategy |
| Q36872325 | Modulating the Amyloidogenesis of α-Synuclein |
| Q47988278 | Modulating the catalytic activity of AMPK has neuroprotective effects against α-synuclein toxicity. |
| Q57064666 | Modulating α-synuclein fibril formation using DNA tetrahedron nanostructures |
| Q46044214 | Modulation effect of filamentous phage on alpha-synuclein aggregation |
| Q42683255 | Modulation of Alpha-synuclein Expression and Associated Effects by MicroRNA Let-7 in Transgenic C. elegans |
| Q33532593 | Modulation of alpha-synuclein aggregation by dopamine analogs |
| Q37483616 | Modulation of alpha-synuclein aggregation by dopamine: a review. |
| Q33392127 | Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze? |
| Q50609868 | Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator. |
| Q40658922 | Modulation of cell death by alpha-synuclein is stimulus-dependent in mammalian cells |
| Q37164196 | Modulation of dendritic cell function by the radiation-mediated secretory protein γ-synuclein |
| Q24320119 | Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress |
| Q39056699 | Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine |
| Q48007169 | Modulation of the extent of structural heterogeneity in α-synuclein fibrils by the small molecule thioflavin T. |
| Q24298523 | Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein |
| Q57821753 | Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: Templation and inhibition involve oligomers with different structure |
| Q54254674 | Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease. |
| Q38644380 | Molecular Dynamics Study to Investigate the Dimeric Structure of the Full-Length α-Synuclein in Aqueous Solution. |
| Q48138690 | Molecular Role of Ca2+ and Hard Divalent Metal Cations on Accelerated Fibrillation and Interfibrillar Aggregation of α-Synuclein |
| Q34695506 | Molecular ageing of alpha- and Beta-synucleins: protein damage and repair mechanisms. |
| Q41627077 | Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity |
| Q37350413 | Molecular and cellular biology of synucleins |
| Q33675844 | Molecular basis for preventing α-synuclein aggregation by a molecular tweezer. |
| Q38038121 | Molecular chaperones, α-synuclein, and neurodegeneration |
| Q44539727 | Molecular cloning, characterization and developmental expression of porcine beta-synuclein |
| Q35565655 | Molecular details of α-synuclein membrane association revealed by neutrons and photons. |
| Q43157334 | Molecular determinants of the aggregation behavior of alpha- and beta-synuclein |
| Q24312185 | Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions |
| Q54441399 | Molecular dynamic simulations of the tubulin-human gamma synuclein complex: structural insight into the regulatory mechanism involved in inducing resistance against Taxol. |
| Q38236857 | Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers |
| Q53356650 | Molecular inscription of environmental information into protein suprastructures: temperature effects on unit assembly of α-synuclein oligomers into polymorphic amyloid fibrils. |
| Q43277862 | Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid |
| Q39787734 | Molecular interaction of α-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells |
| Q37309838 | Molecular mechanisms of alpha-synuclein neurodegeneration |
| Q47611385 | Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease |
| Q45248027 | Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation |
| Q24336019 | Molecular motors implicated in the axonal transport of tau and alpha-synuclein |
| Q46586858 | Molecular understanding of copper and iron interaction with alpha-synuclein by fluorescence analysis |
| Q34115959 | Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. |
| Q38213838 | Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy |
| Q33925977 | Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain |
| Q48187716 | Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation |
| Q37329723 | Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase. |
| Q41256308 | Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates |
| Q34313934 | Monomeric synucleins generate membrane curvature |
| Q34126935 | Monomeric α-synuclein binds Congo Red micelles in a disordered manner |
| Q40037116 | Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells |
| Q39470458 | Moracenin D from Mori Cortex radicis protects SH-SY5Y cells against dopamine-induced cell death by regulating nurr1 and α-synuclein expression |
| Q47906587 | More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases |
| Q47300849 | Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. |
| Q58700494 | Morphological Evaluation of Meta-stable Oligomers of α-Synuclein with Small-Angle Neutron Scattering |
| Q47370368 | Morphological analysis of mitochondria for evaluating the toxicity of α-synuclein in transgenic mice and isolated preparations by atomic force microscopy |
| Q56018194 | Morphological analysis of oligomeric vs. fibrillar forms of α-synuclein aggregates with super-resolution BALM imaging |
| Q30446265 | Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system |
| Q34342813 | Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism |
| Q47872914 | Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study |
| Q60313606 | Motor and Nonmotor Symptoms of Parkinson’s Disease: Antagonistic Pleiotropy Phenomena Derived from α-Synuclein Evolvability? |
| Q40261126 | Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease. |
| Q44260175 | Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice |
| Q46257748 | Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology |
| Q34279665 | Mouse models of alpha-synucleinopathy and Lewy pathology. Alpha-synuclein expression in transgenic mice. |
| Q38128496 | Mouse models of cognitive deficits due to alpha-synuclein pathology |
| Q38409919 | Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model |
| Q33835599 | Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders |
| Q38377819 | Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects |
| Q34074933 | Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates |
| Q51765701 | Multimodal neuroimaging and behavioral assessment of α-synuclein polymorphism rs356219 in older adults. |
| Q46629317 | Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein |
| Q34565111 | Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease |
| Q43678231 | Multiple ligand interaction of alpha-synuclein produced various forms of protein aggregates in the presence of Abeta25-35, copper, and eosin |
| Q34519861 | Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation |
| Q31155710 | Multiple regions of alpha-synuclein are associated with Parkinson's disease |
| Q48523567 | Multiple system atrophy (MSA): topographic distribution of the alpha-synuclein-associated pathological changes. |
| Q33181542 | Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. |
| Q37003479 | Multiple system atrophy: alpha-synuclein and neuronal degeneration |
| Q47309944 | Multiple system atrophy: genetic risks and alpha-synuclein mutations. |
| Q37258811 | Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy |
| Q57652282 | Multiple ways for α-synuclein degradation |
| Q48406192 | Multiple-system atrophy: a new alpha-synuclein disease? |
| Q49139527 | Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease. |
| Q57986239 | Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine |
| Q37252419 | Munc18-1 is a molecular chaperone for α-synuclein, controlling its self-replicating aggregation |
| Q40808027 | Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm |
| Q42089641 | Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy |
| Q48565252 | Mutant A53T α-Synuclein Improves Rotarod Performance Before Motor Deficits and Affects Metabolic Pathways. |
| Q24318474 | Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies |
| Q35649563 | Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain |
| Q33958241 | Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis |
| Q40778644 | Mutant alpha-synuclein overexpression mediates early proinflammatory activity |
| Q52668931 | Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease. |
| Q24299582 | Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase |
| Q35879482 | Mutant protein A30P α-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics |
| Q48095463 | Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease. |
| Q36641684 | Mutant α-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. |
| Q48262721 | Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. |
| Q40501417 | Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein |
| Q48392838 | Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies. |
| Q27860459 | Mutation in the alpha-synuclein gene identified in families with Parkinson's disease |
| Q34538864 | Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation |
| Q34657526 | Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology |
| Q40627442 | Mutations in the lipid-binding domain of α-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity |
| Q34944325 | Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization |
| Q30497967 | Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. |
| Q42972578 | N(ɛ)-(carboxymethyl)lysine linkage to α-synuclein and involvement of advanced glycation end products in α-synuclein deposits in an MPTP-intoxicated mouse model |
| Q47883033 | N-Terminal Acetylation Preserves α-Synuclein from Oligomerization by Blocking Intermolecular Hydrogen Bonds |
| Q57025396 | N-Terminal Fusion Potentiates α-Synuclein |
| Q42247351 | N-Terminal acetylation is critical for forming α-helical oligomer of α-synuclein |
| Q35215613 | N-alpha-acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation |
| Q42247305 | N-terminal acetylation of α-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer |
| Q37563546 | N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. |
| Q39489133 | N-terminal deletion does not affect α-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast |
| Q39930416 | N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules. |
| Q33915588 | NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies |
| Q48498352 | NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC). |
| Q28289929 | NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy |
| Q34157232 | NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases |
| Q35660114 | NADH fluorescence lifetime is an endogenous reporter of α-synuclein aggregation in live cells |
| Q46303329 | NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in a C. elegans model of Parkinson's disease |
| Q38562137 | NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein |
| Q27677491 | NMR Structure of Calmodulin Complexed to an N-Terminally Acetylated α-Synuclein Peptide |
| Q42649841 | NMR determination of pKa values in α-synuclein |
| Q46843110 | NMR mapping of copper binding sites in alpha-synuclein |
| Q40921912 | NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. |
| Q56620168 | Nanobodies Raised against Monomeric α-Synuclein Distinguish between Fibrils at Different Maturation Stages |
| Q40968608 | Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species |
| Q37453948 | Nanomechanical properties of distinct fibrillar polymorphs of the protein α-synuclein |
| Q38993396 | Nanomechanical properties of α-synuclein amyloid fibrils: a comparative study by nanoindentation, harmonic force microscopy, and Peakforce QNM. |
| Q34094699 | Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway |
| Q39149504 | Nanomolar oligomerization and selective co-aggregation of α-synuclein pathogenic mutants revealed by single-molecule fluorescence |
| Q50240778 | Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies. |
| Q36802355 | Nanoscopic insights into seeding mechanisms and toxicity of α-synuclein species in neurons |
| Q50088901 | Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice. |
| Q48202370 | Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. |
| Q36153110 | Native chemical ligation of thioamide-containing peptides: development and application to the synthesis of labeled α-synuclein for misfolding studies |
| Q26269886 | Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2 |
| Q34627859 | Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays |
| Q64103700 | Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology |
| Q45854801 | Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease |
| Q40147786 | Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain |
| Q36913314 | Neonatal exposure to lipopolysaccharide enhances accumulation of α-synuclein aggregation and dopamine transporter protein expression in the substantia nigra in responses to rotenone challenge in later life |
| Q30276423 | Network Analysis Implicates Alpha-Synuclein (Snca) in the Regulation of Ovariectomy-Induced Bone Loss |
| Q36410380 | Network dysfunction in α-synuclein transgenic mice and human Lewy body dementia |
| Q46832286 | Neural activity controls the synaptic accumulation of alpha-synuclein. |
| Q48097777 | Neural expression profile of alpha-synuclein in developing human cortex |
| Q34508711 | Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression |
| Q34332706 | Neurobiology of alpha-synuclein |
| Q64111293 | Neurodegeneration and contralateral α-synuclein induction after intracerebral α-synuclein injections in the anterior olfactory nucleus of a Parkinson's disease A53T mouse model |
| Q50101026 | Neurodegeneration and the ordered assembly of α-synuclein. |
| Q35745646 | Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology |
| Q30454029 | Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. |
| Q49032496 | Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. |
| Q41913912 | Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease |
| Q33649354 | Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? |
| Q27027973 | Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity |
| Q37241917 | Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration |
| Q28512774 | Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction |
| Q35044751 | Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. |
| Q26771536 | Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation |
| Q30817400 | Neuroinvasion of α-Synuclein Prionoids after Intraperitoneal and Intraglossal Inoculation. |
| Q42486578 | Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. |
| Q39421938 | Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells |
| Q51896976 | Neuromuscular pathology in mice lacking alpha-synuclein. |
| Q33874305 | Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia |
| Q36374952 | Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport |
| Q35206648 | Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury |
| Q51841212 | Neuronal Loss and Α-Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. |
| Q28509735 | Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model |
| Q48581887 | Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. |
| Q46314049 | Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses |
| Q48320011 | Neuronal autophagy, α-synuclein clearance, and LRRK2 regulation: a lost equilibrium in parkinsonian brain. |
| Q42613578 | Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice |
| Q36946533 | Neuronal hemoglobin in mitochondria is reduced by forming a complex with α-synuclein in aging monkey brains |
| Q37687353 | Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease. |
| Q44292863 | Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer |
| Q48371876 | Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. |
| Q35786733 | Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy |
| Q28587583 | Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene |
| Q44566946 | Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein |
| Q27320029 | Neuropathology in mice expressing mouse alpha-synuclein |
| Q47341364 | Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology |
| Q33957376 | Neuropathology of synuclein aggregates |
| Q38580816 | Neuropathology of α-synuclein propagation and braak hypothesis |
| Q34648491 | Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation |
| Q41832273 | Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease |
| Q35887788 | Neuroprotection of inositol hexaphosphate and changes of mitochondrion mediated apoptotic pathway and α-synuclein aggregation in 6-OHDA induced parkinson's disease cell model |
| Q39527730 | Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K. |
| Q39460586 | Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity |
| Q46291421 | Neuroprotective effect of chondroitin sulfate on SH‑SY5Y cells overexpressing wild‑type or A53T mutant α‑synuclein |
| Q46337717 | Neuroprotective effect of α-mangostin on mitochondrial dysfunction and α-synuclein aggregation in rotenone-induced model of Parkinson's disease in differentiated SH-SY5Y cells. |
| Q39061385 | Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein |
| Q58805372 | Neuroprotective effects of genistein on SH-SY5Y cells overexpressing A53T mutant α-synuclein |
| Q50175992 | Neuroprotective effects of voluntary running on cognitive dysfunction in an α-synuclein rat model of Parkinson's disease. |
| Q48134401 | Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons. |
| Q37587795 | Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies? |
| Q61445763 | Neurotoxicity of pre-incubated alpha-synuclein with neutral nanoliposomes on PC12 and SHSY5Y cell lines |
| Q29541727 | Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos |
| Q59812935 | New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease |
| Q44603447 | New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. |
| Q41544270 | New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro. |
| Q48125502 | New evidence comes to light: How is α-synuclein aggregation related to mitochondrial protein import in Parkinson's disease? |
| Q38325657 | New evidence on α-synuclein and Tau binding to conformation and sequence specific GC* rich DNA: Relevance to neurological disorders |
| Q38568611 | New insights into cellular α-synuclein homeostasis in health and disease. |
| Q35548527 | New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease |
| Q42062219 | New α- and γ-synuclein immunopathological lesions in human brain |
| Q46422305 | Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease |
| Q44234633 | Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: relation to changes in alpha-synuclein expression. |
| Q48463677 | Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. |
| Q46467299 | Nigral burden of alpha-synuclein correlates with striatal dopamine deficit |
| Q35769443 | Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration |
| Q30633819 | Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein |
| Q31132651 | Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease |
| Q34140861 | Nigrostriatal dynein changes in A53T alpha-synuclein transgenic mice |
| Q30497542 | Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes |
| Q48006941 | Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. |
| Q42711308 | Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models |
| Q33315262 | Nitrated alpha-synuclein and microglial neuroregulatory activities |
| Q33312931 | Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons |
| Q33553317 | Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats |
| Q42521775 | Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease |
| Q37137351 | Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets |
| Q46409443 | Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. |
| Q44428923 | Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers |
| Q60542808 | No alterations in α-synuclein gene dosage observed in sporadic Parkinson's disease |
| Q36344196 | No apparent transmission of transgenic α-synuclein into nigrostriatal dopaminergic neurons in multiple mouse models. |
| Q43070336 | No male predominance in alpha-synuclein Parkinson's disease but the affected female fetus might be less viable |
| Q47935101 | No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy |
| Q57606019 | No pathogenic mutations in the β-synuclein gene in Parkinson's disease |
| Q35788235 | Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. |
| Q48661140 | Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation. |
| Q50790075 | Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases. |
| Q64240303 | Non-Cell-Autonomous Neurotoxicity in Parkinson's Disease Mediated by Astroglial α-Synuclein |
| Q37043549 | Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2 |
| Q43117414 | Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions |
| Q45855349 | Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression |
| Q43089495 | Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function |
| Q40869024 | Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology |
| Q46829340 | Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro |
| Q41331992 | Non-uniform self-assembly: On the anisotropic architecture of α-synuclein supra-fibrillar aggregates. |
| Q33824692 | Nonaggregated α-synuclein influences SNARE-dependent vesicle docking via membrane binding |
| Q42177727 | Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters. |
| Q59351729 | Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound |
| Q37115559 | Noninvasive measurement of protein aggregation by mutant huntingtin fragments or alpha-synuclein in the lens. |
| Q48437595 | Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms. |
| Q39196646 | Normalization of Overexpressed α-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference |
| Q47826150 | Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. |
| Q30352615 | Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. |
| Q57808800 | Novel Alpha-Synuclein Oligomers Formed with the Aminochrome-Glutathione Conjugate Are Not Neurotoxic |
| Q48198568 | Novel Benzothiazole Derivatives as Fluorescent Probes for Detection of β-Amyloid and α-Synuclein Aggregates. |
| Q49024793 | Novel Dimer Compounds That Bind α-Synuclein Can Rescue Cell Growth in a Yeast Model Overexpressing α-Synuclein. A Possible Prevention Strategy for Parkinson's Disease. |
| Q42180919 | Novel Epigenetic Regulation of Alpha-Synuclein Expression in Down Syndrome |
| Q64242771 | Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease |
| Q64061136 | Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson's Disease |
| Q45947142 | Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. |
| Q41311746 | Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein |
| Q37160673 | Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes |
| Q48494226 | Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. |
| Q38848617 | Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. |
| Q47695761 | Novel evidence associates higher plasma α-synuclein levels and cognitive impairment in Parkinson's disease |
| Q41748468 | Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions |
| Q50689906 | Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. |
| Q51535490 | Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties. |
| Q33805560 | Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates |
| Q34356116 | Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening |
| Q26827605 | Novel subcellular localization for α-synuclein: possible functional consequences |
| Q36967979 | Novel suppressors of alpha-synuclein toxicity identified using yeast |
| Q46724154 | Nrf2 inducer and cncC overexpression attenuates neurodegeneration due to α-synuclein in Drosophila |
| Q41827284 | Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis. |
| Q37241387 | Nuclear Magnetic Resonance Observation of α-Synuclein Membrane Interaction by Monitoring the Acetylation Reactivity of Its Lysine Side Chains |
| Q46094666 | Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice |
| Q57157562 | Nuclear localization and phosphorylation modulate pathological effects of Alpha-Synuclein |
| Q46597702 | Nuclear localization of alpha-synuclein and its interaction with histones |
| Q39207279 | Nuclear translocation of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative stress |
| Q39021697 | Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells |
| Q48207550 | Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient |
| Q35816903 | Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression |
| Q24310360 | Nurr1 transcriptionally regulates the expression of alpha-synuclein |
| Q52596328 | Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2 cells. |
| Q24306217 | Nutrient deprivation induces α-synuclein aggregation through endoplasmic reticulum stress response and SREBP2 pathway |
| Q36200921 | O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease |
| Q45937542 | O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein. |
| Q39238586 | O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation |
| Q41064100 | O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease. |
| Q45948370 | O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding. |
| Q47943047 | Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex |
| Q46440075 | Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice |
| Q39093774 | Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo. |
| Q55341800 | Oleuropein aglycone stabilizes the monomeric α-synuclein and favours the growth of non-toxic aggregates. |
| Q28539195 | Olfactory deficits in an alpha-synuclein fly model of Parkinson's disease |
| Q35026044 | Olfactory deficits in mice overexpressing human wildtype alpha-synuclein |
| Q35208334 | Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein |
| Q38333322 | Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages |
| Q51954079 | Oligodendrocytes from neural stem cells express alpha-synuclein: increased numbers from presenilin 1 deficient mice. |
| Q46264316 | Oligomer-prone E57K-mutant alpha-synuclein exacerbates integration deficit of adult hippocampal newborn neurons in transgenic mice |
| Q37704274 | Oligomeric alpha-synuclein and its role in neuronal death |
| Q48234434 | Oligomeric alpha-synuclein inhibits tubulin polymerization |
| Q35897340 | Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease |
| Q46471084 | Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease |
| Q36479597 | Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases |
| Q36282886 | Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). |
| Q52659477 | Oligomers of Parkinson's Disease-Related α-Synuclein Mutants Have Similar Structures but Distinctive Membrane Permeabilization Properties. |
| Q51062625 | Oligomers of α-synuclein: picking the culprit in the line-up. |
| Q44762277 | Oligopeptide-mediated acceleration of amyloid fibril formation of amyloid beta(Abeta) and alpha-synuclein fragment peptide (NAC). |
| Q39849148 | On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft |
| Q33488964 | On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid |
| Q36709104 | On-surface aggregation of α-synuclein at nanomolar concentrations results in two distinct growth mechanisms |
| Q34655246 | One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli. |
| Q44007141 | One-pot total chemical synthesis of human α-synuclein |
| Q37375495 | Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells |
| Q42375123 | Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth |
| Q51610612 | Opposite Structural Effects of Epigallocatechin-3-gallate and Dopamine Binding to α-Synuclein. |
| Q57401259 | Optical Structural Analysis of Individual α-Synuclein Oligomers |
| Q46237585 | Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria |
| Q50000615 | Optical structural analysis of individual α-synuclein oligomers. |
| Q53266680 | Optimizing Western Blots for the Detection of Endogenous α-Synuclein in the Enteric Nervous System. |
| Q42290602 | Optogenetic Rescue of Locomotor Dysfunction and Dopaminergic Degeneration Caused by Alpha-Synuclein and EKO Genes |
| Q47639323 | Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated α-Synuclein in the Enteric Nervous System of A53T Mutant Human α-Synuclein Transgenic Mice |
| Q33680232 | Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α-Synuclein Overexpressing Mice |
| Q38339264 | Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system |
| Q47444791 | Order and disorder in the physiological membrane binding of α-synuclein |
| Q37044665 | Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease |
| Q24297619 | Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation |
| Q37633571 | Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells |
| Q39607464 | Over-expression of α-synuclein 98 triggers intracellular oxidative stress and enhances susceptibility to rotenone |
| Q40090895 | Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway |
| Q37707932 | Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology |
| Q44165281 | Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. |
| Q58586715 | Overexpression of Wild-Type Human Alpha-Synuclein Causes Metabolism Abnormalities in Thy1-aSYN Transgenic Mice |
| Q35696249 | Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. |
| Q40567680 | Overexpression of alpha-synuclein decreased viability and enhanced sensitivity to prostaglandin E(2), hydrogen peroxide, and a nitric oxide donor in differentiated neuroblastoma cells |
| Q43092667 | Overexpression of alpha-synuclein down-regulates BDNF expression |
| Q36653961 | Overexpression of alpha-synuclein following methamphetamine: is it good or bad? |
| Q40511251 | Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease |
| Q42705625 | Overexpression of human E46K mutant α-synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway |
| Q43868527 | Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture |
| Q40877706 | Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. |
| Q43752239 | Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice |
| Q40540903 | Overexpression of synuclein-gamma in pancreatic adenocarcinoma |
| Q36123218 | Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients |
| Q33947949 | Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice |
| Q38701541 | Overexpression of α-synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis. |
| Q35857994 | Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity |
| Q38816358 | Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity |
| Q35797475 | Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease |
| Q38085689 | Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. |
| Q30881832 | Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis |
| Q35170996 | Oxidative modifications of alpha-synuclein. |
| Q32035138 | Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease |
| Q39574774 | Oxidative stress effect of dopamine on α-synuclein: electroanalysis of solvent interactions |
| Q38585651 | Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy |
| Q41646793 | Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro |
| Q40315913 | Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells |
| Q46418746 | Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids |
| Q42519882 | Oxidative stress involvement in manganese-induced alpha-synuclein oligomerization in organotypic brain slice cultures |
| Q39716036 | Oxidative stress partially contributes to iron-induced α-synuclein aggregation in SK-N-SH cells |
| Q39064365 | Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes |
| Q39201466 | Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. |
| Q46864441 | Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation. |
| Q44328423 | Oxidized glutathione stimulated the amyloid formation of alpha-synuclein |
| Q46211319 | Oxidized quercetin inhibits α-synuclein fibrillization |
| Q48682431 | P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. |
| Q54271518 | P2X7 receptor is critical in α-synuclein--mediated microglial NADPH oxidase activation. |
| Q38703135 | P2X7 receptor-pannexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells |
| Q46648354 | PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly |
| Q57982395 | PAMAM Dendrimers as Potential Agents against Fibrillation ofα-Synuclein, a Parkinson's Disease-Related Protein |
| Q35233106 | PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein |
| Q33412371 | PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease |
| Q49509661 | PINK1 suppresses alpha-synuclein-induced neuronal injury: a novel mechanism in protein phosphatase 2A activation. |
| Q39151446 | PLK2 modulates α-synuclein aggregation in yeast and mammalian cells |
| Q28585769 | Pale body-like inclusion formation and neurodegeneration following depletion of 26S proteasomes in mouse brain neurones are independent of α-synuclein |
| Q50532472 | Pale neurites, premature α-synuclein aggregates with centripetal extension from axon collaterals. |
| Q58799123 | Palmitic Acid-Enriched Diet Increases α-Synuclein and Tyrosine Hydroxylase Expression Levels in the Mouse Brain |
| Q52618938 | Paradoxical Effect of Trehalose on the Aggregation of α-Synuclein: Expedites Onset of Aggregation yet Reduces Fibril Load. |
| Q38190542 | Parallel mechanisms for direct and indirect membrane protein trafficking by synucleins |
| Q37337917 | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
| Q34301507 | Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease |
| Q46304295 | Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers |
| Q39971393 | Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein |
| Q28201602 | Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain |
| Q34492912 | Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice |
| Q40079867 | Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity |
| Q44258606 | Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons |
| Q40636500 | Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells |
| Q24291767 | Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease |
| Q44074597 | Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease |
| Q28115384 | Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation |
| Q35351512 | Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo |
| Q45915163 | Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. |
| Q41462411 | Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation |
| Q53437587 | Parkinson disease: Disease-linked morphometric variants of α-synuclein. |
| Q33705614 | Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels |
| Q53837965 | Parkinson disease: Truncated α-synuclein causes mitochondrial toxicity. |
| Q48524311 | Parkinson disease: extranigral, multisystem, and {alpha}-synuclein "plus". |
| Q41147863 | Parkinson disease: α-synuclein mutational screening and new clinical insight into the p.E46K mutation. |
| Q45780402 | Parkinson patient fibroblasts show increased alpha-synuclein expression |
| Q36789528 | Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer |
| Q57886107 | Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate |
| Q41817806 | Parkinson's Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma. |
| Q35847200 | Parkinson's Protein α-Synuclein Binds Efficiently and with a Novel Conformation to Two Natural Membrane Mimics |
| Q64111645 | Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms |
| Q44784009 | Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons |
| Q46884563 | Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. |
| Q38079791 | Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? |
| Q48894182 | Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. |
| Q36346542 | Parkinson's disease and α-synuclein expression |
| Q48170464 | Parkinson's disease and α-synuclein: passing it on. |
| Q48397887 | Parkinson's disease correlates with promoter methylation in the α-synuclein gene. |
| Q27686837 | Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies |
| Q28117589 | Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein |
| Q53599143 | Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. |
| Q35692589 | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus |
| Q33182013 | Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype |
| Q37874205 | Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report. |
| Q35161124 | Parkinson's disease, cortical dysfunction, and alpha-synuclein |
| Q41755571 | Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs |
| Q39520707 | Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1. |
| Q52572188 | Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation. |
| Q47224887 | Parkinson's disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking |
| Q27932080 | Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes |
| Q33576922 | Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma |
| Q38727638 | Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance |
| Q35168775 | Parkinson's disease: alpha-synuclein and parkin in protein aggregation and the reversal of unfolded protein stress |
| Q35032823 | Parkinson's disease: dopaminergic nerve cell model is consistent with experimental finding of increased extracellular transport of α-synuclein. |
| Q53350524 | Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. |
| Q28598223 | Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression |
| Q35813688 | Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation |
| Q43940212 | Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. |
| Q26269955 | Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein |
| Q24305472 | Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model |
| Q24311461 | Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro |
| Q35157623 | Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. |
| Q41618658 | Partial peptide of α-synuclein modified with small-molecule inhibitors specifically inhibits amyloid fibrillation of α-synuclein |
| Q33674814 | Partial regulation of serotonin transporter function by gamma-synuclein |
| Q28740551 | Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease |
| Q41844481 | Pathobiochemical effect of acylated steryl-β-glucoside on aggregation and cytotoxicity of α-synuclein. |
| Q46920062 | Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation |
| Q31120123 | Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein |
| Q64091665 | Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration |
| Q36080000 | Pathogenic effects of alpha-synuclein aggregation. |
| Q38928728 | Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. |
| Q48806783 | Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. |
| Q36739168 | Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. |
| Q37350181 | Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys |
| Q47862762 | Pathological Endogenous α-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. |
| Q34100338 | Pathological alpha-synuclein propagates through neural networks |
| Q38766966 | Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders |
| Q48586171 | Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. |
| Q46773538 | Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies |
| Q47228027 | Pathological role of lipid interaction with α-synuclein in Parkinson's disease |
| Q37947720 | Pathological roles of α-synuclein in neurological disorders |
| Q36581696 | Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology |
| Q39014339 | Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation |
| Q33729317 | Pathological α-synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb |
| Q38381460 | Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients |
| Q41015843 | Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. |
| Q29620597 | Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice |
| Q54981864 | Pathophysiological Consequences of Neuronal α-Synuclein Overexpression: Impacts on Ion Homeostasis, Stress Signaling, Mitochondrial Integrity, and Electrical Activity. |
| Q36317227 | Pathophysiology of synuclein aggregation in Lewy body disease. |
| Q59335760 | Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease |
| Q48298552 | Patterns of Tau and α-Synuclein Pathology in the Visual System |
| Q37968067 | Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease |
| Q46115621 | Peculiarities of copper binding to alpha-synuclein |
| Q33305729 | Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning |
| Q46774944 | Peptides as modulators of α-synuclein aggregation. |
| Q39310986 | Peripheral Elevation of a Klotho Fragment Enhances Brain Function and Resilience in Young, Aging, and α-Synuclein Transgenic Mice |
| Q61807052 | Peripheral Inflammation Regulates CNS Immune Surveillance Through the Recruitment of Inflammatory Monocytes Upon Systemic α-Synuclein Administration |
| Q48505064 | Peripheral blood alpha-synuclein mRNA levels are elevated in cynomolgus monkeys that chronically self-administer ethanol. |
| Q47575506 | Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. |
| Q50439660 | Peripheral synuclein tissue markers: a step closer to Parkinson's disease diagnosis. |
| Q48263744 | Perirhinal accumulation of neuronal alpha-synuclein in a multiple system atrophy patient with dementia. |
| Q43085060 | Perivascular nerve fiber α-synuclein regulates contractility of mouse aorta: a link to autonomic dysfunction in Parkinson's disease |
| Q37257402 | Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease |
| Q41783968 | Peroxidative aggregation of alpha-synuclein requires tyrosines |
| Q28594866 | Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system |
| Q28512814 | Persyn, a member of the synuclein family, influences neurofilament network integrity |
| Q48008557 | Perturbation in Long-Range Contacts Modulates the Kinetics of Amyloid Formation in α-Synuclein Familial Mutants. |
| Q43668015 | Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease |
| Q48194148 | Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. |
| Q35643171 | Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity |
| Q38581165 | Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models |
| Q21131229 | Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism |
| Q34281004 | Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease |
| Q51735817 | Phospholipase D1 downregulation by α-synuclein: Implications for neurodegeneration in Parkinson's disease. |
| Q34393784 | Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates |
| Q57044789 | Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to α-Synuclein Gain |
| Q59439099 | Phosphorus-containing dendrimers against α-synuclein fibril formation |
| Q53290250 | Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies. |
| Q39642185 | Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner |
| Q45013686 | Phosphorylated alpha-synuclein in normal mouse brain |
| Q44177978 | Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions |
| Q47096063 | Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice |
| Q52625125 | Phosphorylated α-Synuclein Accumulations and Lewy Body-like Pathology Distributed in Parkinson's Disease-Related Brain Areas of Aged Rhesus Monkeys Treated with MPTP. |
| Q48246699 | Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease |
| Q50513826 | Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. |
| Q57298310 | Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease |
| Q61413320 | Phosphorylated α-synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease |
| Q30510167 | Phosphorylated α-synuclein in Parkinson's disease |
| Q34460662 | Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity |
| Q48157334 | Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy |
| Q36115621 | Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects |
| Q30496792 | Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions |
| Q30368281 | Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. |
| Q46202469 | Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease |
| Q37419169 | Phosphorylation induces distinct alpha-synuclein strain formation |
| Q27316174 | Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease |
| Q55286336 | Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T α-synuclein model of Parkinson's disease. |
| Q46593989 | Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease |
| Q44265068 | Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila |
| Q46583981 | Phosphorylation of an alpha-synuclein peptide fragment enhances metal binding |
| Q33514979 | Phosphorylation of synucleins by members of the Polo-like kinase family |
| Q46699765 | Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. |
| Q36015338 | Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders |
| Q44215784 | Phosphorylation of α-synuclein at Ser120 accelerates neurodegeneration |
| Q39317644 | Phosphorylation of α-synuclein is crucial in compensating for proteasomal dysfunction |
| Q35802054 | Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans |
| Q39812287 | Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells |
| Q46478232 | Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson |
| Q62083470 | Phosphorylation-dependent metal binding by α-synuclein peptide fragments |
| Q35814444 | Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease |
| Q57129769 | Photoconductivity of pea-pod-type chains of gold nanoparticles encapsulated within dielectric amyloid protein nanofibrils of α-synuclein |
| Q47260012 | Photophysics of diphenyl-pyrazole compounds in solutions and α-synuclein aggregates |
| Q40575486 | Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein |
| Q36866952 | Physiological and pathological properties of alpha-synuclein |
| Q37166339 | Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element |
| Q57458019 | Physiological carboxy-truncation of α-synuclein potentiates the prion-like formation of pathological inclusions |
| Q34148286 | Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. |
| Q37045173 | Piceatannol and Other Wine Stilbenes: A Pool of Inhibitors against α-Synuclein Aggregation and Cytotoxicity |
| Q48456409 | Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus. |
| Q42096504 | Pink1 interacts with α-synuclein and abrogates α-synuclein-induced neurotoxicity by activating autophagy |
| Q51944517 | Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. |
| Q47854549 | Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased β-Synuclein Expression, and Defects in Brain Functions and Pathways. |
| Q64075638 | Plant Extracts and Phytochemicals Targeting -Synuclein Aggregation in Parkinson's Disease Models |
| Q64100766 | Plasma -synuclein levels are increased in patients with obstructive sleep apnea syndrome |
| Q64262808 | Plasma alpha-synuclein detected by single molecule array is increased in PD |
| Q44060578 | Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment |
| Q48295840 | Plasma alpha-synuclein is decreased in subjects with Parkinson's disease |
| Q27322563 | Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. |
| Q40294091 | Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells |
| Q46730330 | Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease |
| Q38760749 | Plasma α-synuclein predicts cognitive decline in Parkinson's disease |
| Q34160489 | Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects |
| Q48661051 | Pluripotent stem cells with triplication of alpha-synuclein locus. |
| Q47770990 | Point Mutations in the α-Synuclein Gene |
| Q37075340 | Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system |
| Q48224865 | Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production |
| Q24320103 | Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo |
| Q58618292 | Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease |
| Q41849419 | Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro |
| Q46713215 | Polychlorinated biphenyls alter expression of alpha-synuclein, synaptophysin and parkin in the rat brain |
| Q47130088 | Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease |
| Q45814729 | Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity. |
| Q44286639 | Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease |
| Q38714779 | Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative. |
| Q47133254 | Polyunsaturated chains in asymmetric lipids disorder raft mixtures and preferentially associate with α-Synuclein |
| Q36202906 | Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells |
| Q39984851 | Porcine gamma-synuclein: molecular cloning, expression analysis, chromosomal localization and functional expression |
| Q36321837 | Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies |
| Q46948742 | Possible implication of ciliary neurotrophic factor (CNTF) and beta-synuclein in the ammonia effect on cultured rat astroglial cells: a study using DNA and protein microarrays. |
| Q36852905 | Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. |
| Q33776138 | Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease |
| Q24633965 | Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153 |
| Q38529282 | Post-translational modification of α-synuclein in Parkinson's disease |
| Q36931291 | Post-translational modifications of α-synuclein contribute to neurodegeneration in the colon of elderly individuals |
| Q35864260 | Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain |
| Q38523536 | Postnatal expression of alpha-synuclein protein in the rodent substantia nigra and striatum |
| Q37196992 | Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage |
| Q38444052 | Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast |
| Q43193570 | Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity |
| Q42653035 | Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. |
| Q39224191 | Potassium depolarization and raised calcium induces α-synuclein aggregates. |
| Q52718516 | Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods. |
| Q39152836 | Potential Modes of Intercellular α-Synuclein Transmission |
| Q38942540 | Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases |
| Q38241802 | Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents |
| Q46464490 | Potential of mean force and molecular dynamics study on the transient interactions between α and β synuclein that drive inhibition of α-synuclein aggregation |
| Q34002451 | Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein |
| Q37303879 | Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation |
| Q42507110 | Potential role of α-synuclein in neurodegeneration: studies in a rat animal model |
| Q39150857 | Pramipexole reduces phosphorylation of α-synuclein at serine-129. |
| Q46236939 | Pre-aggregation kinetics and intermediates of α-synuclein monitored by the ESIPT probe 7MFE. |
| Q24315670 | Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models |
| Q34023955 | Pre-fibrillar α-synuclein mutants cause Parkinson's disease-like non-motor symptoms in Drosophila |
| Q40087267 | Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles |
| Q35043731 | Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation |
| Q57064672 | Predicting the location of the non-local Contacts in α-synuclein |
| Q35854162 | Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer |
| Q45720936 | Predictive atomic resolution descriptions of intrinsically disordered hTau40 and α-synuclein in solution from NMR and small angle scattering |
| Q50692501 | Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture. |
| Q37357416 | Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. |
| Q39025505 | Prefoldin prevents aggregation of α-synuclein |
| Q36884635 | Preparation and Characterization of Stable α-Synuclein Lipoprotein Particles |
| Q62055328 | Preparation of α-synuclein fibrils for solid-state NMR: Expression, purification, and incubation of wild-type and mutant forms |
| Q34631931 | Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha-synuclein in oligodendrocytes |
| Q46348663 | Pressure effects on α-synuclein amyloid fibrils: An experimental investigation on their dissociation and reversible nature. |
| Q48279657 | Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. |
| Q37554972 | Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. |
| Q38224023 | Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins |
| Q58621723 | Prime Time for -Synuclein |
| Q37528739 | Principles of self-organization in biological pathways: a hypothesis on the autogenous association of alpha-synuclein |
| Q36005171 | Prion infection promotes extensive accumulation of α-synuclein in aged human α-synuclein transgenic mice |
| Q40196812 | Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC. |
| Q36321556 | Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein |
| Q36732844 | Prion-like spreading of pathological α-synuclein in brain |
| Q48090188 | Prion-like transmission of α-synuclein pathology in the context of an NFL null background |
| Q37014379 | Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons |
| Q64095970 | Probing Membrane Association of α-Synuclein Domains with VDAC Nanopore Reveals Unexpected Binding Pattern |
| Q34416878 | Probing the Micelle‐Bound Aggregation‐Prone State of α‐Synuclein with 19F NMR Spectroscopy |
| Q37092530 | Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy |
| Q39667579 | Production of a monoclonal antibody, against human α-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the α-synuclein locus |
| Q33317768 | Products of Cu(II)-catalyzed oxidation of alpha-synuclein fragments containing M1-D2 and H50 residues in the presence of hydrogen peroxide. |
| Q33250111 | Products of Cu(II)-catalyzed oxidation of the N-terminal fragments of alpha-synuclein in the presence of hydrogen peroxide. |
| Q42500238 | Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type |
| Q40461584 | Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. |
| Q46679453 | Progressive accumulation of ubiquitin and disappearance of alpha-synuclein epitope in multiple system atrophy-associated glial cytoplasmic inclusions: triple fluorescence study combined with Gallyas-Braak method |
| Q35151971 | Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism |
| Q33847712 | Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein |
| Q34105980 | Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons |
| Q35278967 | Prolongation of Chemically-Induced Methemoglobinemia in Mice Lacking α-synuclein: A Novel Pharmacologic and Toxicologic Phenotype |
| Q46696288 | Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. |
| Q38923732 | Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction |
| Q38732589 | Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture |
| Q46525783 | Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein |
| Q46637747 | Prolyl-isomerase Pin1 accumulates in lewy bodies of parkinson disease and facilitates formation of alpha-synuclein inclusions |
| Q28570621 | Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons |
| Q36197708 | Propagated but Topologically Distributed Forebrain Neurons Expressing Alpha-Synuclein in Aged Macaques |
| Q49083078 | Propagation of Aβ, tau and α-synuclein pathology between experimental models and human reality: prions, propagons and propaganda. |
| Q49353206 | Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies. |
| Q27322513 | Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies |
| Q37621023 | Propagation of pathological α-synuclein in marmoset brain. |
| Q64238991 | Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network |
| Q33971315 | Properties of NACP/alpha-synuclein and its role in Alzheimer's disease |
| Q26269846 | Properties of native brain α-synuclein |
| Q41845296 | Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein |
| Q43161603 | Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice |
| Q44719233 | Proteasomal inhibition by alpha-synuclein filaments and oligomers. |
| Q43718632 | Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells |
| Q48531053 | Proteasome dysfunction in aged human alpha-synuclein transgenic mice. |
| Q42363521 | Proteasome impairment by α-synuclein. |
| Q35085788 | Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation |
| Q41956476 | Proteasome inhibitor-induced autophagy in PC12 cells overexpressing A53T mutant α-synuclein |
| Q44691515 | Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions |
| Q58722552 | Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model |
| Q39902605 | Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors |
| Q45947053 | Protective effect of Curcumin on chronic cerebral ischemia by altering expression of α- synuclein in 2VO model. |
| Q40519448 | Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. |
| Q34095954 | Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons |
| Q44706446 | Protective effect of telmisartan against progressive oxidative brain damage and synuclein phosphorylation in stroke-resistant spontaneously hypertensive rats |
| Q59052625 | Protective effects of hydroxytyrosol against α-synuclein toxicity on PC12 cells and fibril formation |
| Q41126307 | Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells |
| Q34795775 | Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells |
| Q38759798 | Protein Partners of α-Synuclein in Health and Disease |
| Q38303579 | Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation |
| Q33743531 | Protein aggregation containing β-amyloid, α-synuclein and hyperphosphorylated τ in cultured cells of hippocampus, substantia nigra and locus coeruleus after rotenone exposure. |
| Q41202092 | Protein arginylation targets alpha synuclein, facilitates normal brain health, and prevents neurodegeneration |
| Q52587378 | Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins. |
| Q41597801 | Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders |
| Q47821365 | Protein kinase G regulates β-synuclein in response to repeated exposure to cocaine in the rat dorsal striatum in a Ca²⁺-dependent manner. |
| Q41611753 | Protein phosphatase 2A is involved in the tyrosine hydroxylase phosphorylation regulated by α-synuclein |
| Q30371293 | Protein-metal interactions of calmodulin and alpha-synuclein monitored by selective noncovalent adduct protein probing mass spectrometry. |
| Q28202923 | Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells |
| Q45892230 | Protein/lipid coaggregates are formed during α-synuclein-induced disruption of lipid bilayers. |
| Q39722484 | Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice |
| Q48619578 | Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. |
| Q27005843 | Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease |
| Q24301116 | Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases |
| Q36127050 | Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease |
| Q37190514 | Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease |
| Q39639654 | Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis |
| Q37184830 | Proteomic profiling of phosphoproteins and glycoproteins responsive to wild-type alpha-synuclein accumulation and aggregation |
| Q37355257 | Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells |
| Q24311624 | Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions |
| Q33302804 | Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Par |
| Q48492080 | Protocatechuic Acid: Inhibition of Fibril Formation, Destabilization of Preformed Fibrils of Amyloid-β and α-Synuclein, and Neuroprotection. |
| Q48251459 | Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations |
| Q55113852 | Publisher Correction: Alpha-synuclein facilitates to form short unconventional microtubules that have a unique function in the axonal transport. |
| Q51730571 | Pulsed HDX Illuminates the Aggregation Kinetics of Alpha-Synuclein, the Causative Agent for Parkinson's Disease. |
| Q53479855 | Pure autonomic failure without alpha-synuclein pathology: an evolving understanding of a heterogeneous disease. |
| Q52142432 | Purification of α-synuclein containing inclusions from human post mortem brain tissue. |
| Q35001178 | Purification of α-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. |
| Q34570713 | Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. |
| Q58764665 | Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease |
| Q34646732 | Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy |
| Q37800101 | Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies |
| Q38164892 | Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease? |
| Q58099784 | Quantifying Co-Oligomer Formation by α-Synuclein |
| Q36638870 | Quantifying interactions of β-synuclein and γ-synuclein with model membranes |
| Q64107562 | Quantitative Characterization of α-Synuclein Aggregation in Living Cells through Automated Microfluidics Feedback Control |
| Q36500789 | Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy |
| Q34395742 | Quantitative analysis of α-synuclein solubility in living cells using split GFP complementation |
| Q33935711 | Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry |
| Q39093747 | Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants |
| Q35963163 | Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy |
| Q41235948 | Quantitative proteomics in A30P*A53T α-synuclein transgenic mice reveals upregulation of Sel1l |
| Q36804685 | Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease |
| Q58911148 | Quantitative, Label-Free Detection of the Aggregation ofα-Synuclein Using Microcantilever Arrays Operated in a Liquid Environment |
| Q57279402 | Quinolinic Acid Amyloid-like Fibrillar Assemblies Seed α-Synuclein Aggregation |
| Q47689313 | REM sleep behavior disorder, autonomic dysfunction and synuclein-related neurodegeneration: where do we stand? |
| Q37614503 | RNA Interference of Human α-Synuclein in Mouse. |
| Q39998122 | RNA interference mediated silencing of alpha-synuclein in MN9D cells and its effects on cell viability |
| Q39149690 | RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells |
| Q40203572 | RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. |
| Q53175400 | RNAi of cat-2, a putative tyrosine hydroxylase, increases alpha synuclein aggregation and associated effects in transgenic C. elegans. |
| Q47616782 | RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. |
| Q37179079 | Rab11 modulates α-synuclein-mediated defects in synaptic transmission and behaviour |
| Q35621972 | Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein |
| Q47794264 | Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease |
| Q48190256 | Rab7 induces clearance of α-synuclein aggregates |
| Q37857950 | Rabs, SNAREs and α-synuclein--membrane trafficking defects in synucleinopathies |
| Q36319183 | Radiating amyloid fibril formation on the surface of lipid membranes through unit-assembly of oligomeric species of α-synuclein |
| Q43167138 | Radiation-induced gamma-synuclein in regards to DC function |
| Q35026876 | Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein |
| Q38060447 | Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation |
| Q39621864 | Raised calcium promotes α-synuclein aggregate formation |
| Q59888265 | Raman optical activity of human α -synuclein in intrinsically disordered, micelle-bound α -helical, molten globule and oligomeric β -sheet state |
| Q44775680 | Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein |
| Q47099565 | Randomized CRISPR-Cas Transcriptional Perturbation Screening Reveals Protective Genes against Alpha-Synuclein Toxicity. |
| Q47609800 | Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro |
| Q50052758 | Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. |
| Q58720864 | Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment |
| Q44083541 | Rapid purification and analysis of alpha-synuclein proteins: C-terminal truncation promotes the conversion of alpha-synuclein into a protease-sensitive form in Escherichia coli |
| Q33481617 | Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models |
| Q44926886 | Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy |
| Q34662060 | Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease |
| Q39681299 | Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells |
| Q48151369 | Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein |
| Q28582161 | Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex |
| Q33636374 | Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease |
| Q57492112 | Rationally Designed Variants of α-Synuclein Illuminate Its Structural Properties in Health and Disease |
| Q46941585 | Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease |
| Q41085178 | Reactivity of copper-α-synuclein peptide complexes relevant to Parkinson's disease. |
| Q52659687 | Reader response: A new potential biomarker for dementia with Lewy bodies: Skin nerve α-synuclein deposits. |
| Q46248308 | Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1. |
| Q64062738 | Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model |
| Q35681283 | Recent advances in research on Parkinson disease: synuclein and parkin |
| Q38038126 | Recent advances in α-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease |
| Q34173902 | Recent advances on alpha-synuclein cell biology: functions and dysfunctions. |
| Q34117957 | Recent progress in the research of multiple system atrophy with special references to alpha-synuclein and suprachiasmatic nucleus |
| Q48176756 | Reciprocal accumulation of β-synuclein in α-synuclein lesions in multiple system atrophy |
| Q39817121 | Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue |
| Q43721592 | Reciprocal induction between α-synuclein and β-amyloid in adult rat neurons |
| Q38837485 | Reciprocal signals between microglia and neurons regulate α-synuclein secretion by exophagy through a neuronal cJUN-N-terminal kinase-signaling axis |
| Q35670095 | Recombinant Expression and Phenotypic Screening of a Bioactive Cyclotide Against α-Synuclein-Induced Cytotoxicity in Baker's Yeast. |
| Q38614375 | Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays |
| Q33771776 | Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40) |
| Q50663283 | Red blood cells are the major source of alpha-synuclein in blood. |
| Q24299645 | Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease |
| Q24293189 | Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3 |
| Q42426545 | Redox reactions of the α-synuclein-Cu(2+) complex and their effects on neuronal cell viability |
| Q47687664 | Reduced TH expression and α-synuclein accumulation contribute towards nigrostriatal dysfunction in experimental hepatic encephalopathy |
| Q33770294 | Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein |
| Q36527631 | Reduced expression of α-synuclein in alcoholic brain: influence of SNCA-Rep1 genotype |
| Q24324577 | Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease |
| Q31847110 | Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein |
| Q50711777 | Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. |
| Q33865366 | Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models |
| Q37127867 | Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model |
| Q28273075 | Reducing synuclein accumulation improves neuronal survival after spinal cord injury |
| Q51697680 | Reduction of Immunoreactivity Against the C-Terminal Region of the Intracellular α-Synuclein by Exogenous α-Synuclein Aggregates: Possibility of Conformational Changes. |
| Q52596888 | Refolding of helical soluble α-synuclein through transient interaction with lipid interfaces. |
| Q34380871 | Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein |
| Q55691017 | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy. |
| Q37502418 | Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse |
| Q33980640 | Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease |
| Q36486957 | Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease |
| Q42078692 | Regional deficiencies in chaperone-mediated autophagy underlie α-synuclein aggregation and neurodegeneration |
| Q42440540 | Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease |
| Q53875651 | Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. |
| Q55090022 | Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. |
| Q48310927 | Regional levels of physiological α-synuclein are directly associated with Lewy body pathology. |
| Q41982270 | Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein |
| Q44618949 | Regulation Of In Vitro Fibril Formation Of Synuclein Mutant Proteins By Hsp104p |
| Q33967323 | Regulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells |
| Q28569843 | Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons |
| Q39931532 | Regulation of alpha-synuclein expression by liver X receptor ligands in vitro |
| Q33938665 | Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene |
| Q35683947 | Regulation of alpha-synuclein expression in alcohol-preferring and -non preferring rats |
| Q46497170 | Regulation of alpha-synuclein expression in limbic and motor brain regions of morphine-treated mice. |
| Q34344563 | Regulation of alpha-synuclein expression: implications for Parkinson's disease |
| Q48372588 | Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. |
| Q41043578 | Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins |
| Q40090563 | Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules |
| Q48585286 | Regulation of α-synuclein expression in Down syndrome. |
| Q39601978 | Regulation of α-synuclein expression in cultured cortical neurons |
| Q57174175 | Relation of Enteric α-Synuclein to Gastrointestinal Dysfunction in Patients With Parkinson's Disease and in Neurologically Intact Subjects |
| Q48651347 | Relation of quantitative indexes of concurrent alpha-synuclein abnormalities to clinical outcome in autopsy-proven Alzheimer disease. |
| Q48452025 | Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. |
| Q39843305 | Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis |
| Q48618580 | Relationship between mitochondria and α-synuclein: a study of single substantia nigra neurons. |
| Q42002660 | Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease |
| Q46829375 | Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies |
| Q24293089 | Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity |
| Q43574350 | Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole |
| Q50146513 | Release and uptake of pathologic alpha-synuclein. |
| Q33817987 | Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein |
| Q54787321 | Remaining structures at the N- and C-terminal regions of alpha-synuclein accurately elucidated by amide-proton exchange NMR with fitting. |
| Q36216084 | Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. |
| Q46735537 | Remote His50 Acts as a Coordination Switch in the High-Affinity N-Terminal Centered Copper(II) Site of α-Synuclein. |
| Q47549125 | Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo |
| Q64266863 | Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human α-synuclein |
| Q59544593 | Reply to: “Being too inclusive about synuclein inclusions” |
| Q29542272 | Repression of alpha-synuclein expression and toxicity by microRNA-7. |
| Q37622863 | Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species. |
| Q45996034 | Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. |
| Q36683120 | Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease |
| Q24671058 | Residual structure, backbone dynamics, and interactions within the synuclein family |
| Q48386115 | Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein. |
| Q33615838 | Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation |
| Q34075948 | Residue histidine 50 plays a key role in protecting α-synuclein from aggregation at physiological pH. |
| Q34779845 | Residue-specific fluorescent probes of α-synuclein: detection of early events at the N- and C-termini during fibril assembly |
| Q41830649 | Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide |
| Q34394747 | Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. |
| Q39005218 | Resistance of naturally secreted α-synuclein to proteolysis |
| Q28477043 | Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation |
| Q48680527 | Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3. |
| Q36369915 | Retinol (Vitamin A) Increases α-Synuclein, β-Amyloid Peptide, Tau Phosphorylation and RAGE Content in Human SH-SY5Y Neuronal Cell Line. |
| Q33326619 | Retracted: DJ-1 Modulates α-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70 |
| Q48633131 | Retraction of "β-Amyloid and α-Synuclein Cooperate To Block SNARE-Dependent Vesicle Fusion". |
| Q47241738 | Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. |
| Q46427562 | Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. |
| Q36672116 | Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy |
| Q38667942 | Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology |
| Q38669105 | Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein |
| Q38691823 | Review: The spectrum of clinical features seen with alpha synuclein pathology. |
| Q34001314 | Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins |
| Q39141765 | Reynosin protects against neuronal toxicity in dopamine-induced SH-SY5Y cells and 6-hydroxydopamine-lesioned rats as models of Parkinson's disease: Reciprocal up-regulation of E6-AP and down-regulation of α-synuclein |
| Q35184890 | Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease |
| Q33530116 | Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products |
| Q46471751 | Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils |
| Q48334457 | Rifampicin pre-treatment inhibits the toxicity of rotenone-induced PC12 cells by enhancing sumoylation modification of α-synuclein. |
| Q48284257 | Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer |
| Q41078288 | Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy |
| Q48192979 | Risk and protective haplotypes of the alpha-synuclein gene associated with Parkinson's disease differentially affect cognitive sequence learning |
| Q44791898 | Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice |
| Q50281673 | Risk variants of the α-synuclein locus and REM sleep behavior disorder in Parkinson's disease: a genetic association study. |
| Q37560714 | Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils |
| Q50218377 | Robust polydiacetylene-based colorimetric sensing material developed with amyloid fibrils of α-synuclein. |
| Q51465451 | Role and Characterization of Synuclein-γ Unconventional Protein Secretion in Cancer Cells. |
| Q41473324 | Role of C-terminal negative charges and tyrosine residues in fibril formation of α-synuclein. |
| Q28082714 | Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases |
| Q46515634 | Role of N-terminal methionine residues in the redox activity of copper bound to alpha-synuclein |
| Q57795110 | Role of Parkinson's Disease-linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by DOPAL |
| Q36731472 | Role of Ser129 phosphorylation of α-synuclein in melanoma cells |
| Q47754253 | Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity |
| Q42904554 | Role of TPPP/p25 on α-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. |
| Q37858351 | Role of advanced glycation on aggregation and DNA binding properties of α-synuclein. |
| Q47762431 | Role of alpha-synuclein carboxy-terminus on fibril formation in vitro |
| Q44430640 | Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice |
| Q33720362 | Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes |
| Q45182545 | Role of alpha-synuclein in presynaptic dopamine recruitment. |
| Q28586928 | Role of alpha-synuclein in synaptic glutamate release |
| Q34257471 | Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines |
| Q39853847 | Role of autophagy and proteasome degradation pathways in apoptosis of PC12 cells overexpressing human alpha-synuclein |
| Q28566854 | Role of autophagy in arsenite-induced neurotoxicity: the involvement of α-synuclein |
| Q41693341 | Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease |
| Q37436444 | Role of cytochrome c in α-synuclein radical formation: implications of α-synuclein in neuronal death in Maneb- and paraquat-induced model of Parkinson's disease |
| Q46027264 | Role of different regions of alpha-synuclein in the assembly of fibrils. |
| Q35885349 | Role of gamma-synuclein in microtubule regulation |
| Q33201391 | Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein |
| Q34800137 | Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death |
| Q28080047 | Role of microRNAs in the Regulation of α-Synuclein Expression: A Systematic Review |
| Q39043644 | Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation. |
| Q37778899 | Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies |
| Q45960861 | Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. |
| Q37306581 | Role of synucleins in Alzheimer's disease |
| Q48436608 | Role of synucleins in traumatic brain injury — an experimental in vitro and in vivo study in mice. |
| Q28083418 | Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies |
| Q39186311 | Role of α-synuclein aggregation and the nuclear factor E2-related factor 2/heme oxygenase-1 pathway in iron-induced neurotoxicity |
| Q37128532 | Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus |
| Q40960955 | Role of α-synuclein in cognitive dysfunction: Studies in Drosophila melanogaster |
| Q35510197 | Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. |
| Q48599325 | Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease. |
| Q37587111 | Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation |
| Q35124948 | Roles of autophagy in MPP+-induced neurotoxicity in vivo: the involvement of mitochondria and α-synuclein aggregation |
| Q38684340 | Room-temperature in-cell EPR spectroscopy: alpha-Synuclein disease variants remain intrinsically disordered in the cell |
| Q57812787 | Rosmarinic acid protects against MPTP-induced toxicity and inhibits iron-induced α-synuclein aggregation |
| Q46217157 | Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum. |
| Q39103843 | Rotenone upregulates alpha-synuclein and myocyte enhancer factor 2D independently from lysosomal degradation inhibition. |
| Q47260625 | Running wheel exercise reduces α-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson's disease. |
| Q42704578 | S-Nitrosylating protein disulphide isomerase mediates α-synuclein aggregation caused by methamphetamine exposure in PC12 cells |
| Q37704633 | S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation. |
| Q43029209 | SDS-induced fibrillation of alpha-synuclein: an alternative fibrillation pathway. |
| Q35686386 | SIRT1 protects against α-synuclein aggregation by activating molecular chaperones |
| Q35035515 | SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening |
| Q47233712 | SNCA (α-synuclein)-induced toxicity in yeast cells is dependent on sirtuin 2 (Sir2)-mediated mitophagy |
| Q34081400 | SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress |
| Q30497763 | SNCA variant associated with Parkinson disease and plasma alpha-synuclein level |
| Q57484620 | SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinson's disease |
| Q43915320 | SNP rs7684318 of the alpha-synuclein gene is associated with Parkinson's disease in the Han Chinese population |
| Q47359062 | SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation |
| Q58705758 | SUMOylation of Alpha-Synuclein Influences on Alpha-Synuclein Aggregation Induced by Methamphetamine |
| Q55080796 | Salidroside Promotes the Pathological α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells. |
| Q41963683 | Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease. |
| Q37030864 | Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson's disease patients |
| Q42772374 | Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. |
| Q37324687 | Saposin C protects glucocerebrosidase against α-synuclein inhibition. |
| Q48118929 | Screening for α-synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). |
| Q38346854 | Screening of DNA aptamer which binds to alpha-synuclein |
| Q46242764 | Secondary nucleation of monomers on fibril surface dominates α-synuclein aggregation and provides autocatalytic amyloid amplification |
| Q24647859 | Secondary structure and dynamics of micelle bound beta- and gamma-synuclein |
| Q57025391 | Secretion and Uptake of α-Synuclein Via Extracellular Vesicles in Cultured Cells |
| Q40995496 | Secretory carrier membrane protein 5 is an autophagy inhibitor that promotes the secretion of α-synuclein via exosome |
| Q47994208 | Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment. |
| Q39661595 | Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases |
| Q33625757 | Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex |
| Q45355658 | Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology |
| Q53400687 | Seeing Is Believing: Alpha-Synuclein Oligomers in Parkinson's Disease Brain. |
| Q28080551 | Seeking a mechanism for the toxicity of oligomeric α-synuclein |
| Q48168963 | Segmental Deuteration of α-Synuclein for Neutron Reflectometry on Tethered Bilayers. |
| Q53077107 | Segmental conformational disorder and dynamics in the intrinsically disordered protein α-synuclein and its chain length dependence. |
| Q58100370 | Segmental ¹³C-labeling and Raman Microspectroscopy of α-Synuclein Amyloid Formation |
| Q34303977 | Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method. |
| Q27684872 | Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain |
| Q28576367 | Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease |
| Q45340409 | Selective coexpression of synaptic proteins, α-synuclein, cysteine string protein-α, synaptophysin, synaptotagmin-1, and synaptobrevin-2 in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig ileum |
| Q46686370 | Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay |
| Q46203911 | Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon |
| Q41378010 | Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. |
| Q61443234 | Selective inhibition of mitochondrial sodium-calcium exchanger protects striatal neurons from α-synuclein plus rotenone induced toxicity |
| Q35747138 | Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model |
| Q50724606 | Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures. |
| Q48335901 | Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. |
| Q46362244 | Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits |
| Q46157497 | Selective noradrenergic vulnerability in α-synuclein transgenic mice |
| Q34323256 | Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis |
| Q47259722 | Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease. |
| Q46865075 | Selenomethionine prevents degeneration induced by overexpression of wild-type human alpha-synuclein during differentiation of neuroblastoma cells |
| Q46500132 | Self-Assembled Cyclic d,l-α-Peptides as Generic Conformational Inhibitors of the α-Synuclein Aggregation and Toxicity: In Vitro and Mechanistic Studies |
| Q31895751 | Self-oligomerization and protein aggregation of alpha-synuclein in the presence of Coomassie Brilliant Blue |
| Q34837474 | Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody |
| Q50926158 | Semisynthesis and Enzymatic Preparation of Post-translationally Modified α-Synuclein. |
| Q41728474 | Semisynthetic and in Vitro Phosphorylation of Alpha-Synuclein at Y39 Promotes Functional Partly Helical Membrane-Bound States Resembling Those Induced by PD Mutations |
| Q35862005 | Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation |
| Q55515844 | Senkyunolide A protects neural cells against corticosterone-induced apoptosis by modulating protein phosphatase 2A and α-synuclein signaling. |
| Q62561933 | Sensitive Electrochemical Detection of Native and Aggregatedα-Synuclein Protein Involved in Parkinson's Disease |
| Q35923132 | Sensitive analysis of α-synuclein by nonlinear laser wave mixing coupled with capillary electrophoresis |
| Q34127286 | Sensitive and specific detection of α-synuclein in human plasma |
| Q44828365 | Sensitive electrochemical immunosensor for α-synuclein based on dual signal amplification using PAMAM dendrimer-encapsulated Au and enhanced gold nanoparticle labels |
| Q46957875 | Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors. |
| Q38834595 | Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces |
| Q30357845 | Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation |
| Q43612913 | Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice |
| Q40842217 | Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein |
| Q48274855 | Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity |
| Q46950603 | Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein |
| Q46180259 | Sequence and membrane determinants of the random coil-helix transition of α-synuclein |
| Q46762879 | Sequence determinants regulating fibrillation of human alpha-synuclein |
| Q57782145 | Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD) |
| Q38819135 | Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains |
| Q27689470 | Sequestration of a β-hairpin for control of α-synuclein aggregation |
| Q53699381 | Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. |
| Q35589200 | Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. |
| Q48091249 | Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. |
| Q39614419 | Serine 129 Phosphorylation of α-Synuclein Cross-Links with Tissue Transglutaminase to Form Lewy Body-Like Inclusion Bodies |
| Q39971267 | Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death |
| Q36887384 | Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner |
| Q33885205 | Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. |
| Q35792286 | Serological Analysis of Alpha-synuclein and NF-κB in Parkinson's Disease Patients |
| Q37092527 | Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease |
| Q47226931 | Serum Mortalin Correlated with α-Synuclein as Serum Markers in Parkinson's Disease: A Pilot Study |
| Q49795391 | Serum albumin impedes the amyloid aggregation and hemolysis of human islet amyloid polypeptide and alpha synuclein. |
| Q47131590 | Serum from Parkinson’s disease patients presents excess of protein halogenation and nitrosylation, with anomalous nitrosylation of serum α-synuclein as potentially etiological factor |
| Q47227567 | Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood |
| Q30795299 | Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease |
| Q38438454 | Sideroflexin 3 is an α-synuclein-dependent mitochondrial protein that regulates synaptic morphology |
| Q47859033 | Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra |
| Q30496676 | Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. |
| Q55511344 | Significant Changes in Plasma Alpha-Synuclein and Beta-Synuclein Levels in Male Children with Autism Spectrum Disorder. |
| Q50335089 | Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. |
| Q36700077 | Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells |
| Q53441819 | Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated α-Synuclein Mutant A53T and Affects Locomotor Activity. |
| Q38807183 | Silencing of SIAH1 in SH-SY5Y affects α-synuclein degradation pathway |
| Q50183981 | Silencing of Tctex1 impairs autophagy lysosomal degradation of α-synuclein and cell viability. |
| Q40321534 | Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi |
| Q37236525 | Silencing synuclein at the synapse with PLK2 |
| Q38747094 | Silica nanoparticles induce alpha-synuclein induction and aggregation in PC12-cells |
| Q33225632 | Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans |
| Q51691895 | Similar α-Synuclein staining in the colon mucosa in patients with Parkinson's disease and controls. |
| Q44840918 | Simulation studies on the stabilities of aggregates formed by fibril-forming segments of alpha-Synuclein |
| Q47693967 | Simultaneous IR-Spectroscopic Observation of α-Synuclein, Lipids, and Solvent Reveals an Alternative Membrane-Induced Oligomerization Pathway |
| Q57823994 | Single Molecule FRET Characterization of Oligomers from Alpha-Synuclein Early Onset Parkinson's Disease Mutants |
| Q33674189 | Single cell imaging and quantification of TDP-43 and α-synuclein intercellular propagation |
| Q53616981 | Single fibril growth kinetics of α-synuclein. |
| Q34250768 | Single molecule characterization of α-synuclein in aggregation-prone states |
| Q46765690 | Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers |
| Q55443026 | Single-Molecule Characterization of the Interactions between Extracellular Chaperones and Toxic α-Synuclein Oligomers. |
| Q34374310 | Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-synuclein oligomers in lipid membranes |
| Q44454221 | Single-molecule FRET reveals structural heterogeneity of SDS-bound alpha-synuclein |
| Q36298004 | Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants |
| Q56890280 | Single-molecule force spectroscopy of rapidly fluctuating, marginally stable structures in the intrinsically disordered protein α-synuclein |
| Q55636051 | Sir-2.1 mediated attenuation of α-synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of Caenorhabditis elegans. |
| Q28307422 | Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease |
| Q40136303 | Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism |
| Q36237678 | Site-Specific Fluorescence Polarization for Studying the Disaggregation of α-Synuclein Fibrils by Small Molecules |
| Q52313288 | Site-Specific Three-Color Labeling of α-Synuclein via Conjugation to Uniquely Reactive Cysteines during Assembly by Native Chemical Ligation. |
| Q46906785 | Site-specific copper-catalyzed oxidation of α-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease. |
| Q37373657 | Site-specific differences in proteasome-dependent degradation of monoubiquitinated α-synuclein. |
| Q46643028 | Site-specific fluorescence dynamics of α-synuclein fibrils using time-resolved fluorescence studies: effect of familial Parkinson's disease-associated mutations |
| Q24613887 | Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates |
| Q33359146 | Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation |
| Q28487771 | Site-specific perturbations of alpha-synuclein fibril structure by the Parkinson's disease associated mutations A53T and E46K |
| Q39133493 | Site-specific structural dynamics of α-Synuclein revealed by time-resolved fluorescence spectroscopy: a review |
| Q56349405 | Skin Nerve Phosphorylated α-Synuclein Deposits in Parkinson Disease With Orthostatic Hypotension |
| Q53264163 | Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease. |
| Q47735012 | Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder |
| Q56974717 | Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease |
| Q56979083 | Skin sympathetic fiber α-synuclein deposits: a potential biomarker for pure autonomic failure |
| Q58700515 | Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study |
| Q48104086 | Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein |
| Q42380610 | Small Heat-shock Proteins Prevent α-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate of Aggregation |
| Q52721887 | Small Molecules Attenuate the Interplay between Conformational Fluctuations, Early Oligomerization and Amyloidosis of Alpha Synuclein. |
| Q35784396 | Small Molecules Detected by Second-Harmonic Generation Modulate the Conformation of Monomeric α-Synuclein and Reduce Its Aggregation in Cells |
| Q40212840 | Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation |
| Q40282679 | Small molecule inhibitors of alpha-synuclein filament assembly |
| Q57292355 | Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons |
| Q48406052 | Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation. |
| Q39156104 | Small molecules interacting with α-synuclein: antiaggregating and cytoprotective properties. |
| Q40319470 | Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein |
| Q46327855 | Small-Molecule-Induced Soluble Oligomers of α-Synuclein with Helical Structure |
| Q40309471 | Small-angle neutron scattering reveals the assembly of alpha-synuclein in lipid membranes |
| Q37109892 | Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? |
| Q34465204 | Snaring the function of alpha-synuclein |
| Q46047010 | Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease |
| Q38736125 | Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage |
| Q54421311 | Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. |
| Q49065992 | Solid-state NMR sequential assignments of α-synuclein. |
| Q31135512 | Solid-state NMR spectroscopy reveals that water is nonessential to the core structure of alpha-synuclein fibrils |
| Q37278078 | Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. |
| Q28817941 | Solid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-Synuclein |
| Q38617807 | Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress |
| Q58596817 | Soluble α-synuclein facilitates priming and fusion by releasing Ca from thapsigargin-sensitive Ca pool in PC12 cells |
| Q36182604 | Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology |
| Q33985326 | Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. |
| Q52651765 | Solution NMR of SNAREs, complexin and α-synuclein in association with membrane-mimetics. |
| Q33694368 | Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation |
| Q28361893 | Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c |
| Q30626337 | Somatic alpha-synuclein mutations in Parkinson's disease: hypothesis and preliminary data |
| Q58713363 | Sorting Out the Role of α-Synuclein in Retromer-Mediated Endosomal Protein Sorting |
| Q38652662 | Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology |
| Q48524176 | Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus. |
| Q48118789 | Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations |
| Q46916252 | Specific fluorescent detection of fibrillar alpha-synuclein using mono- and trimethine cyanine dyes |
| Q55511905 | Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates. |
| Q39174750 | Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines |
| Q41922349 | Specificity and kinetics of alpha-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe |
| Q34091623 | Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein |
| Q48111672 | Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure |
| Q30369463 | Spermidine protects against α-synuclein neurotoxicity. |
| Q37091555 | Spermine binding to Parkinson's protein alpha-synuclein and its disease-related A30P and A53T mutants |
| Q39004491 | Sphingosine kinases modulate the secretion of amyloid β precursor protein from SH-SY5Y neuroblastoma cells: the role of α-synuclein |
| Q44772162 | Spin-label EPR on alpha-synuclein reveals differences in the membrane binding affinity of the two antiparallel helices |
| Q34211292 | Spinal cord pathology in alpha-synuclein transgenic mice |
| Q40922267 | Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease. |
| Q38840638 | Spine Topographical Distribution of Skin α-Synuclein Deposits in Idiopathic Parkinson Disease |
| Q37612718 | Splice isoform and pharmacological studies reveal that sterol depletion relocalizes α-synuclein and enhances its toxicity |
| Q50527079 | Splitting and self-assembling of far-red fluorescent protein with an engineered beta strand peptide: application for alpha-synuclein imaging in mammalian cells. |
| Q33326248 | Spontaneous aggregation and altered intracellular distribution of endogenous alpha-synuclein during neuronal apoptosis. |
| Q30359033 | Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression |
| Q47361450 | Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term |
| Q64088424 | Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved |
| Q38232241 | Spreading of α-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis |
| Q53512450 | Stabilization of Alpha-Synuclein Oligomers In Vitro by the Neurotransmitters, Dopamine and Norepinephrine: The Effect of Oxidized Catecholamines. |
| Q40524258 | Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. |
| Q29617606 | Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes |
| Q43759039 | Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations |
| Q47136102 | Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity |
| Q34352138 | Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones |
| Q44592783 | Stage-specific expression of breast cancer-specific gene gamma-synuclein |
| Q43006922 | Staging of alpha-synuclein in the olfactory bulb in a model of Parkinson's disease: cell types involved. |
| Q48683712 | Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. |
| Q64056291 | State transitions in the substantia nigra reticulata predict the onset of motor deficits in models of progressive dopamine depletion in mice |
| Q40016826 | Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease |
| Q38705723 | Steady-State Kinetics of α-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species. |
| Q64229161 | Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils |
| Q43038021 | Stimulated dopamine overflow and alpha-synuclein expression in the nucleus accumbens core distinguish rats bred for differential ethanol preference |
| Q47745793 | Stimulation of estrogen receptor signaling by gamma synuclein |
| Q48342632 | Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein. |
| Q52675832 | Stimulation of α-synuclein amyloid formation by phosphatidylglycerol micellar tubules. |
| Q24292861 | Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β |
| Q43921342 | Stress-induced aggregation profiles of GST-alpha-synuclein fusion proteins: role of the C-terminal acidic tail of alpha-synuclein in protein thermosolubility and stability |
| Q28589684 | Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice |
| Q46377450 | Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice |
| Q38717833 | Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease. |
| Q34263294 | Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice |
| Q51653581 | Strong interactions with polyethylenimine-coated human serum albumin nanoparticles (PEI-HSA NPs) alter α-synuclein conformation and aggregation kinetics. |
| Q39097344 | Structural Characteristics of α-Synuclein Oligomers |
| Q58484313 | Structural Characterization of the Intrinsically Unfolded Protein β-Synuclein, a Natural Negative Regulator of α-Synuclein Aggregation |
| Q39837295 | Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein |
| Q41911876 | Structural Ensembles of Membrane-bound α-Synuclein Reveal the Molecular Determinants of Synaptic Vesicle Affinity |
| Q35078181 | Structural and dynamical insights into the membrane-bound α-synuclein |
| Q37305236 | Structural and functional characterization of two alpha-synuclein strains |
| Q44212915 | Structural and functional implications of C-terminal regions of alpha-synuclein |
| Q36796130 | Structural and functional properties of prefibrillar α-synuclein oligomers |
| Q37482190 | Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation |
| Q39551434 | Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid |
| Q45220834 | Structural basis behind the interaction of Zn²⁺ with the protein α-synuclein and the Aβ peptide: a comparative analysis. |
| Q31145567 | Structural basis for the dissociation of α-synuclein fibrils triggered by pressure perturbation of the hydrophobic core |
| Q46241023 | Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers |
| Q37273635 | Structural basis of synaptic vesicle assembly promoted by α-synuclein |
| Q36281848 | Structural changes in alpha-synuclein affect its chaperone-like activity in vitro |
| Q55114623 | Structural characteristics and membrane interactions of tandem α-synuclein oligomers. |
| Q36950121 | Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein |
| Q42782359 | Structural characterization of a high affinity mononuclear site in the copper(II)-α-synuclein complex |
| Q42637643 | Structural characterization of alpha-synuclein in an aggregation prone state. |
| Q33934394 | Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease |
| Q33619357 | Structural characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase protofibrils preventing α-synuclein oligomeric species toxicity |
| Q37173076 | Structural characterization of the interaction of α-synuclein nascent chains with the ribosomal surface and trigger factor |
| Q35549078 | Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. |
| Q44806821 | Structural determinants of PLD2 inhibition by alpha-synuclein |
| Q38799574 | Structural disorder of monomeric α-synuclein persists in mammalian cells. |
| Q45247112 | Structural evidence for alpha-synuclein fibrils using in situ atomic force microscopy |
| Q34964902 | Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy. |
| Q55122147 | Structural insights from lipid-bilayer nanodiscs link α-Synuclein membrane-binding modes to amyloid fibril formation |
| Q42178188 | Structural insights into amyloid oligomers of the Parkinson disease-related protein α-synuclein. |
| Q53825610 | Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer. |
| Q37307280 | Structural insights on physiological functions and pathological effects of alpha-synuclein. |
| Q35902646 | Structural intermediates during α-synuclein fibrillogenesis on phospholipid vesicles |
| Q45112183 | Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling |
| Q57185914 | Structural properties of pore-forming oligomers of alpha-synuclein |
| Q46600485 | Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein |
| Q42590750 | Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations. |
| Q33953809 | Structural role of compensatory amino acid replacements in the α-synuclein protein. |
| Q44062230 | Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation |
| Q34003885 | Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity |
| Q34379131 | Structure and dynamics of micelle-bound human alpha-synuclein |
| Q52319335 | Structure and dynamics of the extended-helix state of alpha-synuclein: Intrinsic lability of the linker region. |
| Q27663303 | Structure and properties of a complex of α-synuclein and a single-domain camelid antibody |
| Q34098577 | Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level |
| Q43072338 | Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process |
| Q38898283 | Structure based aggregation studies reveal the presence of helix-rich intermediate during α-Synuclein aggregation |
| Q24569788 | Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement |
| Q34375103 | Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling |
| Q36685232 | Structure of the toxic core of α-synuclein from invisible crystals |
| Q33701172 | Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease |
| Q38550428 | Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies |
| Q34769957 | Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases |
| Q35168339 | Structured regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites. |
| Q37026033 | Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics |
| Q36713739 | Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics |
| Q37846754 | Structures behind the amyloid aggregation of α-synuclein: an NMR based approach |
| Q27667412 | Structures of segments of α-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation |
| Q22061749 | Structures of the E46K mutant-type α-synuclein protein and impact of E46K mutation on the structures of the wild-type α-synuclein protein |
| Q35903351 | Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice |
| Q35682515 | Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. |
| Q57909066 | Studies of the aggregation of an amyloidogenic α-synuclein peptide fragment |
| Q55688977 | Study of Molecular Mechanisms of α-Synuclein Assembly: Insight into a Cross-β Structure in the N-Termini of New α-Synuclein Fibrils. |
| Q45150014 | Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence |
| Q52638999 | Study of wild-type α-synuclein binding and orientation on gold nanoparticles. |
| Q48838980 | Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein. |
| Q46460788 | Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration. |
| Q49080795 | Subcellular localisation of recombinant alpha- and gamma-synuclein. |
| Q60810356 | Subcellular localization of alpha-synuclein aggregates and their interaction with membranes |
| Q49134694 | Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. |
| Q28509158 | Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain |
| Q44264439 | Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. |
| Q48838725 | Subgroup differences in 'brain-type' transferrin and α-synuclein in Parkinson's disease and multiple system atrophy. |
| Q57825798 | Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease |
| Q42164708 | Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein |
| Q47111833 | Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression. |
| Q38805550 | Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model. |
| Q48452872 | Successful GPi stimulation in genetic Parkinson's disease caused by mosaicism of alpha-synuclein gene duplication: first description. |
| Q44694613 | Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α-synuclein gene. |
| Q55058782 | Sumoylation Protects Against β-Synuclein Toxicity in Yeast. |
| Q35102441 | Sumoylation inhibits alpha-synuclein aggregation and toxicity. |
| Q39127625 | Super-resolution imaging of alpha-synuclein polymorphisms and their potential role in neurodegeneration. |
| Q30446486 | Superficial siderosis associated with abundant τ and α-synuclein accumulation |
| Q54535980 | Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants. |
| Q46382550 | Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein |
| Q43194459 | Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils |
| Q36215480 | Suppression of MAPK attenuates neuronal cell death induced by activated glia-conditioned medium in alpha-synuclein overexpressing SH-SY5Y cells. |
| Q61446669 | Suppression of astrocytic autophagy by αB-crystallin contributes to α-synuclein inclusion formation |
| Q47371555 | Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression |
| Q36341144 | Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy |
| Q35950435 | Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context |
| Q58612205 | Suppression, Disaggregation, and Modulation of γ-Synuclein Fibrillation Pathway by Green Tea Polyphenol EGCG |
| Q58470445 | Supramolecular Modulation of Structural Polymorphism in Pathogenic α-Synuclein Fibrils Using Copper(II) Coordination |
| Q47840731 | Supramolecular Modulation of Structural Polymorphism in Pathogenic α-Synuclein Fibrils Using Cu(II) Coordination |
| Q35810050 | Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation |
| Q48094276 | Surface behavior of α-Synuclein and its interaction with phospholipids using the Langmuir monolayer technique: a comparison between monomeric and fibrillar α-Synuclein |
| Q35982198 | Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice |
| Q36100326 | Sympathetic neurocirculatory failure in Parkinson disease: Evidence for an etiologic role of alpha-synuclein |
| Q47866245 | Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains |
| Q47362946 | Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. |
| Q47317693 | Synaptic regulator α-synuclein in dopaminergic fibers is essentially required for the maintenance of subependymal neural stem cells. |
| Q28511573 | Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein |
| Q37344609 | Synchronous vs asynchronous chain motion in alpha-synuclein contact dynamics |
| Q35840610 | Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline |
| Q39309731 | Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level |
| Q30668488 | Synoretin--A new protein belonging to the synuclein family |
| Q54372671 | Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model. |
| Q22009563 | Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions |
| Q33832846 | Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model |
| Q33742140 | Synphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner |
| Q50554031 | Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. |
| Q24294532 | Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein |
| Q35234760 | Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease |
| Q37160968 | Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates alpha-synuclein monoubiquitylation and inclusion formation. |
| Q47431919 | Synthesis and biological evaluation of novel radioiodinated benzimidazole derivatives for imaging α-synuclein aggregates |
| Q36106447 | Synthesis and in vitro evaluation of α-synuclein ligands. |
| Q57821725 | Synthesis of Multiring Fused 2-Pyridones via a Nitrene Insertion Reaction: Fluorescent Modulators of α-Synuclein Amyloid Formation |
| Q46119614 | Synthesis of a Bis-thio-acetone (BTA) Analogue of the Lysine Isopeptide Bond and its Application to Investigate the Effects of Ubiquitination and SUMOylation on α-Synuclein Aggregation and Toxicity. |
| Q28081548 | Synthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational Modifications |
| Q50630062 | Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. |
| Q48360396 | Synthetic filaments assembled from C-terminally truncated alpha-synuclein. |
| Q37276472 | Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology |
| Q51841001 | Synuclein accumulation is associated with cell-specific neuronal death after spinal cord injury. |
| Q40126232 | Synuclein activates microglia in a model of Parkinson's disease |
| Q38829719 | Synuclein aggregation: When the mouse's away the human will play |
| Q48135905 | Synuclein aggregation: possible role in traumatic brain injury |
| Q50090415 | Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease. |
| Q62055349 | Synuclein and synelfin: The songbird story |
| Q37875341 | Synuclein deposition and non-motor symptoms in Parkinson disease |
| Q46521010 | Synuclein expression in the lizard Anolis carolinensis. |
| Q52173106 | Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine. |
| Q55334340 | Synuclein gamma expression enhances radiation resistance of breast cancer cells. |
| Q40377140 | Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells |
| Q33626102 | Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen |
| Q38977711 | Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption |
| Q34033382 | Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha. |
| Q33819127 | Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease |
| Q37852164 | Synuclein modulation of monoamine transporters |
| Q40397157 | Synuclein proteins and Alzheimer's disease |
| Q48643118 | Synuclein proteins of the pufferfish Fugu rubripes: sequences and functional characterization. |
| Q46840124 | Synuclein γ compromises spindle assembly checkpoint and renders resistance to antimicrotubule drugs |
| Q38982175 | Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption |
| Q36080005 | Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? |
| Q48380725 | Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. |
| Q39846045 | Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma |
| Q39863277 | Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer |
| Q40181688 | Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs |
| Q37391092 | Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease |
| Q37305478 | Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma |
| Q39123683 | Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study |
| Q55058640 | Synuclein-γ promotes migration of MCF7 breast cancer cells by activating extracellular-signal regulated kinase pathway and breaking cell-cell junctions. |
| Q36774569 | Synuclein-γ suppression mediated by RNA interference inhibits the clonogenicity and invasiveness of MCF-7 cells |
| Q36455215 | Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal |
| Q41014171 | Synucleins Have Multiple Effects on Presynaptic Architecture |
| Q41000436 | Synucleins and Gene Expression: Ramblers in a Crowd or Cops Regulating Traffic? |
| Q35926973 | Synucleins and their relationship to Parkinson's disease. |
| Q27310037 | Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking |
| Q28138274 | Synucleins are a novel class of substrates for G protein-coupled receptor kinases |
| Q28567029 | Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons |
| Q28144500 | Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary |
| Q29398839 | Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary |
| Q28580190 | Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve |
| Q43658930 | Synucleins in ocular tissues |
| Q33734797 | Synucleins in synaptic plasticity and neurodegenerative disorders |
| Q62055336 | Synucleins in synaptic plasticity and neurodegenerative disorders |
| Q33865356 | Synucleins regulate the kinetics of synaptic vesicle endocytosis. |
| Q60197534 | Synucleins rule the synaptic domain: Evidence from a topographical point of view |
| Q38059684 | Synucleins: are they two-edged swords? |
| Q35416913 | Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. |
| Q26269871 | Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities |
| Q34376186 | Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice |
| Q30516504 | Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy |
| Q40163812 | T cells from patients with Parkinson's disease recognize α-synuclein peptides |
| Q34648581 | TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice |
| Q36835587 | TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity |
| Q37682407 | TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation |
| Q48163943 | TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells |
| Q34692945 | TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson's disease |
| Q48125960 | TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains. |
| Q37407659 | TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. |
| Q48277557 | Taking a Bite Out of Amyloid: Mechanistic Insights into α-Synuclein Degradation by Cathepsin L. |
| Q35675406 | Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse |
| Q34032393 | Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure |
| Q42571006 | Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease |
| Q38957827 | Targeted suppression of chaperone-mediated autophagy by miR-320a promotes α-synuclein aggregation |
| Q38000741 | Targeting alpha-synuclein for the treatment of Parkinson's disease |
| Q38607819 | Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects |
| Q26827066 | Targeting heat shock proteins to modulate α-synuclein toxicity |
| Q38000327 | Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies |
| Q59353556 | Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease |
| Q28308179 | Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide |
| Q37030872 | Targeting synuclein-gamma to counteract drug resistance in cancer |
| Q38039857 | Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration |
| Q40500370 | Targeting the interface of the pathological complex of α-synuclein and TPPP/p25. |
| Q28539839 | Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease |
| Q53813036 | Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins. |
| Q38541943 | Targeting α-synuclein as a therapeutic strategy for Parkinson's disease |
| Q37566684 | Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations |
| Q38898085 | Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies |
| Q38754587 | Targeting α-synuclein: Therapeutic options |
| Q42502509 | Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. |
| Q42628290 | Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease |
| Q42476364 | Tau and alpha-synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia |
| Q35748075 | Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam |
| Q33750048 | Tau and synuclein and their role in neuropathology |
| Q34062509 | Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy |
| Q34285856 | Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. |
| Q51762778 | Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy. |
| Q45310388 | Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein |
| Q38761739 | Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. |
| Q34704153 | Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease |
| Q47712805 | Tctex1 plays a key role in the α-synuclein autophagy lysosomal degradation pathway |
| Q48415938 | Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. |
| Q39142376 | Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. |
| Q53054608 | Telmisartan reduces progressive oxidative stress and phosphorylated α-synuclein accumulation in stroke-resistant spontaneously hypertensive rats after transient middle cerebral artery occlusion. |
| Q59549671 | Temperature, surface morphology and biochemical cues: A combined approach to influence the molecular conformation of Alpha-synuclein |
| Q57098558 | Temperature-dependent sensitivity enhancement of solid-state NMR spectra of alpha-synuclein fibrils |
| Q34562198 | Temperature-dependent structural changes of Parkinson's alpha-synuclein reveal the role of pre-existing oligomers in alpha-synuclein fibrillization |
| Q43054520 | Temperature-induced reversible conformational change in the first 100 residues of alpha-synuclein |
| Q39147084 | Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. |
| Q45950065 | Tertiary contact formation in alpha-synuclein probed by electron transfer. |
| Q43575943 | Testosterone regulates alpha-synuclein mRNA in the avian song system |
| Q50558906 | Tetrahydroxystilbene glucoside ameliorates memory and movement functions, protects synapses and inhibits α-synuclein aggregation in hippocampus and striatum in aged mice. |
| Q48291224 | Tetrahydroxystilbene glucoside antagonizes age-related α-synuclein overexpression in the hippocampus of APP transgenic mouse model of Alzheimer's disease |
| Q46419738 | Tetrahydroxystilbene glucoside inhibits α-synuclein aggregation and apoptosis in A53T α-synuclein-transfected cells exposed to MPP. |
| Q35764789 | The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture |
| Q38902323 | The A53T mutation is key in defining the differences in the aggregation kinetics of human and mouse α-synuclein |
| Q34117600 | The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein. |
| Q41834257 | The Aggregation of Huntingtin and α-Synuclein |
| Q57577939 | The Ala53Thr mutation in the α-synuclein gene in a Korean family with Parkinson disease |
| Q46231258 | The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils |
| Q57084702 | The Anti-Parkinsonian Drug Selegiline Delays the Nucleation Phase of α-Synuclein Aggregation Leading to the Formation of Nontoxic Species |
| Q30359012 | The Bcl-2 homologue Buffy rescues α-synuclein-induced Parkinson disease-like phenotypes in Drosophila. |
| Q58740165 | The Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide Fibrils |
| Q36372837 | The Breast Cancer Susceptibility Gene Product (γ-Synuclein) Alters Cell Behavior through its [corrected] Interaction with Phospholipase Cβ. |
| Q36926050 | The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation |
| Q36603128 | The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models |
| Q33722313 | The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian Models |
| Q55261587 | The Close Encounter Between Alpha-Synuclein and Mitochondria. |
| Q39108546 | The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy |
| Q54994816 | The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease. |
| Q40998960 | The Coordinated Action of Calcineurin and Cathepsin D Protects Against α-Synuclein Toxicity. |
| Q26785974 | The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis |
| Q30349931 | The E46K mutation in alpha-synuclein increases amyloid fibril formation. |
| Q41635176 | The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome |
| Q38759650 | The Effect of Fragmented Pathogenic α-Synuclein Seeds on Prion-like Propagation. |
| Q55357756 | The Exosomal/Total α-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients. |
| Q57983252 | The Genetics and molecular biology of α‐synuclein |
| Q38672388 | The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion |
| Q24299289 | The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity |
| Q35002998 | The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. |
| Q37693364 | The Identification of Alpha-Synuclein as the First Parkinson Disease Gene |
| Q41549497 | The Impact of N-terminal Acetylation of α-Synuclein on Phospholipid Membrane Binding and Fibril Structure. |
| Q40182206 | The Impact of Paeoniflorin on α-Synuclein Degradation Pathway |
| Q38669687 | The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review |
| Q35833984 | The Interplay between Alpha-Synuclein Clearance and Spreading |
| Q47912686 | The Ketone Body β-Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia. |
| Q41926295 | The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice |
| Q37003482 | The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates |
| Q44282275 | The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation |
| Q35094912 | The N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation. |
| Q34590797 | The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding |
| Q24316619 | The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes |
| Q41359019 | The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease |
| Q42288817 | The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology |
| Q35574641 | The N Terminus of α-Synuclein Forms Cu(II)-Bridged Oligomers |
| Q46962027 | The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome |
| Q47987432 | The PMR1 pump in alpha-synuclein toxicity and neurodegeneration |
| Q37820817 | The Parkinson disease protein α-synuclein inhibits autophagy |
| Q46003820 | The Parkinson disease-associated A30P mutation stabilizes alpha-synuclein against proteasomal degradation triggered by heme oxygenase-1 over-expression in human neuroblastoma cells. |
| Q41900099 | The Parkinson's Disease-Associated Protein α-Synuclein Disrupts Stress Signaling - A Possible Implication for Methamphetamine Use? |
| Q36423369 | The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis |
| Q43977429 | The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro |
| Q48414773 | The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity. |
| Q59791774 | The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease |
| Q64268725 | The Prion 2018 round tables (II): Aβ, tau, α-synuclein… are they prions, prion-like proteins, or what? |
| Q47199216 | The Role Of The Prion Protein In The Internalization Of α-Synuclein Amyloids |
| Q39410832 | The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease |
| Q36012089 | The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease |
| Q38482479 | The Role of α-Synuclein and LRRK2 in Tau Phosphorylation |
| Q64102410 | The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases |
| Q39832644 | The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. |
| Q39077485 | The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease |
| Q50048940 | The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity. |
| Q30376382 | The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers. |
| Q38166437 | The Sybtraps: control of synaptobrevin traffic by synaptophysin, α-synuclein and AP-180. |
| Q27694711 | The Synaptic Function of α-Synuclein |
| Q51082125 | The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. |
| Q51284194 | The Transcellular Propagation and Intracellular Trafficking of α-Synuclein. |
| Q35617879 | The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. |
| Q36596606 | The aggregation and fibrillation of alpha-synuclein |
| Q57909073 | The aggregation and membrane-binding properties of an alpha-synuclein peptide fragment |
| Q46892896 | The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy |
| Q33790013 | The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen |
| Q47671638 | The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease |
| Q37178003 | The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease |
| Q36142276 | The alpha-synuclein gene in multiple system atrophy |
| Q40344442 | The alpha-synuclein mutation E46K promotes aggregation in cultured cells |
| Q36012226 | The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression |
| Q34217806 | The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation |
| Q48676080 | The association of metal ion exposure with alpha-synuclein-like immunoreactivity in the central nervous system of fish, Catostomus commersoni. |
| Q48044175 | The attachment of α-synuclein to a fiber: A coarse-grain approach. |
| Q59087476 | The awakening of α-synuclein |
| Q45975134 | The behavior of alpha-synuclein in neurons. |
| Q42713473 | The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats |
| Q39002911 | The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. |
| Q32062803 | The cDNA cloning and ontogeny of mouse alpha-synuclein |
| Q35769307 | The carbonate radical anion-induced covalent aggregation of human copper, zinc superoxide dismutase, and alpha-synuclein: intermediacy of tryptophan- and tyrosine-derived oxidation products |
| Q34129833 | The cell biology of alpha-synuclein: a sticky problem? |
| Q38651790 | The cellular prion protein (PrPC) as neuronal receptor for α-synuclein |
| Q38062476 | The central theme of Parkinson's disease: α-synuclein |
| Q44230756 | The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro |
| Q33707184 | The chaperone-like activity of α-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein in vitro: plausible cross-talk between isoforms in protein aggregation |
| Q24298721 | The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity |
| Q37593239 | The chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction. |
| Q39094270 | The clathrin-dependent localization of dopamine transporter to surface membranes is affected by α-synuclein |
| Q33736637 | The clustering and spatial arrangement of beta-sheet sequence, but not order, govern alpha-synuclein fibrillogenesis |
| Q40432113 | The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways |
| Q26853537 | The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease |
| Q53841253 | The concept of alpha-synuclein as a prion-like protein: ten years after. |
| Q42912420 | The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region |
| Q36379177 | The conformational ensembles of α-synuclein and tau: combining single-molecule FRET and simulations |
| Q28068464 | The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease |
| Q50895209 | The correlation between expression of synuclein-gamma, glucose transporter-1, and survival outcomes in endometrioid endometrial carcinoma. |
| Q51017944 | The critical role of Nramp1 in degrading α-synuclein oligomers in microglia under iron overload condition. |
| Q53313817 | The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. |
| Q39130671 | The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to α-synuclein inclusions |
| Q41807581 | The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease |
| Q38124187 | The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis |
| Q35055373 | The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease |
| Q47194619 | The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia. |
| Q55511198 | The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson's disease. |
| Q42522017 | The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging |
| Q38115242 | The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside- and cholesterol-binding domains |
| Q54317341 | The dynamic structure of α-synuclein multimers. |
| Q39912501 | The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons |
| Q45930314 | The effect of amino acid substitution in the imperfect repeat sequences of alpha-synuclein on fibrillation. |
| Q51604991 | The effect of fluorescent labeling on α-synuclein fibril morphology. |
| Q34044462 | The effect of small ubiquitin-like modifier-1 modification on the formation of Lewy body-like inclusions in cytoplasm and apoptosis of HEK293 cell induced by overexpression and mutation of alpha-synuclein |
| Q38996646 | The effect of α-synuclein on gliosis and IL-1α, TNFα, IFNγ, TGFβ expression in murine brain |
| Q52589886 | The effects of alpha-synuclein on phospholipid vesicle integrity: a study using 31P NMR and electron microscopy. |
| Q47107297 | The effects of apolipoprotein E genotype, α-synuclein deficiency, and sex on brain synaptic and Alzheimer's disease-related pathology |
| Q38279572 | The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans |
| Q42355152 | The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. |
| Q55283965 | The expression of KATP channel subunits in alpha-synuclein-transfected MES23.5 cells. |
| Q33885462 | The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases |
| Q33572030 | The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast |
| Q44851129 | The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils |
| Q36735295 | The fold of alpha-synuclein fibrils |
| Q48043653 | The fold preference and thermodynamic stability of α-synuclein fibrils is encoded in the non-amyloid-β component region |
| Q40669171 | The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease |
| Q38139561 | The function of α-synuclein |
| Q37901143 | The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain |
| Q41761790 | The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. |
| Q33724101 | The genetics of disorders with synuclein pathology and parkinsonism |
| Q43798526 | The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein |
| Q30249098 | The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review |
| Q39555173 | The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates |
| Q24295205 | The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant α-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteins |
| Q44228295 | The human NACP/α-synuclein gene: chromosome assignment to 4q21.3–q22 and TaqI RFLP analysis |
| Q47649474 | The impact of obesity on brain iron levels and α-synuclein expression is regionally dependent |
| Q48155270 | The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states |
| Q44672985 | The induction of amyloid precursor protein and alpha-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione |
| Q36386314 | The influence of N-terminal acetylation on micelle-induced conformational changes and aggregation of α-Synuclein. |
| Q42141525 | The influence of vesicle size and composition on alpha-synuclein structure and stability |
| Q40893529 | The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein |
| Q46297760 | The inhibitory effects of biomimetically designed peptides on α-synuclein aggregation |
| Q50152448 | The interaction between calcineurin and α-synuclein is regulated by calcium and calmodulin. |
| Q41859697 | The interaction of Hsc70 protein with fibrillar α-Synuclein and its therapeutic potential in Parkinson's disease |
| Q33696177 | The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation |
| Q37246310 | The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding. |
| Q42351555 | The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease |
| Q47666324 | The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies |
| Q46205788 | The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers |
| Q39624081 | The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties |
| Q34107467 | The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms |
| Q52716959 | The localization of α-synuclein in the process of differentiation of human erythroid cells. |
| Q35612163 | The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (α-syn) toxicity to rat nigral neurons |
| Q36749469 | The loss of inhibitory C-terminal conformations in disease associated P123H β-synuclein |
| Q46249781 | The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. |
| Q45387129 | The many faces of alpha-synuclein mutations |
| Q34972009 | The many faces of α-synuclein: from structure and toxicity to therapeutic target |
| Q36296532 | The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease |
| Q34154475 | The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity |
| Q39902422 | The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process |
| Q41987647 | The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. |
| Q38613361 | The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress α-synuclein aggregation |
| Q42703525 | The molecular mechanism of rotenone-induced α-synuclein aggregation: emphasizing the role of the calcium/GSK3β pathway |
| Q46042321 | The mysterious C-terminal tail of alpha-synuclein: nanobody's guess |
| Q48386016 | The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. |
| Q38558384 | The native form of α-Synuclein: Monomer, tetramer, or a combination in equilibrium |
| Q37181875 | The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity |
| Q40227842 | The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-Synuclein, in SH-SY5Y neuroblastoma cells |
| Q42174217 | The neurotransmitter serotonin interrupts α-synuclein amyloid maturation |
| Q48650054 | The new line of genetically modified mice with constitutive knockout of the gene alpha synuclein to study pathogenetic aspects of differential loss of dopaminergic neurons . |
| Q29547174 | The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia |
| Q33991720 | The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. |
| Q33850971 | The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease |
| Q48806643 | The novel mechanism of rotenone-induced α-synuclein phosphorylation via reduced protein phosphatase 2A activity. |
| Q44134726 | The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle |
| Q41961056 | The number of α-synuclein proteins per vesicle gives insights into its physiological function |
| Q28290750 | The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein |
| Q35552497 | The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease |
| Q28087330 | The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease |
| Q36393039 | The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease |
| Q53604260 | The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. |
| Q57954945 | The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's Disease |
| Q39056973 | The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. |
| Q33240068 | The rat brain synucleins; family of proteins transiently associated with neuronal membrane |
| Q46663033 | The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease. |
| Q34155259 | The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling. |
| Q34286365 | The regulation of catalase activity by PPAR γ is affected by α-synuclein |
| Q41295801 | The regulation of synaptic function by alpha-synuclein |
| Q37707160 | The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease |
| Q47552284 | The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease |
| Q38356698 | The relation between α-synuclein and microglia in Parkinson's disease: Recent developments. |
| Q59808210 | The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease |
| Q38104514 | The remarkable conformational plasticity of alpha-synuclein: blessing or curse? |
| Q34537231 | The role of Galectin-3 in α-synuclein-induced microglial activation |
| Q44451851 | The role of His-50 of α-synuclein in binding Cu(II): pH dependence, speciation, thermodynamics and structure. |
| Q48957098 | The role of NUB1 in α-synuclein degradation in Lewy body disease model mice. |
| Q38073616 | The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models |
| Q27005842 | The role of alpha-synuclein in Parkinson's disease |
| Q35209957 | The role of alpha-synuclein in Parkinson's disease: insights from animal models |
| Q36024973 | The role of alpha-synuclein in both neuroprotection and neurodegeneration |
| Q46179016 | The role of alpha-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response. |
| Q34428287 | The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells |
| Q36057488 | The role of alpha-synuclein in neurodegenerative diseases |
| Q33322664 | The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies? |
| Q39883821 | The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area. |
| Q36017890 | The role of alpha-synuclein in the pathogenesis of multiple system atrophy |
| Q34305509 | The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease |
| Q39966981 | The role of gamma-synuclein in cocaine-induced behaviour in rats |
| Q35969703 | The role of quercetin on the survival of neuron-like PC12 cells and the expression of α-synuclein |
| Q46931854 | The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. |
| Q41079401 | The role of the acidic domain of α-synuclein in amyloid fibril formation: a molecular dynamics study |
| Q42091924 | The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom |
| Q39849106 | The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. |
| Q28386471 | The role of α-synuclein and tau hyperphosphorylation-mediated autophagy and apoptosis in lead-induced learning and memory injury |
| Q38125238 | The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches |
| Q37822085 | The role of α-synuclein in neurotransmission and synaptic plasticity |
| Q38116253 | The role of α-synuclein in the pathophysiology of alcoholism |
| Q39208192 | The secreted oligomeric form of α-synuclein affects multiple steps of membrane trafficking. |
| Q36585538 | The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein |
| Q34264641 | The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases |
| Q34326923 | The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia |
| Q42050393 | The slow axonal transport of alpha-synuclein--mechanistic commonalities amongst diverse cytosolic cargoes |
| Q38968679 | The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity |
| Q48139412 | The small heat shock protein Hsp27 binds α-synuclein fibrils, preventing elongation and cytotoxicity |
| Q50308537 | The small heat shock proteins αB-crystallin (HSPB5) and Hsp27 (HSPB1) inhibit the intracellular aggregation of α-synuclein. |
| Q58577817 | The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease |
| Q31807516 | The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease |
| Q43121446 | The structure of dopamine induced alpha-synuclein oligomers. |
| Q22252705 | The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia |
| Q48438704 | The synergistic effect between β-amyloid(1-42) and α-synuclein on the synapses dysfunction in hippocampal neurons. |
| Q34663590 | The synuclein family |
| Q24551013 | The synucleins |
| Q47924844 | The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease |
| Q35593656 | The temporal expression pattern of alpha-synuclein modulates olfactory neurogenesis in transgenic mice |
| Q42116736 | The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease |
| Q37320265 | The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. |
| Q33748087 | The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. |
| Q40946091 | The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of α-synuclein levels in β-cells |
| Q48497553 | The ubiquitin ligase E6-AP promotes degradation of alpha-synuclein. |
| Q47918995 | The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain |
| Q48375102 | The ups and downs of alpha-synuclein mRNA expression. |
| Q58098409 | The yeast stress inducible Ssa Hsp70 reduces α-synuclein toxicity by promoting its degradation through autophagy |
| Q37087338 | The yin and yang of amyloid: insights from α-synuclein and repeat domain of Pmel17 |
| Q47279155 | The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease. |
| Q61570029 | The α-Synuclein Gene and Parkinson Disease in a Chinese Population |
| Q57624033 | The α-synuclein gene is not a major risk factor in familial Parkinson disease |
| Q47567656 | Therapeutic approaches to target alpha-synuclein pathology |
| Q56344227 | Therapeutic implications of how TNF links APOE, P-tau, α-synuclein, β-amyloid, and insulin resistance in neurodegenerative diseases |
| Q57459960 | Thermodynamics imprinting reveals differential binding of metals to α-synuclein: Relevance to parkinson’s disease |
| Q38654031 | Thioredoxin-interacting protein induced α-synuclein accumulation via inhibition of autophagic flux: Implications for Parkinson's disease |
| Q45924913 | Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals. |
| Q48965950 | Thymoquinone protects cultured hippocampal and human induced pluripotent stem cells-derived neurons against α-synuclein-induced synapse damage. |
| Q55000711 | TiO2 Nanoparticles as Potential Promoting Agents of Fibrillation of α-Synuclein, a Parkinson's Disease-Related Protein. |
| Q61587407 | Tilted properties of the 67-78 fragment of α-synuclein are responsible for membrane destabilization and neurotoxicity |
| Q30532478 | Time course and progression of wild type α-synuclein accumulation in a transgenic mouse model |
| Q53084260 | Time-resolved FRET detection of subtle temperature-induced conformational biases in ensembles of α-synuclein molecules. |
| Q44786885 | Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease |
| Q40508676 | Tissue transglutaminase is not involved in the aggregate formation of stably expressed alpha-synuclein in SH-SY5Y human neuroblastoma cells |
| Q41315025 | Tissue transglutaminase modulates alpha-synuclein oligomerization |
| Q34763209 | Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies |
| Q37596779 | Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. |
| Q41997706 | Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. |
| Q35167964 | Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons |
| Q40691639 | TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation |
| Q35726772 | Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease |
| Q30392912 | Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. |
| Q38422514 | Toward the discovery of effective polycyclic inhibitors of alpha-synuclein amyloid assembly. |
| Q28554611 | Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque |
| Q48416321 | Towards multiparametric fluorescent imaging of amyloid formation: studies of a YFP model of alpha-synuclein aggregation. |
| Q28830423 | Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein |
| Q36139079 | Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models |
| Q36205306 | Toxic effects of human and rodent variants of alpha-synuclein in vivo. |
| Q48668545 | Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. |
| Q46238696 | Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. |
| Q38082291 | Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration |
| Q42213761 | Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease |
| Q35924447 | Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression |
| Q26796502 | Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease |
| Q48409310 | Transcriptional profiling of striatal neurons in response to single or concurrent activation of dopamine D2, adenosine A(2A) and metabotropic glutamate type 5 receptors: focus on beta-synuclein expression. |
| Q33840954 | Transcriptional regulation of the beta-synuclein 5'-promoter metal response element by metal transcription factor-1. |
| Q48163645 | Transcriptional regulation of the α-synuclein gene in human brain tissue |
| Q40851527 | Transcriptional suppression of synuclein gamma (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M. |
| Q53595639 | Transduced Tat-alpha-synuclein protects against oxidative stress in vitro and in vivo. |
| Q47189477 | Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein |
| Q24609782 | Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat |
| Q34909750 | Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice |
| Q33762810 | Transgenic mice expressing S129 phosphorylation mutations in α-synuclein |
| Q48165522 | Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. |
| Q46780013 | Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease |
| Q35171026 | Transgenic models of alpha-synuclein pathology: past, present, and future |
| Q43275554 | Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice |
| Q38248885 | Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits |
| Q34365610 | Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast |
| Q37447970 | Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies. |
| Q56979229 | Transient Secondary and Tertiary Structure Formation Kinetics in the Intrinsically Disordered State of α-Synuclein from Atomistic Simulations |
| Q36384806 | Transient β-hairpin formation in α-synuclein monomer revealed by coarse-grained molecular dynamics simulation |
| Q64267548 | Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice |
| Q35759527 | Translocation of alpha-synuclein expressed in Escherichia coli |
| Q34105973 | Transmission electron microscopy characterization of fluorescently labelled amyloid β 1-40 and α-synuclein aggregates |
| Q36303655 | Transmission of Soluble and Insoluble α-Synuclein to Mice. |
| Q35707907 | Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice |
| Q41109426 | Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease? |
| Q50919414 | Treadmill Exercise Attenuates α-Synuclein Levels by Promoting Mitochondrial Function and Autophagy Possibly via SIRT1 in the Chronic MPTP/P-Induced Mouse Model of Parkinson's Disease. |
| Q62684255 | Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy |
| Q41740088 | Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease |
| Q33847750 | Treatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death |
| Q39007523 | Treatments and compositions targeting α-synuclein: a patent review (2010-2016). |
| Q47820515 | Trehalose Inhibits A53T Mutant α-Synuclein Overexpression and Neurotoxicity in Transduced PC12 Cells |
| Q39031406 | Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils |
| Q45303665 | Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. |
| Q43446039 | Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity. |
| Q46523960 | Trifluoroethanol modulates α-synuclein amyloid-like aggregate formation, stability and dissolution. |
| Q34576478 | Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies |
| Q45966104 | Trimethylamine-N-oxide-induced folding of alpha-synuclein. |
| Q38787738 | Triptolide Promotes the Clearance of α-Synuclein by Enhancing Autophagy in Neuronal Cells |
| Q38836746 | Tristetraprolin inhibits mitochondrial function through suppression of α-Synuclein expression in cancer cells |
| Q47782213 | TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease. |
| Q40593287 | Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant |
| Q35008362 | Tryptophan fluorescence reveals structural features of alpha-synuclein oligomers |
| Q33806266 | Tryptophan probes at the alpha-synuclein and membrane interface. |
| Q36928990 | Tubulin polymerization-promoting protein (TPPP/p25α) promotes unconventional secretion of α-synuclein through exophagy by impairing autophagosome-lysosome fusion |
| Q24291881 | Tubulin seeds alpha-synuclein fibril formation |
| Q48251119 | Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein |
| Q58580914 | Tuning the Balance between Fibrillation and Oligomerization of α-Synuclein in the Presence of Dopamine |
| Q42388077 | Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes |
| Q50269760 | Two Parkinson's disease patients with alpha-synuclein gene duplication and rapid cognitive decline. |
| Q64063434 | Two conformationally distinct α-synuclein oligomers share common epitopes and the ability to impair long-term potentiation |
| Q41867402 | Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state |
| Q39406240 | Two-Dimensional Crowding Uncovers a Hidden Conformation of α-Synuclein |
| Q44006670 | Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. |
| Q37403103 | Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation |
| Q42220307 | Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance |
| Q40603171 | Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity |
| Q54290002 | UV-induced selective oxidation of Met5 to Met-sulfoxide leads to the formation of neurotoxic fibril-incompetent α-synuclein oligomers. |
| Q35344983 | Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway |
| Q57457549 | Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies |
| Q35080740 | Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance |
| Q40795664 | Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease |
| Q34740278 | Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. |
| Q50336439 | Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. |
| Q44552114 | Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function |
| Q35791524 | Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies |
| Q40475678 | Ubiquitination of alpha-synuclein. |
| Q33831775 | Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). |
| Q37681819 | Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease |
| Q46975693 | Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein |
| Q57785304 | Ultrasensitive RT-QuIC Seed Amplification Assays for Disease-Associated Tau, α-Synuclein, and Prion Aggregates |
| Q64052834 | Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid |
| Q50442779 | Ultrasonication-dependent formation and degradation of α-synuclein amyloid fibrils. |
| Q59273870 | Ultrastructure of α-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells |
| Q49125650 | Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. |
| Q24304136 | Unconventional secretion of synuclein-γ promotes tumor cell invasion |
| Q48052490 | Uncovering the Binding and Specificity of β-Wrapins for Amyloid-β and α-Synuclein |
| Q46701642 | Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease |
| Q41909087 | Understanding the dynamics of monomeric, dimeric, and tetrameric α-synuclein structures in water |
| Q48588384 | Unexpected rescue of alpha-synuclein and multimerin1 deletion in C57BL/6JOlaHsd mice by beta-adducin knockout. |
| Q39867665 | Unique copper-induced oligomers mediate alpha-synuclein toxicity |
| Q28540502 | Unlike twins: an NMR comparison of two α-synuclein polymorphs featuring different toxicity |
| Q47256813 | Unraveling amyloid formation paths of Parkinson's disease protein α-synuclein triggered by anionic vesicles |
| Q59939951 | Unraveling the Role of Hydrogen Peroxide in α-Synuclein Aggregation Using an Ultrasensitive Nanoplasmonic Probe |
| Q55222924 | Unravelling the inhibitory activity of Chlamydomonas reinhardtii sulfated polysaccharides against α-Synuclein fibrillation. |
| Q41833340 | Unregulated long non-coding RNA-AK058003 promotes the proliferation, invasion and metastasis of breast cancer by regulating the expression levels of the γ-synuclein gene |
| Q26740340 | Untangling the Manganese-α-Synuclein Web |
| Q48236186 | Unusual α-synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without SGCE mutation |
| Q48175893 | Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein |
| Q41758576 | Unveiling the role of the pesticides paraquat and rotenone on α-synuclein fibrillation in vitro. |
| Q36174650 | Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein |
| Q39916795 | Up-regulation of gamma-synuclein contributes to cancer cell survival under endoplasmic reticulum stress |
| Q24314013 | Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages |
| Q44462807 | Upregulation of alpha-synuclein expression in the rat cerebellum in experimental hepatic encephalopathy |
| Q53634898 | Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. |
| Q36456667 | Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways |
| Q35008102 | Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts |
| Q47934028 | Urate promotes SNCA/α-synuclein clearance via regulating mTOR-dependent macroautophagy |
| Q38938325 | Urea and thiourea modified polypropyleneimine dendrimers clear intracellular α-synuclein aggregates in a human cell line |
| Q37536597 | Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer |
| Q35597118 | Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders |
| Q47213644 | Using a FRET Library with Multiple Probe Pairs To Drive Monte Carlo Simulations of α-Synuclein. |
| Q47397920 | Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein |
| Q35107114 | Using gastrocnemius sEMG and plasma α-synuclein for the prediction of freezing of gait in Parkinson's disease patients |
| Q36841771 | Using leucine zipper to facilitate alpha-synuclein assembly |
| Q46568457 | V63 and N65 of overexpressed α-synuclein are involved in mitochondrial dysfunction |
| Q46854670 | VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. |
| Q28116122 | VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease |
| Q53180017 | Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid. |
| Q48135557 | Validation of a new assay for α-synuclein detection in cerebrospinal fluid |
| Q40817419 | Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study |
| Q38786158 | Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid |
| Q40283738 | Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease |
| Q42182667 | Valproic Acid Regulates α-Synuclein Expression through JNK Pathway in Rat Primary Astrocytes |
| Q45922508 | Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. |
| Q28082380 | Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis |
| Q59691337 | Variably protease-sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau, α synuclein and Aβ pathology |
| Q36403908 | Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression |
| Q36718966 | Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein |
| Q44086156 | Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. |
| Q26744659 | Versatile Structures of α-Synuclein |
| Q46252338 | Vertebrate food products as a potential source of prion-like α-synuclein. |
| Q54548113 | Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. |
| Q48830095 | Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. |
| Q27311396 | Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein |
| Q57033938 | Vibrational Circular Dichroism Sheds New Light on the Competitive Effects of Crowding and β-Synuclein on the Fibrillation Process of α-Synuclein |
| Q43436582 | Viologen-Phosphorus Dendrimers Inhibit α-Synuclein Fibrillation. |
| Q36060421 | Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. |
| Q37796011 | Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease |
| Q40181237 | Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy |
| Q57183945 | Vitamins K interact with N-terminus α-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and α-synuclein |
| Q30415147 | Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease |
| Q48224518 | Voltage-dependent anion channel involved in the α-synuclein-induced dopaminergic neuron toxicity in rats |
| Q43192347 | Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein. |
| Q34669733 | Walking deficits and centrophobism in an α-synuclein fly model of Parkinson's disease |
| Q40664492 | What can trigger the onset of Parkinson's disease - A modeling study based on a compartmental model of α-synuclein transport and aggregation in neurons |
| Q38077612 | What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? |
| Q42578520 | Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. |
| Q46403159 | Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of alpha-Synuclein in Drosophila |
| Q30444927 | Widespread alterations of alpha-synuclein in multiple system atrophy |
| Q52568016 | Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. |
| Q34019790 | Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course |
| Q42479971 | Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies |
| Q42423397 | Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells |
| Q39994322 | Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models |
| Q42510607 | Wild-Type Monomeric α-Synuclein Can Impair Vesicle Endocytosis and Synaptic Fidelity via Tubulin Polymerization at the Calyx of Held |
| Q40405034 | Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death |
| Q48297638 | Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. |
| Q22254116 | Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli |
| Q34825913 | Wildtype and A30P mutant alpha-synuclein form different fibril structures |
| Q36781124 | X-ray Crystallographic Structure of Oligomers Formed by a Toxic β-Hairpin Derived from α-Synuclein: Trimers and Higher-Order Oligomers. |
| Q27935534 | YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation |
| Q44012668 | YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression. |
| Q42988614 | Yeast cells provide insight into alpha-synuclein biology and pathobiology |
| Q34281429 | Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein |
| Q34380191 | Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. |
| Q52146660 | Yeast reveals similar molecular mechanisms underlying alpha- and beta-synuclein toxicity. |
| Q37658298 | Yeast unfolds the road map toward alpha-synuclein-induced cell death |
| Q50970317 | Zeroing in on neurodegenerative α-synuclein. |
| Q35166364 | Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease |
| Q50707447 | Zinc finger protein 219-like (ZNF219L) and Sox9a regulate synuclein-γ2 (sncgb) expression in the developing notochord of zebrafish. |
| Q40136973 | Zinc protects SK-N-SH cells from methamphetamine-induced alpha-synuclein expression |
| Q28116171 | Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation |
| Q35106629 | Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease |
| Q53378591 | [Abeta, tau and alpha-synuclein and glial cells]. |
| Q53422958 | [Alpha-synuclein and Alzheimer's disease]. |
| Q53437155 | [An 87-year-old women with the clinical diagnosis of dementia with Lewy bodies without α-synuclein deposition]. |
| Q54478466 | [Analysis of the alpha-synuclein gene dosage variation associated with autosomal dominant form of ParkinsonTs disease] |
| Q54538542 | [Blockade of the aberrant aggregation of alpha-synuclein in HEK293 cells induced by overexpression of wild-type alpha-synuclein by RNA interference]. |
| Q50249884 | [Effect of curcumin on oligomer formation and mitochondrial ATP-sensitive potassium channels induced by overexpression or mutation of α-synuclein]. |
| Q51783454 | [Frequency of single nucleotide polymorphisms and alpha-synuclein haplotypes associated with sporadic Parkinson's disease in the Mexican population]. |
| Q50277597 | [Frequency of the IVS4+66A-G polymorphism in the alpha-synuclein gene in patients with Parkinson's disease in north-western Mexico] |
| Q54399221 | [Identification of antigenic epitope regions recognized by anti-synuclein-gamma monoclonal antibodies]. |
| Q50711666 | [Overexpression of alpha-synuclein in SH-SY5Y cells partially protected against oxidative stress induced by rotenone]. |
| Q53251230 | [Recent advances in the neuropathological evaluation of Alzheimer's disease: the importance of alpha-synuclein]. |
| Q53093979 | [SNCA rs356219 AND rs356165 VARIANTS ARE ASSOCIATED WITH PARKINSON'S DISEASE AND INCREASED ALPHA-SYNUCLEIN GENE EXPRESSION IN THE CD45(+)-BLOOD CELLS]. |
| Q50085010 | [Snitrosylating protein disulphide isomerase mediates increased expression of α synuclein caused by methamphetamine in mouse brain]. |
| Q53224733 | [Synucleins--the key to mechanisms of neurodegenerative diseases?] |
| Q51013855 | [Targeted inactivation of gamma-synuclein gene affects anxiety and exploratory behaviour of mice]. |
| Q54706671 | [The alpha-synuclein gene microsatellite polymorphism and late-onset sporadic Parkinson's disease susceptibility]. |
| Q54566155 | [The correlation of synuclein-γ and matrix metalloproteinase 9 in breast cancer]. |
| Q46181656 | alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates |
| Q33643679 | alpha-Synuclein abnormalities in mouse models of peroxisome biogenesis disorders |
| Q31010246 | alpha-Synuclein affects the MAPK pathway and accelerates cell death |
| Q28264682 | alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease |
| Q53532283 | alpha-Synuclein and Parkinson's disease. |
| Q24301691 | alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton |
| Q21202835 | alpha-Synuclein and neuronal cell death |
| Q33336648 | alpha-Synuclein and parkin: coming together of pieces in puzzle of Parkinson's disease |
| Q43163904 | alpha-Synuclein at the synaptic gate |
| Q34522644 | alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress |
| Q38497779 | alpha-Synuclein enhances bioluminescent activity of firefly luciferase by facilitating luciferin localization |
| Q48918062 | alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. |
| Q44163187 | alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes |
| Q46612185 | alpha-Synuclein expression in the brain and blood during abstinence from chronic alcohol drinking in mice |
| Q48327676 | alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. |
| Q28584216 | alpha-Synuclein filaments bind the transcriptional regulator HMGB-1 |
| Q40327562 | alpha-Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity |
| Q40816103 | alpha-Synuclein forms a complex with transcription factor Elk-1. |
| Q53473267 | alpha-Synuclein gene duplication is present in sporadic Parkinson disease. |
| Q48872159 | alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. |
| Q24653247 | alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies |
| Q28217032 | alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells |
| Q48427123 | alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. |
| Q34980191 | alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity |
| Q55476143 | alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. |
| Q34111460 | alpha-Synuclein is phosphorylated in synucleinopathy lesions |
| Q27860533 | alpha-Synuclein locus triplication causes Parkinson's disease |
| Q34959638 | alpha-Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcohol-preferring and -nonpreferring rats |
| Q33379030 | alpha-Synuclein misfolding: single molecule AFM force spectroscopy study |
| Q39782960 | alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells |
| Q33929879 | alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins |
| Q39771828 | alpha-Synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells |
| Q48366357 | alpha-Synuclein pathology in the spinal cord autonomic nuclei associates with alpha-synuclein pathology in the brain: a population-based Vantaa 85+ study. |
| Q28510893 | alpha-Synuclein produces a long-lasting increase in neurotransmitter release |
| Q54609650 | alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease. |
| Q54699461 | alpha-Synuclein promoter confers susceptibility to Parkinson's disease. |
| Q46097999 | alpha-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress |
| Q40231449 | alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity |
| Q34109337 | alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells |
| Q34319713 | alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease |
| Q40603357 | alpha-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter. |
| Q28139698 | alpha-Synuclein shares physical and functional homology with 14-3-3 proteins |
| Q40190309 | alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity |
| Q36677604 | alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease |
| Q37762567 | alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. |
| Q44986582 | alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis |
| Q36065356 | alpha-Synuclein: a potent inducer of tau pathology |
| Q37070916 | alpha-Synuclein: a therapeutic target for Parkinson's disease? |
| Q35184775 | alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? |
| Q39210190 | alpha-synuclein and LRRK2: partners in crime |
| Q34141041 | alpha-synuclein and Parkinson's disease |
| Q36663027 | alpha-synuclein and Parkinson's disease: the first roadblock |
| Q43811434 | alpha-synuclein and cytosolic dopamine: stabilizing a bad situation |
| Q33872332 | alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. |
| Q41676981 | alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease |
| Q46118888 | alpha-synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy |
| Q57905836 | alpha-synuclein gene haplotypes are associated with Parkinson's disease |
| Q48912115 | alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. |
| Q52165042 | alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. |
| Q34511876 | alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases |
| Q45025020 | alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. |
| Q43816254 | alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome |
| Q35745729 | alpha-synuclein promotes mitochondrial deficit and oxidative stress |
| Q34099593 | beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor |
| Q34375304 | beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein |
| Q33947152 | beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease |
| Q24318974 | c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease |
| Q54436695 | cDNA cloning, prokaryotic expression and purification of rat alpha-synuclein. |
| Q40274137 | gamma-synuclein has a dynamic intracellular localization |
| Q38998659 | iTRAQ-based quantitative proteomics study on the neuroprotective effects of extract of Acanthopanax senticosus harm on SH-SY5Y cells overexpressing A53T mutant α-synuclein |
| Q55713364 | miR-16-1 promotes the aberrant α-synuclein accumulation in parkinson disease via targeting heat shock protein 70. |
| Q36610305 | microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. |
| Q27334018 | n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease |
| Q24320549 | p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies |
| Q52431617 | p27Kip1 regulates alpha-synuclein expression. |
| Q48451250 | p62 Deficiency Enhances α-Synuclein Pathology in Mice. |
| Q34541317 | p62/SQSTM1-dependent autophagy of Lewy body-like α-synuclein inclusions |
| Q34465572 | rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration |
| Q36040166 | shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model |
| Q36001639 | shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity |
| Q34340575 | siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK |
| Q34115757 | {alpha}-Synuclein gene duplication impairs reward learning |
| Q30491703 | {alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics |
| Q38753941 | ɑ-Synuclein strains and the variable pathologies of synucleinopathies |
| Q50485281 | Α-synuclein and β-synuclein enhance secretion protein production in baculovirus expression vector system. |
| Q35542169 | Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration |
| Q51162977 | Α-synuclein induces microglial cell migration through stimulating HIF-1α accumulation. |
| Q37949158 | Α-synuclein misfolding and Parkinson's disease |
| Q35658620 | Α-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease |
| Q26778937 | Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease |
| Q34540556 | Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers |
| Q45899836 | α - synuclein and Parkinson’s disease: the first roadblock. |
| Q41141295 | α -Synuclein Modification in an ALS Animal Model |
| Q42739828 | α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity |
| Q36297384 | α-Synuclein - Regulator of Exocytosis, Endocytosis, or Both? |
| Q45778718 | α-Synuclein A30P decreases neurodegeneration and increases synaptic vesicle release probability in CSPα-null mice |
| Q49240647 | α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. |
| Q38831103 | α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects |
| Q42783371 | α-Synuclein Alters Toll-Like Receptor Expression |
| Q57588743 | α-Synuclein Amyloid Fibrils Formed of Two Protofibrils |
| Q36518311 | α-Synuclein Amyloid Fibrils with Two Entwined, Asymmetrically Associated Protofibrils. |
| Q38601532 | α-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication. |
| Q44641205 | α-Synuclein Association with Phosphatidylglycerol Probed by Lipid Spin Labels |
| Q50583895 | α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. |
| Q49330024 | α-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling. |
| Q42507829 | α-Synuclein Enhances Cadmium Uptake and Neurotoxicity via Oxidative Stress and Caspase Activated Cell Death Mechanisms in a Dopaminergic Cell Model of Parkinson's Disease. |
| Q37098905 | α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly |
| Q51764708 | α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. |
| Q47099710 | α-Synuclein Interacts with Lipoproteins in Plasma. |
| Q44420467 | α-Synuclein Is Degraded by Both Autophagy and the Proteasome |
| Q38241438 | α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling |
| Q36815683 | α-Synuclein Mutation Inhibits Endocytosis at Mammalian Central Nerve Terminals. |
| Q51371427 | α-Synuclein Oligomers Stabilize Pre-Existing Defects in Supported Bilayers and Propagate Membrane Damage in a Fractal-Like Pattern. |
| Q38892026 | α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons. |
| Q44418952 | α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration |
| Q35530006 | α-Synuclein Reduces Tension and Increases Undulations in Simulations of Small Unilamellar Vesicles |
| Q47630370 | α-Synuclein Regulates Neuronal Cholesterol Efflux. |
| Q35883815 | α-Synuclein Shows High Affinity Interaction with Voltage-dependent Anion Channel, Suggesting Mechanisms of Mitochondrial Regulation and Toxicity in Parkinson Disease |
| Q59806475 | α-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models |
| Q34442714 | α-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies |
| Q45305036 | α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. |
| Q47193560 | α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. |
| Q38066091 | α-Synuclein aggregation and modulating factors |
| Q34193470 | α-Synuclein aggregation and neurodegenerative diseases |
| Q39514955 | α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells |
| Q52145259 | α-Synuclein aggregation in the olfactory bulb of middle-aged common marmoset. |
| Q34271447 | α-Synuclein aggregation in the saliva of familial transthyretin amyloidosis: a potential biomarker. |
| Q38669019 | α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease |
| Q46620011 | α-Synuclein aggregation, seeding and inhibition by scyllo-inositol |
| Q41759905 | α-Synuclein amino terminus regulates mitochondrial membrane permeability |
| Q35102466 | α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. |
| Q37820120 | α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease |
| Q38537722 | α-Synuclein and Lewy pathology in Parkinson's disease |
| Q58750079 | α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis |
| Q38742153 | α-Synuclein and Parkinsonism: Updates and Future Perspectives |
| Q47883353 | α-Synuclein and Tau: Mitochondrial Kill Switches |
| Q34533573 | α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls |
| Q37801701 | α-Synuclein and dopamine at the crossroads of Parkinson's disease |
| Q36499643 | α-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane |
| Q36983221 | α-Synuclein and mitochondria: partners in crime? |
| Q39073685 | α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease |
| Q38077665 | α-Synuclein and mitochondrial dysfunction in Parkinson's disease |
| Q38039369 | α-Synuclein and neuronal cell death |
| Q36157306 | α-Synuclein and nonhuman primate models of Parkinson's disease |
| Q38039881 | α-Synuclein and protein degradation systems: a reciprocal relationship |
| Q39783457 | α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study |
| Q60699176 | α-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa |
| Q42530506 | α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies |
| Q38164379 | α-Synuclein as a ferrireductase |
| Q24316089 | α-Synuclein as an intrinsically disordered monomer--fact or artefact? |
| Q26269838 | α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation |
| Q42323946 | α-Synuclein binds and sequesters PIKE-L into Lewy bodies, triggering dopaminergic cell death via AMPK hyperactivation |
| Q35696031 | α-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion |
| Q37242415 | α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease |
| Q38718029 | α-Synuclein binds to cytoplasmic vesicles in U251 glioblastoma cells |
| Q33841149 | α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production |
| Q36806739 | α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers |
| Q48193428 | α-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation |
| Q39372978 | α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. |
| Q42492993 | α-Synuclein deficiency and efferent nerve degeneration in the mouse cochlea: a possible cause of early-onset presbycusis |
| Q40960833 | α-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses. |
| Q49093010 | α-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress. |
| Q36342850 | α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2 |
| Q58755485 | α-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering β-arrestin2-TAB1 interaction in astrocytes |
| Q38040282 | α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. |
| Q37390499 | α-Synuclein enhances histone H3 lysine-9 dimethylation and H3K9me2-dependent transcriptional responses |
| Q48561683 | α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. |
| Q34183367 | α-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration |
| Q36344872 | α-Synuclein expression in the mouse cerebellum is restricted to VGluT1 excitatory terminals and is enriched in unipolar brush cells |
| Q42929094 | α-Synuclein expression is induced by depolarization and cyclic AMP in enteric neurons |
| Q46496494 | α-Synuclein expression is modulated at the translational level by iron |
| Q41211931 | α-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines |
| Q33911222 | α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease |
| Q57341699 | α-Synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease |
| Q35558701 | α-Synuclein fate is determined by USP9X-regulated monoubiquitination |
| Q52092700 | α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. |
| Q53827082 | α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons. |
| Q47127566 | α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. |
| Q48392245 | α-Synuclein forms non-selective cation channels and stimulates ATP-sensitive potassium channels in hippocampal neurons. |
| Q34153997 | α-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease |
| Q21090919 | α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease |
| Q42373959 | α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson's disease |
| Q35005567 | α-Synuclein impairs macroautophagy: implications for Parkinson's disease. |
| Q33864597 | α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy |
| Q48098403 | α-Synuclein in CSF of patients with severe traumatic brain injury |
| Q38781011 | α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities |
| Q48862110 | α-Synuclein in Neurodegeneration-A Good Protein that may go Bad. |
| Q37845823 | α-Synuclein in Parkinson disease and other neurodegenerative disorders |
| Q37987146 | α-Synuclein in Parkinson's disease |
| Q38147871 | α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models |
| Q34252869 | α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer |
| Q37086400 | α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment |
| Q37251637 | α-Synuclein in cutaneous autonomic nerves |
| Q41898776 | α-Synuclein in gut endocrine cells and its implications for Parkinson's disease |
| Q36044595 | α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system |
| Q57611997 | α-Synuclein in the Skin Nerve of Pure Autonomic Failure |
| Q48253622 | α-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects |
| Q38153587 | α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology. |
| Q48891660 | α-Synuclein in the olfactory system of a mouse model of Parkinson's disease: correlation with olfactory projections. |
| Q34286993 | α-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism |
| Q39588900 | α-Synuclein increases U251 cells vulnerability to hydrogen peroxide by disrupting calcium homeostasis |
| Q41944837 | α-Synuclein increases the cellular level of phospholipase Cβ1. |
| Q36277049 | α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP. |
| Q27313863 | α-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter |
| Q36234694 | α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. |
| Q36020832 | α-Synuclein induces both positive mean curvature and negative Gaussian curvature in membranes |
| Q41901772 | α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis |
| Q40788556 | α-Synuclein interactions with phospholipid model membranes: Key roles for electrostatic interactions and lipid-bilayer structure |
| Q58765487 | α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies |
| Q24300131 | α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner |
| Q36608855 | α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease |
| Q30811315 | α-Synuclein is a Novel Microtubule Dynamase. |
| Q45334398 | α-Synuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury. |
| Q28565087 | α-Synuclein is involved in manganese-induced ER stress via PERK signal pathway in organotypic brain slice cultures |
| Q37399930 | α-Synuclein is localized to mitochondria-associated ER membranes |
| Q34265318 | α-Synuclein knockout mice have cognitive impairments. |
| Q55504584 | α-Synuclein leaves autophagy feeling compromised. |
| Q37987766 | α-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology |
| Q34777956 | α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. |
| Q35674687 | α-Synuclein levels modulate Huntington's disease in mice |
| Q46623697 | α-Synuclein levels modulate Huntington's disease in mice. |
| Q47805762 | α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease |
| Q49266303 | α-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking. |
| Q36685114 | α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. |
| Q37351690 | α-Synuclein misfolding assessed with single molecule AFM force spectroscopy: effect of pathogenic mutations |
| Q24298430 | α-Synuclein modifies huntingtin aggregation in living cells |
| Q35163459 | α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila |
| Q34329988 | α-Synuclein modulates neurite outgrowth by interacting with SPTBN1. |
| Q61897247 | α-Synuclein multiplication analysis in Italian familial Parkinson disease |
| Q30430404 | α-Synuclein mutations cluster around a putative protein loop |
| Q28572683 | α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity |
| Q39256792 | α-Synuclein nonhuman primate models of Parkinson's disease |
| Q24605589 | α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation |
| Q35548548 | α-Synuclein oligomerization: a role for lipids? |
| Q36718306 | α-Synuclein oligomers and clinical implications for Parkinson disease |
| Q30541822 | α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. |
| Q57990760 | α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies |
| Q35060948 | α-Synuclein oligomers induced by docosahexaenoic acid affect membrane integrity |
| Q35658734 | α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases |
| Q43056505 | α-Synuclein oligomers pump it up! |
| Q36929059 | α-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles |
| Q38041484 | α-Synuclein oligomers: an amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions |
| Q36034871 | α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits |
| Q39574142 | α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway |
| Q52607897 | α-Synuclein overexpression impairs mitochondrial function by associating with adenylate translocator. |
| Q37259132 | α-Synuclein overexpression represses 14-3-3θ transcription |
| Q35779463 | α-Synuclein pathology accumulates in sacral spinal visceral sensory pathways |
| Q48468473 | α-Synuclein pathology in the amyotrophic lateral sclerosis/parkinsonism dementia complex in the Kii Peninsula, Japan. |
| Q52146886 | α-Synuclein pathology in the cranial and spinal nerves in Lewy body disease. |
| Q46589456 | α-Synuclein pathology is related to postoperative delirium in patients undergoing gastrectomy. |
| Q38002387 | α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease |
| Q38038123 | α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration |
| Q39426452 | α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells |
| Q38746109 | α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. |
| Q38332283 | α-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death |
| Q41757696 | α-Synuclein promotes dilation of the exocytotic fusion pore. |
| Q24633663 | α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells |
| Q28386621 | α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease |
| Q47202550 | α-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway. |
| Q50233758 | α-Synuclein regulates the partitioning between tubulin dimers and microtubules at neuronal growth cone. |
| Q50247013 | α-Synuclein rs356219 polymorphisms in patients with Gaucher disease and Parkinson disease. |
| Q42184977 | α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling |
| Q59901049 | α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies |
| Q44281222 | α-Synuclein staging in the amygdala of a Parkinson's disease model: cell types involved. |
| Q35626155 | α-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. |
| Q41681113 | α-Synuclein strains cause distinct synucleinopathies after local and systemic administration |
| Q33615657 | α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection |
| Q37966263 | α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease |
| Q38671037 | α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading |
| Q43065145 | α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. |
| Q38156223 | α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease. |
| Q39972820 | α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology |
| Q39138968 | α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model |
| Q48046391 | α-Synuclein's Uniquely Long Amphipathic Helix Enhances its Membrane Binding and Remodeling Capacity. |
| Q35484552 | α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation |
| Q35100189 | α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease |
| Q38806229 | α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. |
| Q64283401 | α-Synuclein-Confocal Nanoscanning (ASYN-CONA), a Bead-Based Assay for Detecting Early-Stage α-Synuclein Aggregation |
| Q47135899 | α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin. |
| Q38912683 | α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters |
| Q64073192 | α-Synuclein-derived lipoparticles in the study of α-Synuclein amyloid fibril formation |
| Q35307748 | α-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2. |
| Q35475433 | α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9). |
| Q34503671 | α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons |
| Q40908193 | α-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation |
| Q36607556 | α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models |
| Q33926400 | α-Synuclein-induced membrane remodeling is driven by binding affinity, partition depth, and interleaflet order asymmetry. |
| Q38947516 | α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease |
| Q37017296 | α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy |
| Q42111186 | α-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2. |
| Q30500318 | α-Synuclein-induced tubule formation in lipid bilayers |
| Q24336749 | α-Synuclein-mediated defense against oxidative stress via modulation of glutathione peroxidase |
| Q35569310 | α-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease |
| Q42750858 | α-Synuclein/Amyloid Interactions |
| Q61808010 | α-Synuclein: A Multifunctional Player in Exocytosis, Endocytosis, and Vesicle Recycling |
| Q38915762 | α-Synuclein: Experimental Pathology |
| Q38954592 | α-Synuclein: Multiple System Atrophy Prions |
| Q37760521 | α-Synuclein: membrane interactions and toxicity in Parkinson's disease |
| Q38099072 | α-Synuclein: the long distance runner |
| Q57864543 | α-Synucleins from Animal Species Show Low Fibrillation Propensities and Weak Oligomer Membrane Disruption |
| Q59300701 | α-Synuclein’s Adsorption, Conformation, and Orientation on Cationic Gold Nanoparticle Surfaces Seeds Global Conformation Change |
| Q50145856 | α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. |
| Q47911489 | α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton |
| Q38979838 | α-synuclein aggregation and its modulation. |
| Q42315815 | α-synuclein and p53 functional interplay in physiopathological contexts. |
| Q42476891 | α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons |
| Q57947893 | α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies |
| Q36148374 | α-synuclein assemblies sequester neuronal α3-Na+/K+-ATPase and impair Na+ gradient |
| Q41117719 | α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease |
| Q39841127 | α-synuclein genetic variability: A biomarker for dementia in Parkinson disease |
| Q48705312 | α-synuclein imaging: a critical need for Parkinson's disease research. |
| Q41670950 | α-synuclein induced synapse damage is enhanced by amyloid-β1-42. |
| Q46301248 | α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. |
| Q36354097 | α-synuclein interacts with SOD1 and promotes its oligomerization |
| Q42548002 | α-synuclein multimers cluster synaptic vesicles and attenuate recycling |
| Q64767880 | α-synuclein oligomers enhance astrocyte-induced synapse formation through TGF-β1 signaling in a Parkinson's disease model. |
| Q55221371 | α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease. |
| Q39443981 | α-synuclein phosphorylation and truncation are normal events in the adult human brain |
| Q48830652 | α-synuclein promotes neuroprotection through NF-κB-mediated transcriptional regulation of protein kinase Cδ. |
| Q33889446 | α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. |
| Q39124651 | α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies |
| Q30839760 | α-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson's disease patients |
| Q35932488 | α-synuclein, LRRK2 and their interplay in Parkinson's disease. |
| Q35914281 | α-synuclein-lanthanide metal ions interaction: binding sites, conformation and fibrillation |
| Q56909226 | α-synuclein—a link between Parkinson and Alzheimer diseases? |
| Q38022031 | αSynuclein and Mitochondrial Dysfunction: A Pathogenic Partnership in Parkinson's Disease? |
| Q40986110 | αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease. |
| Q28506296 | αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction |
| Q58277682 | α‐Synuclein induces unfolded protein response via distinct signaling pathway independent of er‐membrane kinases |
| Q54979309 | α‑synuclein induces apoptosis of astrocytes by causing dysfunction of the endoplasmic reticulum‑Golgi compartment. |
| Q35551615 | β-Amyloid and α-synuclein cooperate to block SNARE-dependent vesicle fusion |
| Q34107278 | β-III Tubulin fragments inhibit α-synuclein accumulation in models of multiple system atrophy. |
| Q42374822 | β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces. |
| Q48611768 | β-asarone increases MEF2D and TH levels and reduces α-synuclein level in 6-OHDA-induced rats via regulating the HSP70/MAPK/MEF2D/Beclin-1 pathway: Chaperone-mediated autophagy activation, macroautophagy inhibition and HSP70 up-expression. |
| Q48106900 | β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons |
| Q37679458 | β1-integrin-dependent migration of microglia in response to neuron-released α-synuclein |
| Q48131649 | β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. |
| Q38812113 | γ-Synuclein Expression Is a Malignant Index in Oral Squamous Cell Carcinoma. |
| Q35111136 | γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway |
| Q38877448 | γ-Synuclein confers both pro-invasive and doxorubicin-mediated pro-apoptotic properties to the colon adenocarcinoma LS 174T cell line. |
| Q34384238 | γ-Synuclein interacts with phospholipase Cβ2 to modulate G protein activation |
| Q48871727 | γ-Synuclein is a promising new marker for staining reactive follicular dendritic cells, follicular dendritic cell sarcoma, Kaposi sarcoma, and benign and malignant vascular tumors. |
| Q39343698 | γ-Synuclein: seeding of α-synuclein aggregation and transmission between cells |
| Q37176108 | γ-synuclein is a novel player in the control of body lipid metabolism |
| Q24338953 | δ-Opioid receptor activation reduces α-synuclein overexpression and oligomer formation induced by MPP(+) and/or hypoxia |
| Sinuklein | wikipedia | |
| Synuclein | wikipedia | |
| gl | Sinucleína | wikipedia |
| シヌクレイン | wikipedia | |
| Синуклеины | wikipedia |
Search more.